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ABSTRACT 
 
 
The purpose of this study was to describe the characteristics and findings of antimalarial 
drug efficacy studies conducted in Ethiopia and to use the findings to formulate 
recommendations for antimalarial drug efficacy monitoring and use of evidence to 
inform antimalarial treatment policy for the Ethiopian setting.  
 
This study reviewed 44 antimalarial efficacy studies conducted in Ethiopia from 1974 to 
2011. The analysis of results indicated that chloroquine as the first-line antimalarial drug 
for the treatment of malaria due to Plasmodium falciparum had a 22% therapeutic 
failure in 1985. Chloroquine was replaced with sulfadoxine-pyrimethamine in 1998, 
more than 12 years later, when its therapeutic failure had reached 65%. Sulfadoxine-
pyrimethamine at the time of its introduction had a treatment failure of 7.7%; it was 
replaced after seven years in 2004 by artemether-lumefantrine; by then its treatment 
failure had reached 36%. 
 
The WHO recommends the replacement of a first-line antimalarial drug when more than 
10% of treatment failure is reported. The replacement drug should have a therapeutic 
efficacy of more than 95%; while the change itself should be completed within two years. 
The prolonged delay to replace failing antimalarial drugs in Ethiopia seems to have 
been influenced mainly by the lack of systematic antimalarial drug efficacy data 
collection and pragmatic use of the data and evidence gathered. 
 
 Almost eight years after its introduction, isolated studies show that the efficacy of 
artemether-lumefantrine has decreased from 99% in 2003 to around 96.3% in 2008. 
Though this decrease is not statistically significant (chi-square 1.5; P=0.22) and has not 
reached the threshold of 10%, it is plausible that its efficacy may drop further. This is 
mainly due to regulatory provisions in the country that allow marketing of oral 
artemisinin mono-therapies that are not recommended for malaria treatment, use of less 
effective antimalarial combination drugs in the neighboring countries and widespread 
drug quality problems. 
 
The situation calls for and this study recommends the establishment of stringent drug 
efficacy monitoring and early warning system and alignment of the antimalarial drug 
regulatory practices with recommendations of the WHO. 
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CHAPTER 1 
 
ORIENTATION TO THE STUDY 
 
 
1.1  INTRODUCTION 
 
The Federal Ministry of Health, Ethiopia (2006a:4) estimates that nearly 75% of the 
Ethiopian land where 68% of the population live is at risk of malaria. Adhanom, Deressa, 
Witten, Getachew and Seboxa (2006:556) explain that as a reflection of the diverse 
eco-climatic conditions in the country, the disease (malaria) transmission patterns 
shows seasonal and temporal variability often characterised by focal and cyclic 
epidemics of varying magnitude.  
 
According to the Federal Ministry of Health, Ethiopia (2006b:35), malaria is on one of 
the leading health problems of public health concern and consistently reported as one of 
the leading causes of morbidity and mortality over the past years. In the years 2005/06, 
the Ministry of Health, Ethiopia (2006b:35) reports that malaria as the first cause of out-
patient consultations accounting for 17.8% out-patient visits (1.23 million cases), second 
cause of admissions accounting for 14.1% admissions (45,975 admissions) and first 
cause of in-patient deaths accounting for 21.8% (1,434 deaths). Negash, Kebede, 
Medhin, Argaw, Babaniyi, Guintran and Delacollette (2005:186) also assert that the 
disease burden in-terms of morbidity and mortality are even higher during epidemics 
that occur in the main malaria transmission months from September to December that 
usually affect highland fringe areas where malaria transmission is seasonal.  
 
In addition to direct health effects caused by malaria in Ethiopia, Paulander, Olsson, 
Lemma, Getachew and San Sebastian (2009:1) reported the negative impact of malaria 
in school attendance; while Deressa, Hailemariam and Ali (2007:1148) affirmed in a 
study conducted in selected villages in Ethiopia that malaria also reduces family income.  
 
Malaria control in Ethiopia was started in 1959 in some high risk priority areas and in 
response to the recurrent malaria outbreaks and the wide-spread malaria epidemics 
that affected the highlands of Ethiopia in 1958 (Fountain, Najjar & Prince 1961:795). 
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Gebremariam and Teklehaimanot (1986:2) explained that the main malaria control 
intervention first introduced included treatment with chloroquine and the application of 
indoor residual insecticide spraying (IRS).  
 
The current malaria control interventions in the country rely on malaria early diagnosis 
and treatment delivered through public and private health facilities, application of IRS in 
targeted malaria epidemic prone localities and distribution of Insecticide Treated Nets 
(ITNs) (Federal Ministry of Health, Ethiopia 2006a:13). 
 
As the malaria transmission situation in Ethiopia is seasonal and unstable, the need to 
have a well-organised malaria diagnosis and treatment service is critical to preventing 
severe illness and death. However, the success of malaria treatment in Ethiopia as in 
many low-income settings has been challenged by to low access to health services. 
Beyond problems related to access and health service utilisation, the success of malaria 
treatment has also been seriously challenged due to the emerging problem of malaria 
parasite resistance to antimalarial drugs (Walsh 2012; Wellcome Trust 2012a). 
 
The combined effects of low access to health service and the ever increasing incidence 
of resistance to antimalarial drugs need a coordinated effort to tackle them effectively. 
While increasing access to health services is mainly limited by the resources made 
available by the national government of Ethiopia and international donors, the 
monitoring of antimalarial drug efficacy and malaria parasites resistance to antimalarial 
drugs is mainly a responsibility of the National Health Service system. 
 
Antimalarial drug efficacy monitoring and resistance monitoring in Ethiopia has been 
conducted by the Ministry of Health, Regional Health Bureaus, Academic and Research 
Institutions. However, antimalarial treatment guidelines changes introduced in the 
country in 1999 and 2004 were mainly based on findings of studies conducted by the 
Ministry of Health in Ethiopia. The objectives, findings and relevance of studies 
conducted by other entities and representativeness, timeliness and completeness of 
these studies in collecting data and information that can inform policy has never been 
fully assessed.  
 
This study, therefore, aims to describe the characteristics and findings of the studies 
conducted in the Ethiopian setting from the date of the first study conducted in 1972 
  
3 
through 2011. The findings from the review are to be used to formulate 
recommendations and best practice guidelines to strengthen antimalarial drug efficacy 
monitoring systems and use of evidence to inform antimalarial drug policy and treatment 
guideline development for the Ethiopian setting.  
 
1.2 BACKGROUND INFORMATION ABOUT THE RESEARCH PROBLEM 
 
Abeku, De Vlas, Borsboo, Tadege, Gebreyesus, Gebreyohannes, Alamirew, Seifu, 
Nagelkerke and Habbema (2004:585) assert that large-scale malaria epidemics in 
Ethiopia have mostly been associated with a period of major climatic changes and 
discontinuation of malaria prevention and control activities.  Population movement to 
and from endemic areas have also been indicated as a contributor to increased malaria 
incidence by Deressa, Ali and Berhane (2006:1).  
 
The widespread malaria epidemics that occurred in Ethiopia in 1998 and 2003 have 
been coinciding with a period of confirmed low efficacy of the first-line antimalarial drug 
that has been in use. The malaria epidemics in 1998 coincided with the confirmed 
chloroquine resistance of 65% reported in the same year (WHO 2000:34). The 2003 
malaria epidemics (Negash et al 2005:186) also coincided with the confirmed resistance 
of sulfadoxine-pyrimethamine of 36% (Jima, Tesfaye, Medhin, Kebede, Argaw & 
Babaniyi 2005a:391) around the same period of the epidemic.  
 
While the impact of climatic factors on malaria epidemics and its use to predict 
epidemics has been described in a study conducted by Abeku, Oortmarssen, Borsboom, 
De Vlas and Habbema (2003:331), the contribution of diminishing efficacy of anti-
malarial drugs to the occurrence of epidemics is also expected to contribute to 
increased malarial incidence and high prevalence of gametocytes (White 2008:1) that 
further contribute to increased malaria transmission.  
 
The availability of effective antimalarial drugs is critical for malaria prevention and 
control. Therefore, understanding the representativeness, timeliness and completeness 
of antimalarial efficacy studies and the use of data collected from such studies to inform 
antimalarial treatment policy and treatment guideline development is highly relevant.  
 
  
4 
Findings of the efficacy of chloroquine for the treatment of uncomplicated Plasmodium 
falciparum malaria conducted in 18 study sites from 1997–1998 led to the decision to 
switch from chloroquine to sulfadoxine-pyrimethamine (WHO 2001:34). Findings of the 
efficacy study conducted on sulfadoxine-pyrimethamine in 10 study sites in 2003 led to 
the replacement of the drug by the ACT drug artemether-lumefantrine in July 2004 
(Federal Ministry of Health, Ethiopia 2004a:1).  
 
These relatively large multi-site studies were conducted in a time gap of nearly five 
years in 1998 and 2003. Apart from these major studies, all other studies that have 
been conducted in Ethiopia since the early 1970s were isolated studies carried using 
different study protocols.  
 
The time interval between consecutive antimalarial drug efficacy studies conducted in 
Ethiopia, the number of sites and sample size considered, completeness of the 
information gathered and recommendations drawn from the studies have never been 
fully assessed and described. As a result of this, experiences from the previous studies 
that may help in providing valuable lessons for future studies and best practice 
approaches that can be adapted have not been identified. The research problem is, 
therefore, based on a practical challenge in antimalarial drug efficacy monitoring and 
use of evidence for policy and solving this problem is believed to have significant public 
health relevance for malaria control.  
 
1.3 RESEARCH PROBLEM 
 
Currently, there is no complete description and documentation on the antimalarial drug 
efficacy monitoring system and use of evidence to advice policy in Ethiopia. This gap 
coupled with the high risk of malaria epidemics in the country is likely to aggravate the 
malaria situation and hence increasing the malarial disease burden in the country. 
 
Impact on the prevalence of severe disease and malaria related deaths largely depends 
on the availability of early diagnosis service and prompt treatment with safe and 
effective antimalarial drugs. The researcher’s experience shows that the level of efficacy 
of antimalarial drugs declines through time and requires timely monitoring that can 
advise appropriate actions. To ensure the availability of effective, up-to-date antimalarial 
drug policy and treatment guidelines, therefore, understanding the practices in 
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antimalarial drug efficacy monitoring in Ethiopia is essential to guide evidence-based 
adoption of antimalarial drug policy and treatment guidelines that can effectively 
address the needs of the country.  
 
1.4  AIM OF THE STUDY 
 
1.4.1 Research purpose 
 
The purpose of this study was to describe the characteristics and findings of antimalarial 
drug efficacy studies conducted in Ethiopia and to use the findings to formulate 
recommendations for antimalarial drug efficacy monitoring and use of evidence for 
policy and treatment guidelines development for the Ethiopian setting. Through this 
approach, data and findings from previous antimalarial drug efficacy studies were 
analysed; their strengths and weaknesses identified. The gaps observed in the 
completeness, timeliness and representativeness of the studies reviewed was used to 
formulate recommendations and best practice approaches for antimalarial drug efficacy 
monitoring.  
 
The use of the recommendations and best practice approaches for antimalarial drug 
efficacy monitoring system and the use of data generated from such studies in informing 
antimalarial drug policy and treatment guidelines’ development for the Ethiopian setting 
has also been stipulated.  
 
1.4.2  Research objectives 
 
The main objective of the study was to 
 
• identify, describe and synthesise data and finding from previous antimalarial drug 
efficacy studies in terms of study representativeness, timeline and completeness 
of the studies conducted in Ethiopia 
• identify strengths and weaknesses in the antimalarial drug efficacy studies and the 
antimalarial drug policy environment 
• formulate recommendations and best practice approaches that can contribute to 
the improvement of antimalarial drug efficacy monitoring system and use of 
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evidence collected through such studies to inform antimalarial drug policy and 
treatment guideline development in Ethiopia 
 
1.4.3 Research hypothesis 
 
The researcher hypothesises that, regular antimalarial drug efficacy monitoring 
approaches and use of evidence for policy in Ethiopia has not been optimally 
synchronised to regularly update malaria treatment guidelines in Ethiopia. To prove the 
hypothesis, data and information from published and unpublished antimalarial drug 
efficacy studies was identified, described and analysed to formulate recommendations 
and best practice approaches in antimalarial drug efficacy monitoring.  
 
1.5 SIGNIFICANCE OF THE STUDY 
 
In the absence of a full understanding of the antimalarial drug efficacy trend and its 
monitoring system, the use of antimalarial drug efficacy data to inform antimalarial drug 
policy and guideline development would be challenging.  
 
This study, therefore, aimed to provide significant information on antimalarial drug 
efficacy monitoring studies conducted in Ethiopia. The information collected from such 
studies conducted in Ethiopia from the early 1970s to 2011 was used to develop 
recommendations and best practice guidelines for antimalarial drug efficacy monitoring 
and use of data and information to advice policy and antimalarial treatment guidelines 
development.  
 
The need to regularly assess the therapeutic efficacy of antimalarial drugs to ensure its 
continued parasitological and clinical efficacy is crucial for antimalarial treatment policy. 
However, the availability of complete and timely data on antimalarial drug efficacy in its 
own cannot guarantee timely decision on antimalarial treatment policy and treatment 
guideline change. Amin, Kangwana, Greenfield, Otieno, Akhwale and Snow (2007:1) 
confirms that in some settings, antimalarial treatment policy and guideline development 
can be seriously challenged by budgetary and health system issues.   
 
Even when funding is available to support procurement of effective antimalarial drugs 
and to strengthen the health service delivery system, the use of the funding may not 
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align with the felt need. Attaran, Barnes, Curtis, D’Alessandro, Fanello, Galinski, 
Kokwaro, Looareesuwan, Makanga, Mutabingwa, Talisuna, Trape and Watkins 
(2004:237) criticise the obvious errors of scientific and medical judgment as one of the 
major risks in hindering the appropriate use of international donor fund in the fight 
against malaria. Financing institutions such as the World Bank has also been criticised 
for lack of impact on malaria in Africa as a result of their investment and Hopkin 
(2006:1096) explains how the World Banks defends such criticism.  
 
Irrespective of the criticisms to donors, timely availability of representative and complete 
data on antimalarial drug efficacy remains the most critical to ensure timely review of 
the antimalarial drug policy. In 2003, when Medicines Sans Frontier (MSF) criticised the 
Ministry of Health of Ethiopia for using ineffective antimalarial drugs (The New York 
Times 2003), the Ministry was working to complete the then on-going antimalarial drug 
efficacy studies in a bid to obtain supportive evidence to inform decision.  
 
The WHO (2009a:9) recommends an overall treatment failure of 10% or above to be 
used as a cut-off to introduce an effective antimalarial drug replacement. For treatment 
outcome to be determined, clinical and parasitological assessment should be conducted 
from 28 days for antimalarial drugs with elimination half-life of less than seven days. For 
antimalarial drugs with elimination half-life of more than seven days, a follow-up period 
of 42 days is recommended. Through this follow-up, treatment success is said to be 
achieved for patients who (a) have no parasitaemia on day 28 or day 42, irrespective of 
axillary temperature and (b) have no early treatment failure or late clinical and 
parasitological failure in the days before day 28 (WHO 2009a:6). 
 
The lack of a locally up-to-date and sound antimalarial drug policy and evidence-based 
treatment guidelines can be serious hindrance to ensuring the provision of effective 
treatment services for malaria. Without ensuring effective antimalarial treatment 
services, the health and socio-economic consequences due to malaria can’t be averted. 
This would in turn lead to further deterioration in the health and socio-economic well-
being of the population in malaria endemic areas of the country where an estimated 68% 
or 50 million people live.  
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1.6 FOUNDATIONS OF THE STUDY 
 
1.6.1 Research paradigm assumption 
 
The positivist paradigm in research has ontological, epistemological, axiological, 
rhetoric and methodological assumptions that can be used to characterise the nature of 
the research (Polit & Beck 2008:13). The ontological assumption in the positivist 
research paradigm considers reality as an objective that can be measured and its 
epistemological assumptions reflect that the researcher is independent of the subject 
which is being researched. The axiological assumption in this study which refers to the 
values attached to the findings is one that doesn’t attach special value for certain 
findings which may lead to a bias that can distort the objective findings. 
 
The efficacy of antimalarial drugs is an objective reality that can be measured through 
experimental procedures and the timeliness, representativeness and completeness of 
such studies can be assessed using empirical measurements. The empirical 
measurements for timeliness are the time duration between two consecutive 
antimalarial efficacy studies. Study completeness refers to the number of variables 
recommended to be measured and the actual number measured and 
representativeness refers to the number of study sites and sample size compared to the 
recommended levels.  
 
Based on Williams, Durrheim and Sheretta (2004:356) assertion on incomplete data as 
reported above, it follows that the collection of data and information on antimalarial drug 
efficacy at the right time with a complete set of data for the recommended variables 
related to antimalarial efficacy is a critical step in the process for antimalarial drug policy 
and treatment guideline development (WHO, Regional Office for Africa 2003:20).  
 
Based on the concepts of representativeness, timeliness and completeness of 
antimalarial efficacy studies, this research theorises that the lack of representative, 
timely and complete data on antimalarial drug efficacy studies in Ethiopia has an 
implication on the success of malaria control in the country. This chapter, therefore, 
presents the theoretical framework description and its application in the context of the 
research conducted. Based on this background, the main foundations of quantitative 
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research of ontological, epistemological, axiological and rhetorical assumptions in 
relation to this research are described below. 
 
1.6.2 Methodological assumptions 
 
The methodological assumption in the positivist research paradigm describes the 
research process as deductive process that measures the cause and effect, with a 
defined category of outcome categories of the study set before the study. Based on the 
outcomes of the observations, generalisations leading to prediction, explanation, and 
understanding are made in an accurate and reliable way where validity and reliability of 
the findings are well tested.  
 
The assessment of antimalarial efficacy and use of study findings to inform decision 
requires multi-disciplinary approach. Even in a resource limited setting, Hedt (2011:1) 
explains that the availability of a minimal expertise in clinical and laboratory assessment 
and basic infrastructure is essential. An antimalarial drug efficacy study team, therefore, 
should ideally ensure the participation of medical doctors, laboratory technical, 
pharmacist and epidemiologist at the right stage of the study design, data collection, 
analysis and report writing.  
 
The effective conduct of antimalarial efficacy studies can ensure collection of data and 
information of high importance for antimalarial drug policy and treatment guideline 
development. However, delay in translating the study findings to inform policy can be 
another challenge. Mubyazi and Gonzalez-Block (2005:1) affirm that changing a 
national drug policy being a sensitive and time taking process, a systematic involvement 
of all main interested parties that includes policy makers, drug companies, health 
personnel, media and the general public is critical to ensure recognition of research 
findings and acceptance of recommendation formulated based on the study findings.  
 
Various study techniques such as in vivo, in vitro and molecular methods may help 
detect trends in the efficacy of antimalarial drugs. All such studies should be 
representative, complete and timely in order to ensure use of their findings to inform 
antimalarial drug policy. Price, Dorswy, Ashley, Barnes, Baird, d’Alessandro, Guerin, 
Laufer, Naidoo, Nosten, Olliaro, Plowe, Ringwald, Sibley, Stepnieska and White (2007:1) 
indicate that a complete global database that includes the main determinants of clinical 
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response to antimalarial drugs with in vitro, molecular and pharmacokinetic parameters 
may help guide national drug policies. However, the WHO (2009a:9) recommends that 
national antimalarial drug policy changes to be based on data collected from 
representative sites. Accordingly the WHO (2009a:3) recommends the use of 4–8 
sentinel study sites, depending on the size and malaria epidemiology of the country, 
and enrollment of statistically determined number of study subjects.  
 
1.6.3 Rhetorical assumption 
 
The rhetoric assumption in the positivist research paradigm describes that the research 
language used is clearly defined, formal and based on a set of definitions that are not 
personal but accepted quantitative words. In this research, the terms and definitions 
used in antimalarial drug efficacy studies are based on formal and standard definitions 
used by experts in the field.  
 
This study uses the formal definitions of the variables measured and also uses standard 
dictionary definitions of representativeness, timeliness and completeness to determine if 
the variables measured met the desired level of attributes needed for antimalarial drug 
efficacy studies. The terms and concept and their definition is presented in section 1.7.  
 
1.6.4 Theoretical framework description 
 
The nature of a health research could be of an empirical or theoretical type. Empirical 
research which is mostly used in quantitative studies is based on an object of study with 
some aspects of reality and data is obtained through a systematic method of empirical 
observation. On the other hand, theoretical research which is mainly used in 
quantitative research focuses on problems and issues related to concepts, perspectives 
or theories of a given field of study or discipline and the research data consists of 
analysis and synthesis of theory. 
 
A theory is a logical view that analytically explains the relationship of a phenomenon 
while theoretical framework in studies refers to the theoretical concept behind the 
research (Polit & Beck 2008:143; 768). Although the scope of use of theoretical 
frameworks may vary depending on the studies, research with well-articulated 
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theoretical framework can help obtain research findings that are meaningful and 
generalisable (Polit & Beck 2008:144).  
 
The theoretical framework for this study consists of three components related to the 
factors that determine the quality and use of antimalarial efficacy studies. The factors 
identified as critical to the quality of antimalarial efficacy studies relate to 
representativeness, completeness and timeliness of the studies to inform antimalarial 
policy decision and development of antimalarial treatment guidelines.  
 
Policy decision on antimalarial drugs or development of malaria treatment guidelines 
should ideally be based on complete set of information collected and used in a timely 
manner. Williams et al (2004:356) asserted that incomplete data and information with 
missing elements can delay the process to change of antimalarial drug policy and 
antimalarial treatment guideline development. Therefore, the collection of data and 
information on antimalarial drug efficacy at the right time with a complete set of data for 
the recommended variable related to antimalarial efficacy is a critical step in the process 
for antimalarial drug policy and treatment guideline development (WHO, Regional Office 
for Africa 2003:20).  
 
1.6.5 Application of the theoretical framework 
 
The three most important issues considered in this investigation are related to the 
representativeness, timeliness and completeness of antimalarial efficacy studies and 
their use to inform decision on antimalarial drug policy matters and development of 
guidelines. Delay in obtaining information on the efficacy of antimalarial drugs leads to 
delayed corrective action that can guarantee delivery of effective malaria treatment 
services. Moreover, if the data collected through such studies is not complete, the 
action that may be proposed and implemented based on incomplete and inadequate 
data may not be appropriate to addressing the antimalarial treatment needs of the 
population in need.  
 
This research aimed to investigate the duration of the antimalarial efficacy studies 
conducted in the country, amount and completeness of the data collected and its 
appropriateness in reference to the standard 24 months recommended by the WHO 
(2009a:3).  
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For the purpose of this investigation, therefore, data from published and unpublished 
antimalarial drug efficacy studies was collected. The data collected was tested and 
scored for representativeness, timeliness and completeness taking the WHO set of 
recommendations as the standard and the information collected from this assessment is 
used to formulate recommendations and best practice approaches for the Ethiopia 
setting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic presentation of the theoretical framework 
 
1.6.6 Justification for the proposed theoretical framework approach 
 
1.6.6.1 The relevance of study representativeness, timeliness and completeness 
 
The health and socio-economic impact of malaria can be alleviated when effective 
prevention and control interventions are applied at acceptably high levels of coverage. 
The WHO (2005a:60) indicates that malarial prevention and control interventions can 
provide better result in reducing the level of malaria when they are applied in an 
integrated approach.  
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Malaria treatment is one of the most life-saving interventions that need to be delivered 
to all population at risk of malaria. The effectiveness of malaria treatment interventions 
depend on prompt access to efficacious antimalarial drugs that are used appropriately 
as prescribed by a service provider. Even when promptly available, if the efficacy of the 
antimalarial drug in use is compromised, access to such drugs will not attain the desired 
treatment objective of complete parasitological and clinical cure.  
 
Frosch, Venkatesan and Laufer (2011:1) explain that although chloroquine has been 
one of the most widely used antimalarial drug for the treatment of malaria in Sub-
Saharan Africa, its continued use has been challenged due to parasite resistance. 
Resistance to the subsequently introduced replacement drug, sulfadoxine-
pyrimethamine, was also relatively fast. 
 
While addressing the main challenge of ensuring delivery of effective treatment for 
malaria requires introduction of an effective antimalarial drug options, some researchers 
recommend the need to strengthen other intervention. Lusingu and Von Seidleing 
(2008:253), for example, explain that the growing problem of drug resistance is driving 
the need to strengthen the existing interventions including the development of vaccines 
to augment the effect of the currently applied interventions. 
 
However, to achieve the desired impact on malaria, the primary action should focus at 
ensuring the use of effective antimalarial drugs that are needed to save the lives of 
patients who are suffering and for whom other control interventions are not of immediate 
help. Therefore, a system for timely detection of decline in the efficacy of antimalarial 
drugs that eventually leads to full-blown resistance should be in place in order to ensure 
timely introduction of effective alternative antimalarial drugs.  
 
The introduction of the new ACTs to overcome problems of malaria drug resistance and 
to ensure effective treatment for malaria has been praised for attaining the expected 
results. However, reports of emerging resistance to Artemisinin are yet again a new 
challenge which is threatening the effective use of the only effective ACTs available 
today (Mok, Imwong, Mackinnon, Sim, Ramadoss, Yi, Mayxay, Chotivanich, Liong, 
Russell, Socheat, Newton, Day, White, Preiser, Nosten, Fondorp & Bizdech 2011:391). 
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The WHO (2011a:7) reports that resistance to Artemisinin, which is one of the basic 
components of the ACTs antimalarial drugs, has been recently reported in the Thailand-
Cambodian border which led to the launch of global plan to contain Artemisinin 
resistance. Anderson (2009:1) illustrates that, historically, the South-East Asian region 
has been the starting point of resistance to a number of antimalarial drugs and the 
emergence of resistance to Artemisinin in the same Geographic location may follow the 
same spreading pattern. This emerging problem is yet another challenge that calls for a 
stringent antimalarial drug efficacy monitoring system to be in place. In response to this 
growing concern, Noedl (2005:404) proposes methods on how to monitor and detect 
artemisinin resistance. 
 
Vestergaard and Ringwald (2007:153) state that methods such as therapeutic efficacy 
tests, in vitro tests, and analyses of molecular markers can be used to monitor 
antimalarial drug resistance. However, Vestergaard and Ringwald (2007:153), stress 
that data obtained from therapeutic efficacy studies conducted based on the WHO 
recommended study protocols are the most important input to ensure timely updating of 
malaria treatment policies and guidelines. The use of data from such studies, therefore, 
should be representative, timely and must contain all the data and information needed.  
 
To ensure scientifically correct, complete and timely conduct of antimalarial efficacy 
studies and to enable sound use of the data collected to inform decision, reviewing 
previous practices can help identify the strengths and weaknesses and lessons learned 
based on which future antimalarial drug efficacy approaches could be oriented. The 
theoretical framework outlined in this chapter, therefore, presents the description and 
application of the approaches used in previous studies so as to describe and identify 
gaps and shortcoming in order to formulate recommendations and best practice 
approaches for now and the future. 
 
1.6.6.2 Disciplinary basis of antimalarial efficacy studies 
 
The assessment of antimalarial efficacy and use of study findings to inform decision 
requires multi-disciplinary approach. Even in a resource limited setting, Hedt (2011:1) 
explains that the availability of a minimal expertise in clinical and laboratory assessment 
and basic infrastructure is essential. An antimalarial drug efficacy study team, therefore, 
should ideally ensure the participation of medical doctors, laboratory technical, 
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pharmacist and epidemiologist at the right stage of the study design, data collection, 
analysis and report writing.  
 
The effective conduct of antimalarial efficacy studies can ensure collection of data and 
information of high importance for antimalarial drug policy and treatment guideline 
development. However, delay in translating the study findings to inform policy can be 
another challenge. Mubyazi and Gonzalez-Block (2005:1) affirm that changing a 
national drug policy being a sensitive and time taking process, a systematic involvement 
of all main interested parties that includes policy makers, drug companies, health 
personnel, media and the general public is critical to ensure recognition of research 
findings and acceptance of recommendation formulated based on the study findings.  
 
Various study techniques such as in vivo, in vitro and molecular methods may help 
detect trends in the efficacy of antimalarial drugs. All such studies should be 
representative, complete and timely in order to ensure use of their findings to inform 
antimalarial drug policy. Price et al (2007:1) indicate that a complete global database 
that includes the main determinants of clinical response to antimalarial drugs with in 
vitro, molecular and pharmacokinetic parameters may help guide national drug policies. 
However, the WHO (2009a:9) recommends that national antimalarial drug policy 
changes to be based on data collected from representative sites. Accordingly the WHO 
(2009a:3) recommends the use of four to eight sentinel study sites, depending on the 
size and malaria epidemiology of the country, and enrollment of statistically determined 
number of study subjects.  
 
1.6.6.3 Scope and measurement in antimalarial drug efficacy studies 
 
The WHO (2009a:26) emphasises that the objective of antimalarial treatment is to 
achieve complete clinical and parasitological cure. In line with this objective, the scope 
of antimalarial efficacy studies is intended to inform national antimalarial policy based 
on parasitological and clinical response of patients to the antimalarial drug tested (WHO 
2009a:42). 
 
Antimalarial drug efficacy can be assessed using different methods that include in vivo, 
and in vitro assessment and analysis of molecular markers to map gene region that 
confer resistance to antimalarial drug. The use of one or the other method has its own 
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strength and weaknesses. Laufer (2009:59) recommends an integrated use of different 
methods to ensure rapid detection and characterisation of resistance, especially to the 
newly introduced class of antimalarial drugs, ACTs. Antimalarial drug efficacy studies 
can be conducted to assess the efficacy of drugs currently is use or new drugs that are 
in considered for introduction.  
 
Röshammar (2009:27) explains the importance of characterisation of the 
pharmacodynamics of antimalarial drugs that refers to the association between drug 
levels at the site of action and its effect and pharmacokinetics data that refers to the 
pattern of absorption, distribution, metabolism, and elimination. The presence of 
parasites in blood samples of patients following administration of a full course of the 
antimalarial drug being evaluated may not necessarily reflect parasite resistance or 
treatment failure unless proof of availability of adequate blood levels of the antimalarial 
drug administered is demonstrated. Barnes, Lindegardh, Ogundahunsi, Olliaro, Plowe, 
Randrianarivelojosia, Gbotosho, Watkins, Sibley and White et al (2007:1) emphasise 
that pharmacokinetic and pharmacodynamics data of antimalarial drugs should be used 
in the assessment efficacy of antimalarial drugs more strictly.  
 
In low income malaria endemic countries, ensuring the availability of all the required 
expertise and capacity for parasite genetic analysis and antimalarial drug 
pharmacokinetics may be challenging. As a result of this challenge, the timeliness and 
completeness of antimalarial drug efficacy studies to inform policy may be seriously 
challenged. Therefore, while building the required capacity in malaria endemic 
developing countries is the ultimate solution, Guerin, Bates and Sibley (2009:593) 
suggest that international support available from the World Wide and the WHO can be 
of help to overcome challenges in antimalarial drug efficacy studies in developing 
countries. 
 
1.7 DEFINITIONS OF TERMS AND CONCEPTS 
 
The key variables in this study are related to antimalarial drug efficacy, treatment failure 
and drug resistance. The conceptual definition and relevance of these variables to the 
study and the operational definition of the concepts in relation to the measuring 
instrument, method of test and decision criteria is presented below. 
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1.7.1 Antimalarial treatment policy 
 
According to the WHO (1994) antimalarial treatment policy is “a set of recommendations 
and regulations concerning the availability and rational use of antimalarial drugs in a 
country.  It should be part of the national drug policy and national malaria control policy 
and in line with overall national health policy”. 
 
1.7.2 Antimalarial treatment guideline 
 
Antimalarial treatment guideline is a guide that provides global, evidence-based 
recommendations on the treatment of malaria (WHO 2010b:1). 
 
1.7.3 Antimalarial drug efficacy 
 
Antimalarial drug efficacy is defined as the ability of an antimalarial drug to clear clinical 
sign and symptoms and parasitaemia (Fidock, Rosenthal, Croft, Brun & Nwaka 
2004:509). Antimalarial drug efficacy can be assessed by employing different methods 
such as in vivo,  in vitro and molecular methods (WHO 2010a:15). In this study, the 
measuring instrument of antimalarial drug efficacy is based on data related to parasite 
detection through microscopy and PCR based methods and assessment of malaria 
clinical sign and symptoms. The efficacy of an antimalarial drug that needs to be 
introduced to replace a failing antimalarial drug should have a clinical and 
parasitological efficacy of 95% and above (WHO 2010b:9). 
 
1.7.4 Therapeutic efficacy study 
 
Therapeutic efficacy is defined as the clinical and parasitological efficacy of antimalarial 
drugs on Plasmodium falciparum infections through defined follow-up criteria (WHO 
2010a:16). Operationally, therapeutic efficacy is measured using parasite density count 
in blood films and assessment of malaria clinical sign and symptoms assessed through 
physical and clinical assessment including measurement of actual body temperature 
and history of fever in the last 48 hours. The decision criteria for therapeutic efficacy are 
based on complete clearance of parasitemia and clinical sign and symptoms of the 
disease.  
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1.7.5 In vitro sensitivity assay 
 
In vitro parasite sensitivity test is exposure of parasites in culture medium to antimalarial 
drugs with a range of varying strengths (WHO 2010a:16). In this study, in vitro parasite 
growth rates in the presence of different levels of concentration of the test antimalarial 
drug is collected. The decision criteria are based on the percentage of parasite growth 
and maturation from ring stage to schizont stage. High percentage growth to a schizont 
stage of the parasite indicates that the amount of test drug in the respective test well 
was tolerated by the parasite.  
 
1.7.6 Molecular markers 
 
Polymorphic genes that are responsible for modifying the response of the parasite to a 
given antimalarial drug can be used as markers or indicator for resistance (WHO 
2010a:16). Genetic markers are analysed through Polymerase Chain Reaction (PCR) 
and enzyme digestion of the parasite dioxyribose nucleic acid regions containing the 
genes of interest (WHO 2008:1). 
 
1.7.7 Drug concentration 
 
Drug concentration is an estimate of the concentration of the active chemical 
component and metabolite of an antimalarial drug in whole blood, plasma or serum 
(WHO 2010a:16). In this study, data on drug concentration in whole blood or serum 
determined using high performance liquid chromatography  method (Debrus, Lebrun, 
Kindenge, Lecomte, Ceccato, Caliaro, Mbay, Boulanger, Marini, Rozet & Hubert 
2011:5205) or other methods (WHO 2011j:11) reported in the studies is analysed. The 
decision criteria are based on the amount of drug metabolite detected in the blood 
sample. The presence of parasites in the blood sample with drug concentration above 
the minimum effective concentration for the specific antimalarial drug is an indicator for 
parasite resistance.  
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1.7.8 Treatment failure 
 
The WHO (2010a:9) defines antimalarial treatment failure "as inability to clear malarial 
parasitaemia or resolve clinical-l symptoms despite administration of an antimalarial 
medicine." Treatment failure could be due factors related to the incorrect dosage, lack 
of patient compliance to the prescribed quantity and duration of treatment, poor drug 
quality, low drug absorption and interaction with a another drug concomitantly 
administered, rapid elimination due to poor metabolism of the drug.  
 
In this study, treatment failure data is collected based on confirmed detection of 
parasites in the blood of the patient accompanied by the presence of malaria clinical 
sign and symptoms is compared. The decision criteria for treatment failure, therefore, 
are the presence of parasitemia and clinical sign and symptoms of malaria following 
completion of a full course of treatment.  
 
1.7.9 Drug resistance 
 
According to the WHO (2010a:9) antimalarial drug resistance is defined as "the ability of 
malaria parasite strain to survive and/or to multiply despite the administration and 
absorption of an antimalarial drug medicine given in doses equal to or higher than those 
usually recommended but within the tolerance of the subject, provided that drug 
exposure at the site of action is adequate." Resistance to antimalarial drugs arise as a 
result of genetic changes such as random gene mutations and/or gene intensification 
that can show reduced susceptibility and the continued selection and proliferation of 
such strains in the parasite population.  
 
In this study, drug resistance is measured based on data collected from the studies 
reviewed to determine the presence of parasitemia and malaria clinical sign and 
symptoms in the patients assessed. The decision criteria of drug resistance are based 
on the presence of parasite development in the presence of the recommended amount 
of drug and require confirmation of parasitemia and determination of blood 
concentration of the drug and its metabolite.  
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1.7.10 Representativeness 
 
Representativeness is defined as serving as a typical or characteristic example 
(Merriam-Webster Incorporated Online Dictionary 2011). Due to the logistic and 
resource requirements and the need to collect representative data in a short period of 
time, studies on antimalarial drug efficacy may not be conducted in all parts of a country, 
region or district. To avoid the unnecessary challenge of trying to reach everywhere, 
statistical methods such as sampling are used to focus the study only on a manageable 
but representative sample.  
 
The findings from such sample on the level of antimalarial drug efficacy can then be 
used to make inference about the rest of the Geographic area, which the sample 
represents. In the absence of representative sampling, the study findings and 
conclusion that may be derived, therefore, would also not be representative and may be 
misleading. In this study, representativeness is measured based on assessment of the 
antimalarial efficacy studies coverage in terms of statistically acceptable minimum 
sample size of 50 subjects per site and use of four to eight study sites.  
 
1.7.11 Timeliness 
 
Timeliness is defined as appropriate or adapted to the time or the occasion (Merriam-
Webster Incorporated Online Dictionary 2011). Monitoring the efficacy of antimalarial 
drugs at regular and appropriate time interval and use of the evidence to guide policy is 
an important aspect of antimalarial efficacy study. Studies of irregular interval may fail to 
detect trends of an imminent or potential health threat.  
 
Delays in making use of evidence from such studies to update or change a health 
service policy or guideline also contributes to further deterioration in the quality of 
treatment that may result in more health problems. In this study, timeliness is measured 
based on the time lapse between two consecutive antimalarial efficacy studies. A time 
lapse of two years between two consecutive studies is considered to have the desired 
timeliness (WHO 2009a:3).  
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1.7.12 Completeness 
 
Completeness is defined as having all the necessary parts, elements and steps 
(Merriam-Webster Incorporated Online Dictionary 2011). This is usually assessed on a 
case-by-case audit of the variables included and reported by a study compared to the 
recommended or ideal list of variables that are expected to be included in a study. In 
this study, completeness is measured based on the availability of data on quality of the 
antimalarial drug tested and pharmacokinetic data that show presence of adequate 
concentration of test drug in blood sample of the patients. The decision criteria are 
based on the availability of these two key measures and a study is deemed in complete 
if it lacks one or both of the required data variables.  
 
1.8 RESEARCH DESIGN AND METHODS 
 
The research design used for this study was a descriptive epidemiological analytical 
study design based mainly on data extracted from published and unpublished reports 
and other relevant sources. To compare treatment failure and/or drug resistance levels 
from different studies, statistical comparison of proportions and means with the 
corresponding 95% confidence intervals and P-values reported by the original studies 
was used. For the comparison of time lapse between studies, duration in years was 
calculated by taking in to consideration the years during which time the studies were 
conducted.  
 
The data collection method mainly involved search for published scientific articles from 
scientific journal available electronically and on printed copies. Other relevant reports 
and information was also searched through internet based search using Google Scholar, 
scientific publication repository of the National Centre for Biotechnology Information 
(NCBI) and by consulting websites of relevant institutions. A detailed description of the 
research design and method used in the study is presented in chapter 3 and highlights 
of the main components are presented in the following sections.   
 
1.8.1 Study sample and population 
 
The study sample and population was the same as what was considered and analysed 
in the studies conducted from 1972 to 2011. With the exception of two antimalarial 
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efficacy studies conducted in the capital city of Addis Ababa, where local malaria 
transmission is rarely reported, most of the studies were conducted in malaria endemic 
areas where malaria transmission occurs. The subjects who were involved in the 
antimalarial efficacy study conducted in Addis Abeba were residents or short-time 
visitors to malarious localities in other parts of the country and most of the locations are 
towns along the frontier with Kenya and the Sudan.  
 
1.8.2 Data collection and analysis approach and the instrument 
 
Country data on antimalarial drug efficacy studies was collected from available 
published and unpublished records and was entered in Microsoft Excel based spread 
sheet developed for this purpose for further analysis. The list of variables on which data 
collection was based and the data collection tool for the different type of studies is 
presented in Annexure B. The data collected was further analysed to determine 
representativeness, timeliness and completeness based on a scoring method 
developed for the purpose.  
 
1.9 ETHICAL CONSIDERATIONS 
 
This study was mainly based on analysis of study findings extracted from antimalarial 
drug efficacy studies conducted in Ethiopia. Due to the study approach applied, the 
study didn't involve in-person participation of patients, biological sampling or interview 
with patients and other informants or laboratory based experimentation or use of 
laboratory animals. The study also didn’t involve the use of raw secondary data from the 
original studies that could have required permission from the originators. 
 
Data and information that were collected from included published and unpublished 
documents and web based resources have been acknowledged and included in the 
citation and list of bibliography.  
 
1.10 SCOPE OF THE STUDY 
 
The study was based on retrospective review of published and unpublished antimalarial 
drug efficacy study reports and other relevant web based resources. Published and 
unpublished reports on antimalarial drug efficacy studies conducted in Ethiopia are 
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available and fairly complete. The study, therefore, was not seriously challenged by lack 
of data and information from previous studies.  
 
The scope of the study is limited to the analysis of past studies and drawing conclusion 
and recommendation for future on antimalarial drug efficacy studies and use of 
evidence for policy and guideline development. However, testing the feasibility and 
appropriateness of the recommendation and best practice guideline proposed by this 
study for the Ethiopian setting was beyond the scope of the research objective.  
 
Therefore, the recommendations and best practice guideline proposed, although have 
been justified for soundness and feasibility of application, will need to be tested and this 
is considered as the main limitation of the study.  
 
1.11 STRUCTURE OF THE THESIS 
 
This thesis is presented in five chapters, organised in the following order: 
 
Chapter 1: Orientation of the study, covering the background information about the 
research problem, definitions of key terms and concept, statement of the research 
problem, aim of the study, significance of the study, foundations of the study, research 
design and method, scope of the study and the structure of the thesis. 
 
Chapter 2: Literature review, covering the malaria situation in Ethiopia, malaria 
prevention and control activities, the role of malaria diagnosis and treatment, efficacy 
profile antimalarial drugs used in the country and the region, drug regulatory practices 
and malaria diagnosis and treatment policy issues.  
 
Chapter 3: Research design and methods, including sample and study population 
characteristics, ethical consideration, data collection approach and method and data 
analysis.  
 
Chapter 4: Analysis, presentation and description of the research findings. In this 
section results of the antimalarial drug efficacy studies reviewed and the use of the data 
collected from these studies in the context of the WHO recommendations is reviewed. A 
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summary of the antimalarial drug policy in other countries including explanation on the 
commonalities and differences is also presented in context.  
 
Chapter 5: Conclusions and recommendations including best practice approaches for 
antimalarial drug efficacy monitoring and use of antimalarial drug efficacy data to inform 
policy for the Ethiopian setting.  
 
1.12 CONCLUSION 
 
The main aim of the study was to describe the characteristics and findings of 
antimalarial drug efficacy studies conducted in Ethiopia and to use the findings to 
formulate recommendations for antimalarial drug efficacy monitoring and use of 
evidence for policy and treatment guidelines development for the Ethiopian setting. The 
approach allowed to fully describe the antimalarial drug efficacy studies conducted in 
Ethiopia and to draw recommendations and best practice approach for antimalarial drug 
efficacy monitoring for now and the future.  
 
The study involved mainly search of data and information from published and 
unpublished printed reports obtained from national workshops on antimalarial drug 
efficacy studies convened by the Federal Ministry of Health of Ethiopia. The scope of 
the study was mainly influenced by the amount of past and current information available. 
Based on the data currently collected during the study, there was a great deal of 
information and obtaining data and information collected by the studies was possible.  
 
The conclusions and recommendation drawn from this study and the best practice 
guideline proposed are expected to provide technically sound approaches on the way 
forward. However, the recommendations on best practice approaches proposed by this 
study, although based on sound justification, will need to be tested and the proposed 
approaches are expected to motivate other investigators and the health authorities to 
pursue the idea further.  The next chapter will address the theoretical framework of the 
study with further description on the relevance of timeliness, representativeness and 
completeness of antimalarial drug efficacy studies for antimalarial drug policy and 
treatment guidelines development. 
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In the following chapter 2, detailed literature review is presented. The literature review 
covers epidemiology of malaria and history of malaria control in Ethiopia. In addition to 
the basic information on malaria distribution, its socio-economic impact and prevention 
and prevention and control efforts in the country, description on the drug policy in 
general and antimalarial drug efficacy monitoring and use of findings from such studies 
for policy is presented.  
 
The literature review also covers information on the distribution of malaria in other 
endemic countries and the commonalities and differences in malaria diagnosis and 
treatment approaches provided in these countries. The literature search has also 
attempted to cover issues related to health care financing, price of antimalarial drugs 
and availability of antimalarial drugs in the private and public sectors.  
 
The overall strategy of the literature search focused on the importance of antimalarial 
drug resistance monitoring and practices on the use of evidence for policy at 
international level and in the geographic region where Ethiopia is located. The next 
chapter will address the findings of the relevant literature reviewed. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
2.1 INTRODUCTION 
 
The literature review section in this chapter presents background information on the 
epidemiological and eco-climatic factors that determine distribution of malaria in 
Ethiopia. A description of the malaria situation in the neighbouring countries and 
commonalities and difference in the malaria diagnosis and treatment approaches 
including policy on the prevention of malaria during pregnancy is presented.  
 
The chapter also presents information on the type of antimalarial drugs included in the 
national drug list of Ethiopia and profile of efficacy of the antimalarial drugs used as first-
line treatment against the disease. Health service delivery and access to antimalarial 
drugs being one of the major factors that can determine the success of a malaria control 
program in a given setting, issues related to access to antimalarial drugs through public 
and the private sector including quality and price of antimalarial drugs and financing for 
antimalarial drugs is presented.   
 
Due to the different factors that influence antimalarial drug policy and development of 
treatment guidelines, literature reviewed in this study has been broadened to cover 
aspects that directly or indirectly influence access to antimalarial drugs and 
development of antimalarial treatment policy.  
 
2.2 BACKGROUND 
 
The appropriateness of an antimalarial drug policy and antimalarial treatment guidelines 
developed based on these policies can be affected by a number of factors. The WHO 
(2001:25) illustrates that antimalarial policy on which treatment guidelines are based is 
a set recommendations and regulations related to the availability and appropriate use of 
antimalarial drugs in the country for which the policy is needed. The WHO (2001:33) 
also asserts that antimalarial drug policy development is a dynamic process which is 
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based on the disease epidemiology, transmission, drug resistance patterns and socio-
economic and political contexts. 
 
Therefore, issues related to the quality of the antimalarial drugs, their efficacy profile, 
registration status in the national formulary and essential drug list, supply chain 
management system, price, availability and access by end users can influence the 
scope of an antimalarial drug policy and the antimalarial treatment guideline (WHO 
2007a).  
 
Findings of the literature review presented in this chapter, therefore, provide a detailed 
description of the different factor listed above that have direct and indirect influence on 
antimalarial drug policy and treatment guideline in Ethiopia in the context of the 
Geographic region of the Horn of Africa.   
 
2.3 ECO-CLIMATIC FEATURES OF ETHIOPIA 
 
The diverse topography of the country with altitude ranges from 110 meter below sea 
level in the Danakil depression in north-eastern Ethiopia to 4620 meters above sea level 
in northern mountains ranges renders high eco-climatic variability. As a result, Ethiopia 
has three distinct eco-climatic zones. These include the hot lowland region of altitude 
below 1000 meters, the mid-land region with altitude of 1,001–1,500 meters and the 
highland region with altitude of above 1,500 meters above sea level. The mean annual 
temperature in Ethiopia in the three eco-climatic zones of the low-land, mid-land and 
high-land areas range from 10–16°C, 16–29°C and 23–33°C, respectively (Federal 
Ministry of Health, Ethiopia 2006a:7).  
 
The Federal Ministry of Health, Ethiopia (2006a:7) reports show that Ethiopia has two 
rainy seasons but generally erratic that makes the country prone to periodic drought, 
loss of agricultural production and disease epidemic of which malaria is the most 
common. Adhanom et al (2006:556) describe that, as a result of the diverse eco-climatic 
conditions, malaria in Ethiopia is generally seasonal and unstable and its seasonality 
and intensity is often determined by rain in the low-land area and temperature in the 
high-land and highland fringe areas.  
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As described above the eco-climatic features in Ethiopia have significant influence on 
the distribution and seasonality of malaria. Cognisant of this phenomenon, malaria 
diagnosis and treatment services in Ethiopia need to target priority areas depending on 
the level of endemicity of malaria. For an effective malaria treatment service to be 
implemented in all areas where the service is needed, understanding the efficacy profile 
of the antimalarial drugs is critical. Talisuna, Okello, Erhart, Coosemans and Alessandro 
(2007:170) confirm that malaria transmission intensity as an important factor for the 
spread of drug resistant falciparum malaria. Therefore, understanding the malaria 
transmission intensity and the factors that influence malaria transmission intensity is of 
importance in identifying areas where antimalarial drug efficacy studies should be 
conducted.  
 
2.4 SOCIO-ECONOMIC CONDITIONS IN ETHIOPIA 
 
According to the third population and housing census conducted in 2007 by the 
Population Census Commission, Federal Democratic Republic of Ethiopia (2008:83), 
the Ethiopian population was 73.9 million with an average household size of 4.7 
persons per household. An estimated 85% of the population live in rural areas and 23.2% 
of the population densely live in 9% of the highland area while nearly 50 per cent of the 
arid and semi-desert plains in the peripheries of the country are sparsely populated 
(Federal Ministry of Health, Ethiopia 2006a:8).  
 
The socio-economic conditions in Ethiopia are one of the lowest in the world. The report 
of the Ministry of Finance of Ethiopia (Ministry of Finance and Economic Development 
2006:55) indicates that the average per capita income in the country which is US$100 
or US$720 in purchasing power parity terms in 2010 leaves an estimated 39% of the 
population under extreme poverty with income of less than US$1.25 per day.  
 
The United Kingdom Department for International Development (2011:1) report 
indicates that poverty in Ethiopia is still high with more than 30 million people living in 
poverty. Although the level of poverty is high, access to primary education in Ethiopia 
has been increasing significantly over the past few years.  
 
The Ministry of Education (2010:10) estimates that primary school enrolment has 
increased from 61.6% in 2001/2002 to 79.8% in 2004/2005. However, literacy rate in 
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the general population, although it has increased from 18% in 1995/1996 to 31% in 
2004/05 is still very low. With the increasing government allocation of budget for the 
education sector from 13.8% in 2000/2001 to 19% in 2004/2005 (Ministry of Education 
2005:10), further positive development in the sector is anticipated. The improved level 
of education is also expected to improve health awareness and Paulander et al (2009:1) 
report that increasing level of literacy in Ethiopia can positively influence knowledge, 
attitude and practice on malaria prevention and treatment.  
 
2.5 HEALTH STATUS IN ETHIOPIA 
 
The WHO (1948) defines health as “a state of complete physical, mental, and social 
well-being and not merely the absence of disease or infirmity”. The definition asserts 
social well-being as one of the essential needs for every human being to enjoy good 
health. Whitehead and Dahlgren (1991:1059) illustrate that social well-being relies on 
the level access to food, shelter, education, employment and security among other 
necessities for everyday human life.  
 
The Commission on Social Determinants for Health (2008:12) affirms that socio-
economic development in rich countries is supported by publicly financed infrastructure 
while low-income countries do not have the financial resources to support services such 
as health care in an equitable manner to the population in need. The level of economic 
development of a country, its equitable distribution among the population and the 
political will to implement healthy social policies is, therefore, basic for good health 
standards to prevail.  
 
As a result of the economic disparities between the low and high-income countries, the 
health status of the population in different countries shows variability. To measure the 
health status of populations, the WHO (2004) applies the disability-adjusted life year 
which is defined as the number of life years lost due to premature death, illness and 
disability from a health risks. Based on the disability adjusted life years (DALYs) 
estimated by the WHO (2004), the leading global health risks that have the highest 
contribution to the DALYs are underweight, unsafe sex, alcohol use and unsafe water, 
sanitation and hygiene. These leading causes of disability mainly affect populations in 
low-income countries, especially in the regions of South-East Asia and sub-Saharan 
Africa.  
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The Federal Ministry of Health, Ethiopia (2005:4) asserts that as a result of the low 
socio-economic conditions in the country; the health status of the population is one of 
the lowest in Africa. According to the Federal Ministry of Health, Ethiopia (2005:4), an 
estimated 60-80% of the health problems in the country are due to communicable 
diseases and nutritional deficiencies. The WHO (2004) estimates a DALYs of 47,528 
per 100,000 population for Ethiopia, which is one of the highest in the world. The 
highest DALYs of 82,443 per 100,000 are estimated for Sierra Leon while the lowest of 
9803 DALYs per 100,000 population is estimated for Iceland and Kuwait.  
 
Although the health status of nations can be compared based on DALYs, the actual 
assessment of progress towards improved health conditions is measured through a 
selected set of indicators. The WHO (2004) uses infant and child mortality, maternal 
mortality and life expectancy as some of the most important health indicators. According 
to the WHO estimates (2004), Ethiopia has one of the lowest life expectancy at birth of 
54 years, high maternal mortality ratio of 470 per 100,000 live births and infant and 
children less than five year of age mortality of 63 and 106 per 1000 live births, 
respectively.  
 
The WHO (2004) estimates show low infant, child and maternal mortality rates and high 
life expectancy in high income countries compared to low-income countries. Infant 
mortality rate as low as 2 per 1000 live births was estimated for Finland, Iceland, Japan, 
Luxembourg, Singapore Slovenia and Sweden while as high as 174 deaths per 1000 
live births was estimated for Sierra Leon. Similarly, mortality of children under five years 
of age is lower in high income countries such as Finland and Iceland with 2 deaths per 
1000 live births compared to the highest of 209 deaths per 100 live births in Chad. 
 
Malaria is prevalent mainly in the hot tropical region of the world and Africa is the most 
affected continent due to its location in the tropics. The WHO (2011a:ix) estimates 216 
million malaria episodes and 655,000 malaria deaths in 2010 of which 81% of the cases 
and 91% were in Africa with approximately 86% of the global malaria deaths occurring 
in children under 5 years of age. The DALYs discounted due to malaria in Africa is also 
one of the highest in the world. The WHO (2004) estimates DALYs lost due to malaria in 
Africa to range from 1 in Mauritius to 8,212 in Niger per 100,000 population while that of 
Ethiopia is 2347.  
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The Roll Back Malaria Partnership (2007:4) affirms that the reason for the high malaria 
morbidity and mortality in Africa to be partly due to the high level of decline in the 
efficacy of the most widely available and affordable antimalarial drugs such as 
chloroquine and sulfadoxine-pyrimethamine due to lack of access to effective alternative 
antimalarial drugs. To impact on the morbidity and mortality caused due to malaria, the 
Roll Back Malaria Partnership (2011:51) calls for improved access and high coverage 
with safe and effective drugs for malaria treatment and prevention interventions to the 
populations at risk of malaria. ` 
 
2.6 HEALTH CARE DELIVERY SYSTEM IN ETHIOPIA 
 
The Federal Ministry of Health, Ethiopia (2005:2) implements health service delivery 
organised with a four tier system that includes Primary Health Care Unit (PHC), health 
centres, zone and regional hospitals. A PHC which has one health centre and five 
health posts is designed to serve 25,000 people, while a district and a zone hospital are 
intended to serve 250,000 and 1 million people, respectively. 
 
To ensure reach and equitable health service to the vast majority of the rural population, 
the Federal Ministry of Health, Ethiopia (2005:1) implements the Health Service 
Extension Program (HSEP). The HSEP program was launched in 2003 has completed 
its plan of training and deployment of 30,000 female Health Extension Workers (HEWs) 
assigned in a ratio of 2 HEWs per 5,000 inhabitants. The primary task of the HEWs is to 
provide promotive and preventive health care services and diagnosis and treatment for 
acute illnesses such as malaria.  
 
As a result of implementation of the HSEP, the Federal Ministry of Health, Ethiopia 
(2006a:4) estimates a significant increase in the health service coverage from 76.9% to 
100%. The health service coverage which is expressed in percentage is calculated 
based on the number of inhabitants living within 5 kilometres radius from the most 
peripheral health facility. Based on this calculation, the Federal Ministry of Health, 
Ethiopia (2010a:21) reports an increase in the potential health service coverage from 45% 
in 1996/97 to 64% in 2003/4 and the overall goal was to attain universal primary health 
service coverage by the end of 2008. 
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The Federal Ministry of Health, Ethiopia (2006b:4) had a plan to achieve a significant 
increase in the ratio of medical doctors to population from 1:42,706 in 2006 to 1:14,662 
by the end of the year 2010.  Despite the relative increase in the health service 
coverage and ratio of health workers to the population, the Federal Ministry of Health, 
Ethiopia (2006b:4) report confirms that the out-patient health service utilisation per 
capita still remains as low as 0.32. 
 
The cause of the low health services utilisation in Ethiopia is believed to be due to a 
number of factors related to the limitation of access and consumer awareness. 
Fantahun and Degu (2003:141) report that problems of accessibility, illiteracy and 
assumption by service users that modern health institutions are not helpful for certain 
diseases contributes to the low health service utilisation in some parts of the country. 
 
Consumer user fees for health services provided in Ethiopia do not seem to have 
negative influence on health service utilisation. El-Saharty, Kebede, Dubusho, and 
Siadat (2009:35) report that the user fee introduced in Ethiopia 50 years ago used to 
help recover the service cost. However, with the introduction of user fee exemptions 
based on proof of inability to pay, health service user fee in Ethiopia remained only 
symbolic.  
 
To better understand the health service delivery system in Ethiopia, a comparison of the 
system with the system in developed countries and low-income developing countries 
that have similar socio-economic level of development as Ethiopia may be important. 
Doorslaer, Masseria and the Economic Cooperation and Development (OECD) Health 
Equity Research Group Members (2004:6) report that income related health inequalities 
in the Organization for Economic Cooperation and Development member countries 
where the rich are more likely to access specialist medical service than the poor exist to 
a larger extent in countries such as Portugal, Finland and Ireland.  
 
The main reason for the disparity in health service utilisation in the OECD countries is 
more related to the income of the individuals and ability to pay for health services than 
the overall country budget allocated for health services. Squires (2011:2) for example, 
reports the health care spending in the United States of America in 2008 was US$7,538 
per capita which is more than double of the median per capita expenditure in the rest of 
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OECD countries. However, access to health services in the United States is pro-rich 
and less equitable compared to the rest of the OECD countries.  
 
Carmen, Proctor and Smith (2011:1) explain decline in median household income, 
increase in poverty rate and increase in the number of people without health insurance 
to be the main contributors for the inequitable access to health services in the United 
States of America. Confirming this assertion, report of the Centres for Disease Control 
and Prevention (2011:35) indicates that the number of people without health insurance 
in the United States was estimated to reach 52 million by the end of 2010 which is likely 
to further impose a negative impact on access to health services.  
 
The impact of user fee on individuals and families in low income and developing 
countries could also be a factor for low service utilisation. Lagard and Palmer (2011:34) 
suggest that reducing or removing user fees increases the utilisation of certain 
healthcare services while it may have unintended consequences on utilisation of 
preventive services and service quality.  
 
The WHO (2011c:128) estimates government expenditure on health as per cent of total 
expenditure in Ethiopia to be at 51.9% while the private expenditure share is 48.1%. 
There is a relatively similar pattern of share between the public and private expenditure 
for health in many African countries while the share of the private expenditure is higher 
in Kenya and South Africa which is 63.7% and 60.3%, respectively.  
 
In low income malaria endemic countries where the level of poverty is relatively higher, 
user fees for malaria diagnosis and treatment services may limit access to service. Alba, 
Hetzel, Goodman, Dillip, Liana, Mshinda and Lengeler (2010:1) reports that non-
adherence to user fee exemptions in the public health sector in Tanzania to be 
associated with low utilisation of the most effective ACT drugs such as AL. To overcome 
the lack of access to affordable effective antimalarial medicines, the Roll Back Malaria 
Partnership (2007: xi) calls for mechanism to ensure affordability and increase access 
to ACTs.  
 
The Carter Centre (2010:3) asserts that malaria diagnosis and treatment service and 
ITNs are provided in Ethiopia free of charge. Although malaria diagnosis and treatment 
services are provide free of charge, Deressa, Chibsa and Olana (2003:9) report that 
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distance to malaria control laboratories and household workload have been shown to 
cause delay in seeking early diagnosis and treatment by patients in the Eastern Shoa 
zone of Ethiopia. Therefore, the need to ensure wider access of services closer to the 
population through the Health Extension Program in Ethiopia is expected to improve 
access to malaria diagnosis and treatment services.  
 
2.7 MALARIA IN ETHIOPIA 
 
In this section, description of the malaria distribution and transmission pattern, disease 
burden and malaria prevention and control interventions applied reduce the impact of 
the disease on the socio-economic conditions in Ethiopia is presented.  
 
2.7.1 Malaria distribution and transmission pattern in Ethiopia 
 
Malaria in Ethiopia is generally prevalent in areas below 2000 meters above sea level. 
However, Negash et al (2005:186) in a study conducted in 50 malaria epidemics 
affected districts in 2004 indicated malaria transmission at altitude ranges as high as 
2,400 meters above sea level. The dominant malaria parasite species are Plasmodium 
falciparum and Plasmodium vivax accounting for approximately 60% and 40% of the 
total malaria cases, respectively while Plasmodium malariae is rarely reported, and 
Plasmodium ovale is not prevalent (Federal Ministry of Health, Ethiopia 2006a:3).  
 
Armstrong and Mathews (1981:299) confirm that the prevalence of Plasmodium vivax in 
the Ethiopia population is associated with high frequency of the duffy positive blood 
types and Collins and Jeffery (2005:570) report that Plasmodium ovale is more 
prevalent in the western part of Africa where the duffy-negative blood type is dominant. 
The main malaria vector in Ethiopia is Anopheles arabiensis and Anopheles pharoensis, 
Anopheles funestus and Anopheles nili have been reported as secondary vectors in 
some parts of the country (Ribeiro, Seulu, Abose, Kidane & Teklehaimanot 1996:299). 
 
The main malaria transmission season in Ethiopia is generally from September to 
December following the major rainy season from June to September and a shorter 
transmission season also occurs from February to March following the short rainy 
season from April to May. Following the bimodal rainfall pattern, the major malaria 
transmission season occurs in all parts of the country situated below 2000 meters of 
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altitude while the shorter transmission season is mainly limited to the Eastern part of the 
county (Federal Ministry of Health, Ethiopia 2005:2).   
 
Based on the eco-climatic factors related to altitude, annual rainfall and mean monthly 
temperatures, the Federal Ministry of Health, Ethiopia (2005:2) stratifies the malaria 
transmission pattern in Ethiopia in to seven different transmission regions as shown in 
Figure 2.1.  
Figure 2.1 Distribution of malaria in Ethiopia 
(Federal Ministry of Health, Ethiopia 2006a:2)  
 
Knowledge of the malaria distribution seasonality and relative prevalence of the malaria 
parasite species is of high importance in antimalarial drug efficacy study planning and 
site selections. However, although the malaria transmission map shown in figure 2.1 
provides the different malaria transmissions patterns in the country, it provides no 
specific information on the reported relative prevalence of the malaria parasite by area.  
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The Plasmodium falciparum risk map developed based on estimates by Hay, Guerra, 
Gething, Patil, Tatem, Abdisalan, Noor, Kabaria, Manh, Elyazar, Brooker, Smith, 
Moyeed and Snow (2009) shown in figure 2.2 indicates a more specific distribution 
pattern of Plasmodium falciparum malaria which is the main parasite species of interest 
in antimalarial drug efficacy studies due to the ability of the parasite to developing 
resistance to different antimalarial drugs.  This map also lacks information on the 
seasonal distribution of Plasmodium vivax malaria infections. 
 
 
Figure 2.2 Spatial distribution of plasmodium falciparum malaria endemicity in Ethiopia 
(Hay et al 2009:1) 
 
2.7.2 Malaria disease burden in Ethiopia 
 
As a reflection of the unstable and seasonal nature of malaria transmission in Ethiopia, 
parasite prevalence rates show variability depending on the season. Alemayehu, 
Ghebreyesus, Bosman, Witten and Teklehaimanot (1998:259) report that parasite rates 
varying from 3–10% during high transmission season months and 0–3% during low 
transmission confirmed in a community based survey conducted in the northern part of 
  
37 
Ethiopia. Shargie, Gebre, Ngondi, Graves, Mosher, Emerson, Ejigsemahu, Endeshaw, 
Olana, WeldeMeskel, Teferra, Tadesse, Tilahun, Yohannes and Richards (2008:1) also 
report that in a community malaria parasite prevalence survey conducted in the regions 
of Oromiya and Southern Nations, parasite rates of 0.9% and 5.4%, respectively were 
detected.  
 
In the 2007 malaria indicator survey conducted during the major malaria transmission 
season in a selected representative sites across the country, Jima, Getachew, Bilak, 
Steketee, Emerson, Graves, Gebre, Reithinger, Hwang and the Ethiopia Malaria 
Indicator Survey Working Group (2010:1) report an overall malaria parasite rate 
confirmed by microscopy of 1% (95% CI 0.5–1.5). Of the 7,167 individuals of all ages 
included in the survey, the relative rates of the malaria parasite rate by species were 0.7% 
for Plasmodium falciparum and 0.3% Plasmodium vivax. 
 
Abeku et al (2003:331) affirm that malaria epidemic risk in Ethiopia shows geographical 
and temporal variability as a result of altitudinal and weather variations. Deressa et al 
(2006:1) also highlight that in areas where malaria transmission is known to occur, 
imported malaria due to population movement to and from malaria endemic lowland 
areas is common. Negash et al (2005:186) also confirm that malaria deaths are much 
higher during malaria epidemic season, and that death rates decrease during the non-
epidemic season indicating the instability of the risk and the lack of protective immunity 
in the population. 
 
According to the Federal Ministry of Health, Ethiopia (2006a:5) the annual number of 
malaria cases reported by health facilities in Ethiopia in the period from 2001–2005 was 
9.4 million (range 8.4–11.5) while the annual average number of microscopically 
confirmed malaria cases was 487,984 (range 392,419–591,442). However, due to the 
limited access of health services in the Ethiopian setting, the annual number of malaria 
cases reported through health facilities is not expected to be representative of the 
overall burden of malaria in the community.  
 
Considering fever based estimates of annual number of malaria cases in Ethiopia, 
Teklehaimanot, Singer, Spielman, Tozan, Schapira (2005:98) estimate that the number 
of malaria cases that are likely to occur annually in the period from 2005 to 2015 is as 
high as 13.7 million. Apart from the high disease burden especially during epidemics as 
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observed in the most recent epidemic in 2003 that caused more than 2 million cases 
and over 3,000 deaths in just four months in 211 districts (Negash et al 2005:186), the 
Federal Ministry of Health, Ethiopia (2006a:12) indicates that the DALYs lost due to 
malaria annually is estimated at 30%. 
 
2.7.3 Malaria control in Ethiopia 
 
The WHO (2005b:30) recommends provision of early diagnosis and treatment for 
patients and prevention using Indoor Residual Insecticide Spraying (IRS), Insecticide 
Treated Nets (ITNs) and Intermittent Presumptive Therapy (IPT) for the prevention of 
malaria during pregnancy. Although services for early diagnosis and prompt treatment 
of malaria is mandatory for all areas where malaria is endemic, the application of IRS, 
distribution of ITNs and IPT seems not to be uniformly applied in all malaria endemic 
countries.  
 
In Ethiopia, the Federal Ministry of Health, Ethiopia (2006a:4) implements provision of 
early diagnosis and treatment for malaria and vector control through the use of Indoor 
IRS and ITNs while IPT is not applied. The study finding on the burden of malaria during 
pregnancy in Ethiopia by Newman, Hailemariam, Jima, Degifie, Kebede, Rietveld, 
Nahlen, Barnwell, Steketee and Parise (2003:1765) indicating the need for further 
evidence on the effectiveness of IPT supports the Federal Ministry of Health decision 
not to apply IPT in Ethiopia.  
 
In other parts of Africa such as the Southern Africa Economic Cooperation (SADC) 
region, all malaria prevention and control interventions are applied in the 11 member 
countries of the region. The continuation of application of some intervention seems to 
relate with some technical and managerial problems associated to its application. The 
use of IPT for the prevention of malaria during pregnancy, for example, is partly 
challenged by the spreading resistance to sulfadoxine-pyrimethamine, the 
recommended drug for IPT. Vinetz (2010:755) explains that the increasing level of 
resistant to sulfadoxine-pyrimethamine makes the intervention less effective. This trend 
may eventually lead to the discontinuation of the intervention unless an effective 
replacement drug is identified.   
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The application of Indoor Insecticide Spraying (IRS) has not also been uniform in all 
endemic countries in Africa. Sadasivaiah, Tozan and Breman (2007:249) asserts that 
although IRS achieved significant reduction on malaria transmission during the malaria 
eradication era, the introduction of ITNs in some countries has been associated with 
reduced application of IRS.  
 
For a significant impact on malaria transmission, the WHO (2005b:36) recommends an 
integrated application of malaria vector control interventions. The integrated vector 
control approach that can impact on malaria transmission can also benefit the malaria 
diagnosis and treatment intervention as it helps reduce the number of new malaria 
cases.  
 
2.7.3.1 Malaria control program objectives in Ethiopia 
 
Malaria control activities in Ethiopia first started as a pilot project in 1955 which was 
then scaled-up to national eradication program in the 1960's. In 1969 the 22nd World 
Health Assembly (WHO 1973:66) decides to apply malaria control activities in areas 
where malaria eradication was not feasible in the near future based on socio-economic 
and epidemiological factors. The WHO (2011d) explains that the malaria eradication 
program in Ethiopia was then re-organised in to vertical Malaria and Other Vector-Borne 
Disease Control Program that operated from 1976 to 1993 and then integrated in to the 
general health service system introduced in 1993. 
 
The Federal Ministry of Health, Ethiopia (2006a:20) malaria prevention and control 
national strategic plan in Ethiopia aims to achieve a 50% reduction in malaria morbidity 
and mortality by 2010 as compared to the 2005 levels. The plan includes malaria 
diagnosis and treatment service as one of the major interventions that will be applied 
during the implementation period for the strategic plan. This intervention is of significant 
relevance to malaria control in Ethiopia as protective immunity to malarial disease in the 
population is low and all age groups are at risk the disease.  
 
Alamirew and Equbazghi (1998:69) confirm that asymptomatic parasitaemia as is the 
case in other hyperendemic African countries where protective immunity against malaria 
in the adult population is well developed is not common in Ethiopia. This 
epidemiological characteristic of the disease in the country, therefore, makes malaria 
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diagnosis and treatment a top priority intervention. To ensure effective treatment for 
malaria, the availability of safe, effective, affordable, and accessible anti-malarial drugs 
is one of the major pre-requisites. In this context, therefore, further details on the 
malaria diagnosis and treatment service in Ethiopia are presented in the following 
sections. 
 
2.7.3.2 Malaria diagnosis in Ethiopia 
 
Laboratory based malaria diagnosis services in Ethiopia are available only in hospitals 
and health centres. However, Tegbaru, Meless, Kassu, Tesema, Gezahegn, Tamene, 
Hailu, Birhanu and Messele (2004:43) report that shortage of essential equipment and 
laboratory supplies as one of the major and chronic problems that has been limiting the 
reach of the service to the population in need. Shortage of trained laboratory 
technicians is also a major problem that has been limiting expansion of the service.  
 
The Federal Ministry of Health, Ethiopia (2005:69) reports that the total number of 
laboratory technicians deployed by the end of 2010 was 4,200 and the ratio of 
laboratory technicians to population of 1 to 7,600 population reflects the low level of 
access to the service.  
 
As a result of the limited availability and access to laboratory diagnostic services, 
malaria diagnosis at the most peripheral health facilities such as the health posts is 
done predominantly based on clinical sign and symptoms while Rapid Diagnostic Tests 
(RDTs) are used rarely when available. The Federal Ministry of Health, Ethiopia 
(2004a:7) indicates that, in health centres and hospitals, malaria diagnosis is based on 
clinical history of mainly fever or history of fever in the last 48 hours and parasitological 
confirmation of cases using microscopy based diagnosis while in most peripheral health 
facilities such as health posts, diagnosis based on clinical sign and symptom is the main 
approach.  
 
The Federal Ministry of Health, Ethiopia (2005:4) introduces the use of RDTs in 2004 
mainly for use in areas where microscopy based diagnosis is not available. However, 
access to diagnosis with RDTs has not been widely available in the following years. The 
WHO (2010c:186) estimates that about 108,324 malaria RDTs were used in Ethiopia in 
2009 alone while the number of tests procured and used prior to 2009 is not known.  
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Most of the RDTs used in Ethiopia were tests that detect Plasmodium falciparum only.  
The use of single species RDTs in a setting where Plasmodium falciparum and 
Plasmodium vivax co-exist in considerably comparable proportions may not be an 
appropriate choice for malaria treatment to be based on. In an effort to collect evidence 
that can be used to guide RDT product selection and procurement decisions, Ashton, 
Kefyalew, Tesfaye, Counihan, Yadeta, Cundill, Reithinger and Kolaczinski (2010:1), 
compare three different multi-species RDTs, namely: CareStart®, ParaScreen® and 
ICT Combo® and reported that the brand CareStart had high sensitivity and specificity 
for diagnosis of both Plasmodium falciparum and Plasmodium vivax. Due to the 
availability of a wide range of malaria RDTs, WHO (2009b:3) advises national programs 
to use the test results provided by its product testing program to make their product 
selection and procurement decisions for RDTs. 
 
The cost of RDTs varies by type and selecting the right test with a reasonable cost is of 
high importance. Lemma, San Sebastian, Löfgren and Barnebas (2011:1) report that for 
malaria diagnosis in the health posts in rural areas, the use of parascreen pan/pf based 
tests are a preferable option in terms of cost and quality.  
 
2.7.3.3 Malaria treatment and antimalarial drugs in Ethiopia 
 
Chloroquine, primaquine and quinine were the most popular antimalarial drugs that 
have been in use for malaria treatment in Ethiopia in the period pre-1998 (table 2.1). 
The Federal Ministry of Health, Ethiopia (2004a:7) recommends the use of quinine 
tablets and injection for the treatment of severe malaria. The WHO (2000:34) reports 
that the detection of widespread treatment failure to chloroquine by Plasmodium 
falciparum in 1997–1998 in Ethiopia led to the introduction of sulfadoxine-
pyrimethamine for the treatment of Plasmodium falciparum malaria, while chloroquine 
remained in use for the treatment of Plasmodium vivax. 
 
The first edition of the malaria diagnosis and treatment guideline in Ethiopia was revised 
in 2004 following report by Jima et al (2005a:391) high level of (35.6%) treatment failure 
of sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium 
falciparum malaria. This led the Federal Ministry of Health, Ethiopia (2004a:18) to 
introduce artemether-lumefantrine for the treatment of falciparum malaria while 
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chloroquine and Quinine remained to be is use for the treatment of Plasmodium vivax 
malaria and severe malaria, respectively. While changing the first-line antimalarial drugs 
based on the efficacy study reports, the Federal Ministry of Health, Ethiopia (2004a:13) 
decides to introduce mefloquine for prophylactic use and Artemether injection for the 
pre-referral treatment of cases with severe malaria based on recommendations of the 
WHO. 
 
The national malaria diagnosis and treatment guidelines provide instructions for dose 
regimen of antimalarial drugs based on age and body weight (Federal Ministry of Health, 
Ethiopia 2004:57). Personal experience shows that drug dose regimen is based on age-
group based treatment regimen than dose regimen based on an actually measured 
body weight. The treatment of malaria in special population groups such as pregnant 
mothers and infants with body weight of less than five kilogram differs from the rest of 
the population. The Federal Ministry of Health, Ethiopia (2004a:13) recommends the 
use of quinine for the treatment of malaria in children under five kilograms of body 
weight and pregnant women. The administration of quinine for the treatment of malaria 
requires careful management due to the adverse effects the drug may cause. Achan, 
Talisuna, Erhart, Yeka, Tibenderana, Baliraine, Rosenthal and D’Alessandro (2011:1) 
confirm that despite the long history of use of quinine for the treatment of malaria, its 
continued use is challenged by poor tolerance by patients, low compliance and its 
complex dose regimen.  
 
A comparative efficacy study on artesunate injection versus quinine intravenous 
conducted by Dondorp, Fanello, Hendriksen, Gomes, Seni, Chaganlal, Bojang, 
Olaosebikan, Anunobi, Maitland, Kivaya, Agbenyega, Nguah, Evans, Gesase, 
Kahabuka, Mtove, Nadjm, Deen, Mwanga-Amumpaire, Nansumba, Karema, Umulisa, 
Uwimana, Mokuolu,  Adedoyin, Johnson, Tshefu, Onyamboko, Sakulthaew, Ngum, 
Silamut, Stepniewska, Woodrow, Bethell, Wills, Oneko, Peto, Von Seidlein, Day, White 
and the AQUAMAT Group (2010:1647) for the treatment of severe malaria in children 
conducted between 2005–2010 in 11 African countries proved the superior level of 
efficacy, safety and ease of administration of artesunate injection compared to quinine.  
 
Comparative safety and efficacy study on the use of rectal artemisinin versus quinine 
Intravenous by Biruk, Makonnen and Bjorkman (1999:154) in Ethiopia also showed 
rectal artesunate to provide better parasite and fever clearance and recovery of patients 
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from comma. Based on available evidence, the WHO (2011e:37) now recommends the 
use of artesunate administered by intravenous or intramuscular route for the treatment 
of severe malaria replacing quinine. The study evidence showed that, artesunate was 
significantly better than quinine in reducing the risk of death from severe malaria and 
hypoglycemia.  
 
Table 2.1 Malaria diagnosis and first-line anti-malaria drugs used in Ethiopia 
 
Facility 
level 
Pre-1998 1998–2004 2004 to present 
Diagnosis Treatment Diagnosis Treatment Diagnosis Treatment 
Health 
post Clinical Chloroquine (CQ) Clinical 
CQ and 
Sulfadoxine-
Pyrimethamine 
(SP) combined 
Clinical and 
Rapid 
Diagnostic 
Tests 
(RDTs) 
when 
available 
 Artemether-
Lumefantrine 
(AL)- 
Health 
Centre 
Clinical and 
microscopy 
based 
 CQ for 
Plasmodium 
falciparum  
infection 
 CQ plus PQ 
for 
Plasmodium 
vivax 
infection  
Clinical and 
microscopy 
based 
 CQ and 
sulfadoxine-
pyrimethamin
e combined 
for clinical 
cases  
 CQ for 
Plasmodium 
vivax and 
 SP for 
Plasmodium 
falciparum  
Clinical and 
Rapid 
Diagnostic 
Tests 
(RDTs)  or 
microscopy 
when 
available 
 AL – for 
Plasmodium 
falciparum  
cases 
 CQ - for 
Plasmodium 
vivax 
 
Hospital 
Parasito-
logical 
confirmation 
by 
microscopy 
 CQ for 
Plasmodium 
falciparum  
infection 
 CQ plus PQ 
for 
Plasmodium 
vivax 
infection 
 Quinine (QN) 
for severe 
cases 
Parasito-
logical 
confirmation 
by 
microscopy 
 CQ for 
Plasmodium 
vivax 
 SP for 
Plasmodium 
falciparum  
 Quinine (QN) 
for severe 
cases 
Parasito-
logical 
confirmation 
by 
microscopy 
 AL – for 
Plasmodium 
falciparum  
cases 
 CQ – for 
Plasmodium 
vivax 
 QN for severe 
cases 
 
(Ministry of Health1999:28; Federal Ministry of Health, Ethiopia 2004a:7) 
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2.7.3.4 Malaria prevention and treatment during pregnancy 
 
Desai, Kuile, Nosten, McGready, Asamoa, Brabin and Newman (2007:93) affirm that 
malariaas one of the major contributors to anaemia and low birth weight during 
pregnancy in areas with high malaria transmission. To prevent the consequences of 
malaria during pregnancy, the WHO (2007b:1) recommends the administration of IPT 
with sulfadoxine-pyrimethamine in areas with high malaria transmission where the risk 
of malaria in pregnancy is greatest.  
 
Based on annual incidence of malaria, the WHO (2011a:82), classifies areas with 
annual malaria incidence of 1 or more per 1,000 population as high transmission areas. 
Based on this classification, most countries in Sub-Saharan Africa fall in to this category, 
with the exception of countries such as Ethiopia where transmission is seasonal and 
epidemic type and a few other countries such as South Africa where malaria is 
prevalent in limited parts of the country and Lesotho and Mauritius where malaria 
transmission is non-existent. Following the recommendation and the need to reach the 
beneficiaries in rural settings where access to health services is limited, Mbonye, 
Bygbjerg and Magnussen (2008:22) report that IPT delivery though community-based 
approaches as instrumental in expanding access to the service.  
 
Malaria transmission in Ethiopia is seasonal and the population that live in high 
transmission areas with annual incidence of 1 or more malaria cases per 1,000 
population is around 1% while the vast majority of 66% of the population lives in areas 
with annual incidence of less than 1 malaria case per 1000 population (WHO 
2010c:117). As a result of the variable malaria transmission pattern, the effect of 
malaria during pregnancy shows variability. In a cross-sectional study conducted in four 
sites in Ethiopia, Newman et al (2003:1765) report placental parasitaemia of 6.5% 
(12/185) in two study sites with relatively stable malaria transmission compared to 2.5% 
(21/833) is two other sites with unstable malaria transmission.  
 
The risk of low-birth weight was higher in the unstable transmission area (Relative Risk, 
3.9; p=0.01) compared to the stable transmission area (Relative Risk, 2.7; p=0.04) while 
the risk of stillbirth was seven folds higher in the stable transmission sites.  Newman et 
al (2003:1765) also reported that the level of Plasmodium vivax detected in the study 
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site with unstable or seasonal malarial transmission was an additional risk that might 
have contributed to the relatively higher risk of low-birth weight.  
 
Based on the highly seasonal pattern of malaria transmission in Ethiopia and the lack of 
evidence to support the application of IPT with sulfadoxine-pyrimethamine, the 
intervention was not recommended and has not been applied in Ethiopia (Federal 
Ministry of Health, Ethiopia 2006a:4).  
 
2.7.4 Drug regulatory services in Ethiopia 
 
The Food, Medicine and Healthcare Administration and Control Authority of Ethiopia is 
the sole agency responsible for the quality control of food, medicines and health service. 
According to the Ethiopian Food, Medicine and Healthcare Administration and Control 
Authority of Ethiopia (2010a), 13 drug and medical product manufacturers, 3,228 
registered drug retail outlets that include pharmacies, drug shops and rural drug 
vendors operate in Ethiopia.  
 
According the Federal Negarit Gazeta of the Federal Democratic Republic of Ethiopia 
(2010:1), monitoring and ensuring the safety, efficacy, quality and proper use of 
medicines is one of the major responsibilities of the institution. An estimated 4,000 
medical products are registered in the country and most of the products are imported 
from abroad. To ensure quality assurance of locally produced and imported medical 
products, the Ethiopian Food, Medicine and Healthcare Administration and Control 
Authority of Ethiopia (2010a) operates a central drug quality control laboratory. The 
laboratory has technical capacity and equipment to conduct quality testing on only 346 
medical products.  
 
Mohammed (2008:7) indicates that most of the 300 essential drugs listed, only 90 drugs 
are locally produced while the bulk of the remaining products are imported from abroad. 
The basic antimalarial drugs chloroquine and sulfadoxine-pyrimethamine are locally 
produced while the no ACTs are produced locally. Mohammed (2008:6) also reports 
that of the 17 local manufacturing plants registered in the country, none have 
international certification for Good Manufacturing Practice (GMP) while six of these 
manufacturing plants are GMP certified by the local regulatory authority. Drug quality 
problems pose multifaceted public health problems in developing countries, especially 
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Africa (Wellcome Trust 2012b) and solving the problem requires coordinated approach 
(Newton, Green & Fernández 2010:99).  
 
Newton, Amin, Bird, Passmore, Dukes, Tomson, Simons, Bate, Guerin and White (2011) 
call for an international treaty under the umbrella of the WHO as an important step to 
strengthen the effort to control the counterfeit and substandard medical products. 
Durrheim and Williams (2005:178) emphasises that without a strict control of the quality 
of drugs, monitoring the efficacy of the drugs alone can’t ensure good quality treatment 
service. Onwujekwe, Kaur, Dike, Shu, Uzochukwu, Hanson, Okoye and Okonkwo 
(2009:22) calls for legal measures to ensure stringent control on stockpiling and 
circulating poor quality drugs and for countries who manufacture and export medical 
products to apply strict quality and standard assurance checks (United Nations Office 
on Drugs and Crime 2012). 
 
2.7.4.1 Ethiopian formulary of essential drugs list (EDL) 
 
The most recent Ethiopian national drug formulary was revised in 2007 by the Drug 
Administration and Control Authority of Ethiopia (2007: vi). The Drug policy in Ethiopia 
first developed by the Transitional Government of Ethiopia (1993:1) envisages the 
availability of a regularly updated list of essential medicines that can address the priority 
health care needs of the population. The identification and selection of medicines is 
based on epidemiological needs and the proven safety, efficacy, quality, price and ease 
of use of the products for the patients.  
 
The main purpose of the Essential Medicines List in Ethiopia is to guide all those 
involved in health services delivery in the selection, procurement, production, 
distribution and storage of medicines. According to the Food, Medicine and Healthcare 
Administration and Control Authority of Ethiopia (2010c:v), preparation process of the 
list involves a technical working group of the authority composed of an internist, a nurse 
and a pharmacist who prepare the initial working draft of the list. The draft version is 
then further enriched through a national consultative workshop with participants from 
various areas and specialties in medicine. Participants of the workshop also include 
delegates from medical schools, relevant professional associations, Regional Health 
Bureau, and departments of the Ministry of Health, pharmaceutical manufacturers and 
importers, government hospitals and other related organisations.  
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Based on the additional input and recommendations from the national workshop, the 
revised list of Essential Medicines is reviewed and finalised by the National Drug 
Advisory Committee. During the revision process, medicines of proven quality 
formulated with a single compound are prioritised for inclusion in to the list. Fixed dose 
formulations are selected only when they have proven advantage over single compound 
presentations and the issues of safety, efficacy, adherence and ability to combat drug 
resistance. 
 
The essential drug list presents products in their generic and international non-
proprietary names according to their pharmaco-therapeutic areas. Once the essential 
drug list is disseminated, a mechanism to collect views and opinions though email and 
telephone system is made available for patients and prescribers to give their feedback 
on the list (Food, Medicine and Healthcare Administration and Control Authority of 
Ethiopia 2010c: xi).  
 
2.7.4.2 Antimalarial drugs in the essential drug list 
 
The Food, Medicine and Healthcare Administration and Control Authority of Ethiopia 
(2010b:49) indicate that the 6th edition of the essential medicines for Ethiopia published 
in 2010 as the current list in use. The previous editions were published in 1985, 1987, 
2004, 2007 and 2010. The number of years between the versions is not uniform and it is 
not clear as to what the reasons could have been.  The antimalarial medicines included 
in the national essential drug list have been changing in accordance with the changing 
pattern of efficacy of the antimalarial drugs and their recommended use for the 
treatment of malaria.  
 
Table 2.2 below summarises the antimalarial drugs included in the sixth edition of the 
national drug list for Ethiopia (Food, Medicine and Healthcare Administration and 
Control Authority 2010b:49).  The latest list includes oral Artemisinin monotherapies that 
are not recommended by the WHO (2010b:1). 
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Table 2.2 Anti-malarial drugs included in the Ethiopia National essential drug 
list 
 
No Product  Presentation 
1 Alpha, Beta Arteether Injection, 150 mg/2ml 
2 Artemether Oral Suspension,  40 mg/0.5 ml, 80 mg/ml; Injection, 20 mg/ml, 40 mg/ml, 80 
mg/ml; Suppository, 40 mg 
3 Artesunate  Tablet, 100 mg, 200 mg; Injection, 60 mg/vial 
4 Artemether +Lumefantrine  Tablet and dispersible, 20 mg artemether+120 mg 
lumefantrine 
5 Chloroquine Phosphate  Tablet, 250 mg, 500 mg (equivalent to 150 mg, 300 mg 
base) Syrup, 50 mg base/5 ml; Injection, 50 mg/ml 
(equivalent to 40 mg/ml base) 
6 Dihydroartemisinin  Tablet, 60 mg 
7 Dihydroartemisinin + Piperaquine  Tablet, 40 mg + 320 mg 50 Phosphate 
8 Mefloquine Hydrochloride  Tablet, 250 mg 
9 Primaquine Phosphate  Tablet, 7.5 mg base, 15mg base 
10 Quinine Dihydrochloride  Injection, 300 mg/ml in 1 ml ampoule Tablet, 300 mg, 600 
mg 
11 Proguanil Hydrochloride  Tablet, 100 mg 
12 Sulfadoxine +Pyrimethamine  Injection, 500 mg sulfadoxine +25 mg pyrimethamine in 2.5 
ml ampoule; Tablet, 500 mg sulfadoxine +25 mg 
pyrimethamine 
 
(Food, Medicine and Healthcare Administration and Control Authority 2010b:49) 
 
The list of antimalarial drugs in the Ethiopian National essential drug list includes 
products such as Artemisinin and dihydroartemisinin oral formulations. However, the 
revised WHO malaria treatment guideline recommends the use of ACTs. The use of 
artemisinin oral mono-therapies has been identified as a major risk to artemisinin 
resistance. To minimise the risk of resistance to artemisinin, the WHO (2007a:2) 
endorses to ban the use of oral artemisinin mono-therapies at its 60th Assembly. 
 
2.7.4.3 Access to antimalarial drugs through the public and private sectors in 
Ethiopia 
 
The Federal Ministry of Health, Ethiopia (2007:3) reports that 10,744 government 
owned health facilities and 2,153 private sector health facilities operate in the country. A 
large majority (92%) of the government owned health facilities are peripheral health 
posts health facilities that provide mainly primary level of care. The health facilities in 
the private sector are licensed and supervised by the Ministry of Health. The main 
source of medical supply for the private sector is through the 17 government and private 
owned importers and manufacturers registered in the country. 
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Regular information on the availability of essential medicines in the public and private 
sector is not usually available. Carasso, Lagarde, Tesfaye and Palmer (2009:1394) 
survey report shows that, most essential medicines were available in private health 
facilities and dispensaries with the exception of the newly introduced antimalarial drug, 
artemether-lumefantrine.  Carasso et al (2009:1394) also report that although essential 
medicines were available at the time of the survey in both the public and private sector 
facilities surveyed, prices of medicines was more than twice in the private out-lets 
compared to prices in the budget pharmacies operating in the public sector.  
 
The limited availability of the first-line antimalarial ACT drug in the private sector 
(Carasso et al 2009:1394) shows that the market penetration of the ACT drug 
artemether-lumefantrine which was first introduced in July 2004 was quite slow and this 
is likely to have a significant impact on the success of malaria treatment in Ethiopia.  
 
2.7.4.4 Drug supply chain management, availability and stock-outs 
 
A Federal Ministry of Health and WHO (2010:3) survey finding affirms that availability of 
the necessary structure and mechanisms required to implement the National Drug 
Program was "more or less in place" within the health sector of the country. However, 
the survey finding identifies lack of appropriate stock control system in 60% of the 
health facilities surveyed as the major problem of the pharmaceutical supply 
management system in health facilities.  
 
Daniel and Hailu (2009:10) also reported medical and laboratory supply chain and stock 
management related problems in a survey conducted involving 19 hospitals, 31 health 
centres, 27 health posts, 33 private drug outlets, nine Regional Health Offices, 18 zone 
health offices, 29 district health offices and 44 laboratories. The major problems 
identified include antimalarial drug stock-out in health facilities for a period of 1–2 
months, low stock of paediatric antimalarial drugs, significant problems in monitoring 
expiry dates of antimalarial and anti-tuberculosis drugs.  
 
In addition to the technical problems, administrative challenges such as lack of 
adequate coverage of training on the management of the new antimalarial drugs, limited 
availability of the new antimalarial treatment guideline, absence of stock control cards 
and lack of adequate storage and shelving facilities were identified as some of the major 
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gaps in the drug management system. The combined effect of these shortcomings can 
pose serious challenges on the quality and coverage with malaria diagnosis and 
treatment services in the country.  
 
2.7.4.5 Quality of antimalarial drugs 
 
Drug registration in Ethiopia is required by law both for the purpose of production, and 
importation. The Food, Medicine and Healthcare Administration and Control Authority 
(2008:1), specifies the requirements for the application and registration of new medical 
products. The accepted pharmacopeia includes the United States Pharmacopeia (USP), 
British, European pharmacopeia and other applicable Ethiopian standards as relevant. 
The quality testing of antimalarial drugs is conducted as per the methods described in 
the pharmacopeia relevant to the product. 
 
There are no local reports that provide regular information on the quality of antimalarial 
drugs that are being sold in the country. Such drug quality activities are sometime done 
by international institutions such as the WHO. The WHO (2011f:52) reports no drug 
quality problems in 102 antimalarial drug samples collected from four different parts of 
the country. The sample included 47 artemether-lumefantrine and 55 sulfadoxine-
pyrimethamine tables collected from different batches traced in the public and private 
drug outlets.  
 
Although quality of the sampled antimalarial drugs was confirmed to have the required 
properties for quality, nearly 41% of the samples collected were not products registered 
in the country. The fact that a significant proportion of the antimalarial drugs were not 
registered was identified as a major concern as the lack of such regulatory measures 
can be vulnerable to the entry of poor quality drugs. Smine and Bempong (2009:6) 
confirms that the US President's Malaria Initiative (2011) is providing training and 
capacity building support in collaboration with the USP. Technical support in the area of 
drug quality control is expected to improve the local capacity.  
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2.7.4.6 Financing and cost of antimalarial drugs 
 
The Federal Ministry of Health, Ethiopia (2005:111) reports that although the budget for 
health care services has been increasing over the years. However, the overall health 
expenditure per capita in Ethiopia remains below the US$12 average for Sub-Saharan 
Africa. The funding for health care services in the country is provided both through the 
public and the private sectors.  
 
The Federal Ministry of Health, Ethiopia (2005:112) explains that an estimated 49% of 
the funding which accounts for US$2.77 of the health expenditure per capita in the 
public sector is covered from internal and external sources. Private health service 
utilisation including out-of-pocket spending represents 36% which represents US$ 1.96 
per capita. The contribution of the private sector and non-governmental organizations is 
5% and 10%, respectively.  
 
Barnett and Tefera (2010:4) report that health facilities charge separately for every type 
of service provided including registration, consultation, laboratory investigation and 
inpatient, treatment and other services. As reported by Barnett and Tefera (2010:4) fees 
for drug prescriptions are usually equal to the purchasing price or sometimes above with 
additional cost ranging from 20–40 percent for imported drugs and 5–10 percent for 
local manufactured drugs.  
 
Asfaw and Braun (2005:241) report that market reform actions and expansion of the 
private sector health service has been associated with considerable increase in prices 
for health care services and price of drugs. In an effort to protect the health needs of 
households with low income, fee adjustment and exemptions are wide used in Ethiopia. 
Barnett and Tefera (2010:4) cite that the waiver and exemption system usually lacked 
appropriate targeting and coverage and fee waivers are partial leaving much of the cost 
for drugs and laboratory service left to be covered by the patient.  
 
The Health Sector Development Plan (HSDP III) adopted by the Federal Ministry of 
Health, Ethiopia (2005:29) for the period from 2005–2010 plans to increase health 
service user-fees to improve its share for the overall health spending. The Federal 
Ministry of Health, Ethiopia (2010:30) also aims to introduce a health insurance scheme. 
However, Save the Children UK (2005) contests that the approach may impoverish poor 
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families as they will be forced to sell assets they have in order to meet the required fees 
for the health service they need. According to a sources cited in Barnett and Tefera 
(2010:4) the Federal Ministry of Health of Ethiopia has now developed a plan to 
introduce a nationwide health insurance scheme in the near future.  
 
The overall situation of service delivery in Ethiopia is compounded by lack of equitable 
access and high level of poverty which deters the population from accessing available 
health services. The high cost of drugs and the inability of the community to afford for 
malaria diagnosis and treatment services may lead to the use of other cheap but in 
effective medications such as chloroquine and sulfadoxine-pyrimethamine. In the 
absence of an equitable access to health services, malaria diagnosis and treatment 
services in Ethiopia may face a serious challenge.  
 
2.8 PROFILE OF THERAPEUTIC EFFICACY OF ANTI-MALARIAL DRUGS 
 
Gebremariam and Teklehaimanot (1986:1) report that chloroquine in Ethiopia was the 
most popular, safe, effective and affordable antimalarial drug that has been in use for 
the treatment of all forms of malaria for more than three decades. Although Dennis, 
Doberstyn, Sissay and Tesfai (1974:241) report the tolerance of Ethiopian Plasmodium 
falciparum  parasite strains to a single dose of treatment with chloroquine at 10 mg per 
kilogram of body weight, Plasmodium falciparum  resistance to standard regiment of 
chloroquine at 25 mg/kg has never been reported in Ethiopia until the mid-1980s. 
Armstrong, Asfaha and Palmer (1976:5) also report no recrudescent cases of 
Plasmodium falciparum in a study conducted on 150 patients in four malarious villages 
in the central and western Ethiopia over a follow-up period of 6 to 11 following treatment 
with chloroquine at a dose of 25 mg/kg. 
 
Following reports of increasing complaints on slow response to treatment with 
chloroquine and reports on Plasmodium falciparum resistance to chloroquine in 
neighbouring East African countries of Kenya and Sudan, a study to assess the efficacy 
of chloroquine for the treatment of Plasmodium falciparum was first conducted by 
Gebremariam and Teklehaimanot (1986:1) following the WHO study protocol with a 
follow-up period of 7 and 28 days. In this study conducted in 1983–1984, Gebremariam 
and Teklehaimanot (1986:1) report that  no resistant cases were detected in a total of 
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159 and 133 Plasmodium falciparum  patients treated with 25 mg/kg of chloroquine 
administered over a period of three days and followed for 7 and 28 days, respectively.  
 
Teklehaimanot (1986:127) reports the first cases of chloroquine resistant falciparum 
malaria cases in a follow-up conducted on 28 patients who visited or resided in areas 
bordering Kenya, Somalia and Sudan.  Assefa (1997:209) also reports another 
chloroquine resistant Plasmodium falciparum case in a staff member of the Ethiopia 
National Research Institute of Health who visited the town of Gambella situated in the 
malaria endemic area in Western Ethiopia bordering the Sudan in 1997.  
 
Although the initial reported chloroquine resistant Plasmodium falciparum  cases were 
few in number and restricted to areas bordering other countries, report of chloroquine 
resistant cases started to increase in number and Geographic distribution. Alene and 
Bennett (1996:810) report that out of the 39,824 patients diagnosed and treated with 
chloroquine for Plasmodium falciparum in 36 malaria case detection and treatment 
posts run by the national malaria control program between August 1989 to July 1991, 
around 4% returned back to the posts within two weeks after treatment with complaints 
of no health improvement. Of the returning patients, 87% were confirmed as treatment 
failure cases and treated with sulfadoxine-pyrimethamine (Fansidar®).  
 
The increasing risk of Plasmodium falciparum resistance and the growing concern over 
its efficacy to achieve the intended cure rate, the national malaria control program 
decided to conduct a nationwide representative study. The WHO (2001:34) reports that 
the first nationwide study on the efficacy of chloroquine for the treatment of Plasmodium 
falciparum was conducted in 18 sites by the Ministry of Health in the period from 1997–
1998. According to the WHO (2001:34), an overall chloroquine treatment failure of 65% 
was detected and the finding led to the decision of introducing sulfadoxine-
pyrimethamine (Fansidar®) in 1998 to replace the failing chloroquine as the first-line 
antimalarial drug for the treatment of uncomplicated Plasmodium falciparum. 
 
The WHO (2001:34) report also shows that at the time of introduction of sulfadoxine-
pyrimethamine (Fansidar®), its baseline level of efficacy observed in four study sites 
was 92.3%. However, in a study conducted in 2002, nearly four years after the 
introduction of sulfadoxine-pyrimethamine, Kassa, Mekonnen, Wolde-Micheal, 
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Mohamed and Bulcha (2005:167) report a higher treatment failure rate of 12.7% in one 
study site in Central Ethiopia.  
 
Following these observations and the growing concern and complaints of patients and 
health care providers, a nationwide study on the therapeutic efficacy of sulfadoxine-
pyrimethamine (Fansidar®) was conducted in 10 sentinel sites from October to 
December in 2003. At the end of the study, Jima et al (2005a:391) report a mean 
treatment failure rate of 36% (range 20–54%) which is much higher than the treatment 
failure detected by Kassa et al (2005b:167).  
 
Cognisant of the high treatment failure rates of sulfadoxine-pyrimethamine and expert 
advice and locally confirmed safety and efficacy of artemether-lumefantrine (Coartem®) 
for the treatment of uncomplicated falciparum malaria by Jima, Tesfaye, Medhin, 
Kebede, Argaw and Babaniyi (2005b:387), the Federal Ministry of Health, Ethiopia 
(2004a:8) decides to introduce the ACT, AL, as a first-line drug for the treatment of 
Plasmodium falciparum  malaria in July 2004 while the use of chloroquine for the 
treatment of vivax malaria was recommended to continue.  
 
The efficacy of chloroquine for the treatment of Plasmodium vivax malaria has never 
been widely evaluated in the Ethiopian setting. Tulu, Webber, Schellenberg and Bradley 
(1996:556) report the first chloroquine resistant Plasmodium vivax malaria cases in 
Debrezeit, Central Ethiopia with an overall treatment failure of 2%. Yeshiwondim, Tekle, 
Dengela, Yohannes and Teklehaimanot (2010:105) also report treatment failure of 2.9% 
and 0.74% after treatment Plasmodium vivax cases with chloroquine alone and 
combined administration of chloroquine plus primaquine, respectively.   
 
In later similar studies conducted in Debrezeit and Nazareth, Yohannes, Teklehaimanot, 
Bergqvist and Ringwald (2011:137) confirm Plasmodium vivax resistance to chloroquine 
of 4.8% and Teka, Petros, Yamuah, Tesfaye, Ibrahim, Elhassan, Muchohi, Kokwaro, 
Aseffa, Engers (2008:1) also report Plasmodium vivax chloroquine resistance of 3.5%. 
In a most recent study, Ketema, Bacha, Birhanu and Petros (2009:1) report an even 
higher treatment failure rate of 7% in a study site located in the western part of Ethiopia.  
 
Despite the growing levels of chloroquine treatment failure and confirmed Plasmodium 
vivax resistance to chloroquine, the Federal Ministry of Health, Ethiopia (2004a:7) 
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recommends the continued use of chloroquine for the treatment Plasmodium vivax 
malaria as the reported level of treatment failure is localised and generally less than 
10%. 
 
2.9 ANTI-MALARIAL TREATMENT POLICY CHANGES IN ETHIOPIA 
 
The Ministry of Health (1999:1) develops the first edition of the malaria diagnosis and 
treatment guideline in 1998 following the change from chloroquine to sulfadoxine-
pyrimethamine as the first-line drug for the treatment of Plasmodium falciparum malaria. 
Prior to the first edition of the malaria diagnosis and treatment guideline, all malaria 
prevention and control technical guidelines including malaria diagnosis and treatment 
was bound in a single document. From experience the book known to the malaria 
control program personnel as the "green book" was the main guideline for malaria 
prevention and control activities.   
 
The WHO (2000:34) asserts that malaria diagnosis and treatment guideline change 
process in Ethiopia involved a broad-based discussions and consultations with various 
stakeholders. Revision of the malaria diagnosis and treatment guideline in Ethiopia in 
2004 was initiated after evidence of treatment failure of the drugs in use was confirmed.  
 
The Federal Ministry of Health, Ethiopia (2004a:2) confirms that, antimalarial drug 
efficacy study results are presented to a national workshop for discussion and 
recommendation. In line with approach, a national workshop attended by experts from 
the Ministry of Health, academic and research Institutions, referral hospitals, Regional 
Health Bureaus, drug regulatory authority, the private sector, non-governmental 
organizations and United Nations (UN) agencies such as the WHO and UNICEF was 
convened in May 2004 (2004b:4).  
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The decision involved consideration of the findings of the antimalarial efficacy study, 
recommendations by international organisations such as the WHO and suitability of the 
recommended replacement medicine for use in the local setting. Upon agreement, the 
guidelines were revised by a selected group of experts from the Ministry of Health, 
academic institutions and referral hospitals.  
 
The original versions of the malaria diagnosis and treatment guidelines for health 
workers in Ethiopia were prepared in English. From personal experience, translation to 
other official languages such as Amharic was partly done by the Federal Ministry of 
Health. The regional health offices also translate the guideline in to other official 
languages such as Oromiffa and Tigrigna. In Tigray region where the researcher 
worked, the guideline translated in to Tigrigna were pre-tested and re-checked for 
consistency with the original versions and their technical quality was double checked 
before printing and distribution.  
 
2.10 MALARIA DIAGNOSIS AND TREATMENT PRACTICES IN OTHER 
COUNTRIES: COMMONALITIES AND DIFFERENCES 
 
According to the WHO (2010c:185), malaria treatment in the horn of African region is 
mainly based on clinical diagnosis while microscopy and rapid diagnostic test (RDT) 
based diagnosis and treatment is relatively widely implemented in Djibouti, Eritrea and 
Ethiopia (table 2.3).  
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Table 2.3 Trends in health facility malaria cases and deaths in the Horn of 
Africa, 2005–2009 
Country 
Population 
at risk of 
malaria in 
2009 in 
millions 
and per 
cent at risk 
Diagnosis 
Number of cases by year 
2005 2006 2007 2008 2009 
Djibouti 0.43 (50) 
Suspected 
malaria 3,969 6,457 7,945 6,305 7,120 
Plasmodium 
falciparum  413 1,796 210 119 - 
Plasmodium 
vivax - - - - - 
other malaria - - - - - 
Deaths - 29 1 - 0 
Eritrea 3.6 (71) 
Suspected 
malaria 64,056 49,703 80,428 62,449 77,946 
Plasmodium 
falciparum  7,506 5,750 3,006 1,519 3,358 
Plasmodium 
vivax 1,567 791 6,508 2,832 3,244 
other malaria - - 0 0 0 
Deaths 49 47 42 19 23 
Ethiopia 55.5 (67) 
Suspected 
malaria 4,727,209 3,375,994 2,844,963 3,060,407 4,335,001 
Plasmodium 
falciparum  374,335 293,326 269,514 274,657 594,751 
Plasmodium 
vivax 158,658 149,020 171,710 173,300 287,114 
other malaria - - - - 0 
Deaths 1,086 1,357 991 1,169 1,121 
Kenya 30.2 (76) 
Suspected 
malaria 9,181,224 8,926,058 9,610,691 - 8,123,689 
Plasmodium 
falciparum  - - - 839,904 - 
Plasmodium 
vivax - - - - - 
other malaria - - - - - 
Deaths 44,328 40,079 - - - 
North  Sudan 33.4 (100) 
Suspected 
malaria 2,515,693 2,117,514 4,597,254 4,555,054 4,440,882 
Plasmodium 
falciparum  - - - - - 
Plasmodium 
vivax - - - - - 
other malaria - - - - - 
Deaths 1,789 1,193 1,254 1,125 1,142 
South Sudan 8.9 (100) 
Suspected 
malaria 337,582 116,473 101,008 136,492 325,634 
Plasmodium 
falciparum  - - - - - 
Plasmodium 
vivax - - - - - 
other malaria - - - - - 
Deaths - - - 263 254 
 
(WHO 2011a:194) 
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The malaria diagnosis approaches in the region lacks uniformity and uses a mix of 
clinical and confirmed diagnostic approaches using microscopy and RDTs. The 
coverage of microscopy or RDT based diagnosis in 2009 in the region showed high 
variability ranging from 30% in North Sudan to 55% in Eritrea while data on percentage 
of confirmed malaria is not reported for Kenya and South Sudan. The overall 
percentage of confirmed malaria cases showed remarkable increase in Djibouti, 
Ethiopia and North Sudan diagnostic percentage of confirmed malaria cases in Eritrea 
has been declining (table 2.4).   
 
Table 2.4 Annual trends of malaria cases in the Horn of Africa countries, 2005–
2009 
 
Country Diagnosis 
Annual number of cases 
2005 2006 2007 2008 2009 
Djibouti 
 
Probable and confirmed 2,469 6,457 4,694 3,528 7,120 
% Confirmed malaria 16.7 27.8 4.5 3.4 37.7 
Eritrea 
 
Probable and confirmed 24,192 10,148 19,568 10,572 21,298 
% Confirmed malaria 37.5 64.5 79.5 82.9 55.2 
Ethiopia 
 
Probable and confirmed 3,901,957 3,038,565 2,557,152 2,532,645 3,043,203 
% Confirmed malaria 13.8 14.7 17.7 18.1 34.1 
Kenya 
 
Probable and confirmed 9,181,224 8,926,058 9,610,691 839,904 8,123,689 
% Confirmed malaria No data (ND) ND ND ND ND 
N. Sudan 
 
Probable and confirmed 2,515,693 2,117,514 3,040,181 3,073,996 2,361,188 
% Confirmed malaria 25.0 34.1 22.6 18.5 30.1 
S. Sudan Probable and confirmed 337,582 116,473 101,008 71,948 325,634 
% Confirmed malaria No data ND ND ND ND 
 
(WHO 2010a:185) 
 
The types of antimalarial drugs used in the countries of the region vary. The ACT drug 
artemether-lumefantrine is used as the first-line antimalarial drug in Kenya and Ethiopia 
while the rest of the countries still use combination drugs with partner drugs such as 
amodiaquine and sulfadoxine-pyrimethamine that are long known to have low level of 
efficacy against Plasmodium falciparum parasites in Ethiopia (WHO 2001:34).  
 
The use of artemisinin derivatives such as artesunate in combination with failing drugs 
such as amodiaquine and sulfadoxine-pyrimethamine bears a risk of exposing 
artesunate that may lead to development of resistance by Plasmodium falciparum  
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(Nosten & White 2007:181). The drug of choice for the treatment of Plasmodium vivax 
malaria, chloroquine and primaquine is uniform across all countries of the region. 
However, primaquine, which is essential to fully eliminating Plasmodium vivax parasites 
that may cause relapses, is not included in the Kenya list of antimalarial drugs probably 
due to the low level of Plasmodium vivax malaria in the country (table 2.5). 
 
IPT for the prevention of malaria during pregnancy is with sulfadoxine-pyrimethamine is 
applied in Kenya, North Sudan, South Sudan and Somalia while the intervention is not 
implemented in Djibouti, Eritrea and Ethiopia.  
 
Table 2.5 Antimalarial drugs used for the treatment of malaria in the Horn of 
Africa countries 
 
Country 
Type of antimalarial drugs used by diagnosis 
Unconfirmed 
clinical malaria 
Uncomplicated 
confirmed 
malaria 
Confirmed 
sever malaria IPT8 
Treatment for 
Plasmodium vivax 
Djibouti AS1+SP2 AS+SP QN6  NA9 CQ plus PQ for 14 days 
Eritrea CQ3+SP AS+AQ QN  No  CQ+PQ 
Ethiopia AL4 AL QN  No  CQ  
Kenya AL AL QN SP  None 
Somalia AS+SP AS+SP QN SP  CQ+PQ for 14 days 
North Sudan  AS+SP AS+SP AM7 or QN SP  CQ+PQ for 14 days 
South Sudan  AS+AQ5 AS+AQ QN SP  CQ+PQ for 14 days 
 
Key: 1= Artesunate; 2= sulfadoxine-pyrimethamine; 3= chloroquine; 4= artemether-lumefantrine; 
5=amodiaquine; 6=quinine; 7=artemether; 8= Intermittent presumptive therapy; 9=Not applied. 
 
 
(WHO 2010a:168) 
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2.11 CONCLUSION 
 
The literature search and review findings indicate that malaria is one of the leading 
public health problems in Ethiopia. Although there has been on-going effort to prevent 
malaria in Ethiopia, the socio-economic level of development was not supportive to 
carry the resource intensive malaria prevention and control activities in the country.  
 
The spread of treatment failure and resistance to a number of antimalarial drugs mainly 
by Plasmodium falciparum has been posing serious problems in the effort to ensure 
effective malaria treatment services. Efforts to monitor the efficacy of antimalarial drugs 
and timely action to introduce more effective antimalarial treatment have been 
challenged by lack of coordinated system and monitoring protocol.  
 
The antimalarial drug quality regulatory and quality control monitoring system in the 
country also needs systematised approach to ensure availability, marketing and use of 
antimalarial drug of good quality. The literature search findings also indicate that malaria 
in Ethiopia being mainly of epidemic nature, population in rural areas where the health 
system coverage is low are the most affected. Access to health services is not affected 
only by low coverage, but also by users fees which most of the population can’t afford 
due to the low level of household income in the population. 
 
The WHO (2001:23) provides a list of recommended of antimalarial drug combination 
therapies based on their efficacy and irrespective of cost to be considered when 
selection replacement drugs. Before the selection of the alternative antimalarial drugs, 
the antimalarial drug changing process needs to be based on evidence on the efficacy 
of the antimalarial drug currently in use. Plow (2005:55) asserts the suitability of the in 
vivo antimalarial drug efficacy testing for on-going efficacy monitoring while emphasises 
the importance of using longitudinal studies focused on incidence on uncomplicated 
malaria as the best source of information on which antimalarial treatment policy change 
should be based on.  
 
However, such approaches may not be focused on the main issue that matter which is 
efficacy of the antimalarial drug current in use. To guide the discussion and decision-
making process for antimalarial drug policies, a set of minimum criteria set by the WHO 
(2001:25) is more practical.  
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Currently, the first-line antimalarial drug for the treatment of uncomplicated malaria in 
Ethiopia is AL. At the time of its introduction in 2004, baseline efficacy of the drug was 
99% (Jima et al 2005b:387). However, Kebede, Woyessa, Urga, Messelle and Jima 
(2010:246) report that wider access to the new antimalarial drug access is still a major 
problem due to its cost and recommends the participation of various stakeholders to 
ensure adequate supply and distribution of the ACT drug.  
 
Moreover, treatment based on confirmed diagnosis in Ethiopia is low and most of the 
treatment is provided based on clinical sign and symptom. D'Alessandro and Buttiens 
(2001:845) explain that the use of antimalarial drugs based on clinical diagnosis only 
results in the over utilisation of the antimalarial drugs and is known to facilitate the 
selection of resistant strains through drug pressure.  
 
Historically, resistance to chloroquine was first reported in South East Asia (Hasting 
2004:512). Trape, Pison, Spiegel, Enel and Rogier (2002:224) affirm that In the 1980s 
and 1990s, significant increase of malaria related mortality ranging from 2 to 5.5% 
detected in many African countries has been shown to have been associated with 
decreasing efficacy of the then widely used antimalarial drug chloroquine.  
 
In the Ethiopian context the risk that will contribute to the development of resistance to 
artemether lumefantrine is high due to the marketing of artemisinin oral monotherapies 
that are not recommended by the WHO and the use of less effective artemisinin based 
combination drugs in the neighbouring countries. This situation calls for speedy 
revitalisation of the antimalarial monitoring system and alignment of the drug regulatory 
and quality control approaches in line with international standards.  
 
With these major findings in the background, the next section, chapter 3 presents the 
research design and method designed to conduct the study at depth. In chapter 4, the 
specific data search, collection and analysis approaches are presented in details. The 
research design and methods provides detailed study specific scoring for 
representativeness, timeliness and completeness of the antimalarial efficacy studies 
conducted in Ethiopia and the relevance and use of evidence collected from the studies 
to inform antimalarial drug policy and antimalarial treatment guideline updating.  
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CHAPTER 3 
 
RESEARCH DESIGN AND METHODS 
 
 
3.1 INTRODUCTION 
 
The study was designed to extract and analyse data from antimalarial drug efficacy 
studies conducted in Ethiopia.  The variable collected and analysed in the study varied 
depending on the antimalarial drug efficacy study method employed, the malaria 
parasite species subjected and the antimalarial drug tested. The nature of the data 
collected and analysed, therefore, was the main aspect of the study that determined the 
data collection method and format employed and the design selected. Accordingly, data 
collection was done using different formats for the vivo, in vitro and molecular studies, 
separately. 
 
A description of the study design and approaches used in the original anti-malarial drug 
efficacy studies conducted in the country from which the data was extracted is also 
presented. In the following sections, further details on the research design, methodology, 
study population, data variables, collection and analysis method and ethical 
considerations relevant to the study are presented. 
 
3.2 RESEARCH DESIGN 
 
The study design applied is this research was the epidemiological analytical study 
approach based on analysis of data collected from various antimalarial efficacy studies 
conducted in Ethiopia in the period from 1974 to 2011. The data collected was analysed 
to describe the occurrence of events related to antimalarial drug efficacy failure and 
resistance, its public health significance and implication and the policy related actions 
that were taken as a result of the findings.  
 
The study approach used in the original studies analysed in this research included 
observational, case-control and comparative study designs. In the in vivo method of 
studies, observational studies, subjects who met inclusion criteria were enrolled and 
observed for a pre-defined follow-up period of 7, 14 or 28 days after treatment with the 
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test drug. At the end of the follow-up period treatment outcomes classified based on the 
parasitological and clinical observations were determined and recorded. In the in vitro 
experimental studies, parasite growth in culture medium containing different 
concentration levels of the test drug was used. Genetic analysis of parasite sample 
collected from blood sample of patients with treatment failure was conducted to analyse 
polymorphic gene regions associated with resistance to the antimalarial drug being 
tested taking the gene markers of the same locus from parasites sensitive to the drug 
being used as a comparator.  
 
The epidemiological descriptive study design was identified as the most appropriate 
method for the study. The main reason for the selection of this method was to ensure 
appropriate handling of the variables measured in the source studies that were not 
uniformly the same. The use of meta-analytical study design approach was not 
preferred due to the different types of study designs applied in the original antimalarial 
drug efficacy studies conducted in the country and the diverse variables measured in 
each of the studies which do not permit merging of the data for pooled analysis.  
 
The epidemiological study design can be used to evaluate health interventions and to 
assess the level of delivery and impact of health programs. Martine (2006:98) states 
that data can be extracted from existing information or through data collected using 
epidemiological study design. Cullinan (2006:47) describes that study designs such as 
systematic review for research methodological description and meta-analysis for 
generating quantitative data and inference based on data pooled from separate studies 
are effective when the variables are amenable to pooling. However, these approaches 
were not considered appropriate for this study as the study design and data points 
collected in the original studies varied and the time gaps between some of the studies 
was considerably long.  
 
Moreover, the studies employed different lengths of follow-up duration, tested different 
antimalarial drugs and parasite species and were conducted in different areas where 
the malaria transmission situation is identical. Therefore, to ensure maintaining the 
specific characteristics of the studies, applying the descriptive epidemiological study 
method was preferred. To critically assess previous practices on antimalarial drug 
efficacy studies and to learn from the gaps and shortcoming in in order to improve the 
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use of current evidence for policy, therefore, the application of epidemiological 
descriptive study approaches could provide practical use. 
 
3.3 RESEARCH METHOD 
 
3.3.1 Sampling 
 
3.3.1.1 Study population 
 
The population included in the original studies reviewed in this research included 
predominantly residents in places where active malaria transmission occurs. In some 
isolated cases, antimalarial efficacy studies were also conducted in areas where malaria 
transmission does not normally occur, such as the capital Addis Ababa, in patients who 
contracted the infection elsewhere.  
 
In the studies conducted between the years from 1996 to 2002, a study protocol for the 
in vivo assessment of the therapeutic efficacy of antimalarial drugs for the treatment on 
uncomplicated Plasmodium falciparum infections developed by the WHO (1996:2) was 
used. This protocol was mainly developed for the assessment of antimalarial drug 
efficacy in areas with intense malaria transmission and primarily recommends the 
enrolment of patients aged 6 to 59 months who meet the clinical and parasitological 
criteria for inclusion in the study (WHO 1996:7). 
 
Enrolment of children less than five years of age is generally recommended for the 
evaluation of the efficacy of antimalarial drugs as this age group is the most vulnerable 
to severe malaria and have low level of protective immunity (WHO 2003:7). However, in 
case of lack of adequate number of subjects in this age group who can meet the criteria 
for inclusion, children above five years of age and adults who can meet inclusion criteria 
(WHO 1996:6) were included in the studies. Therefore, meeting the inclusion criteria 
was more determining and the reliance of age limits was not strictly delineated. 
 
Malaria in Ethiopia is seasonal and of epidemic type characterised by low transmission 
(Adhanom et al 2006:556). In areas where malaria transmission is low, the WHO 
(2003:33) recommends the enrolment of children above five years of age and adults. 
Based on this provision, the study population enrolled in most of the studies conducted 
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in Ethiopia involved children above five years of age and adults who met the specific 
clinical and parasitological criteria for enrolment in the study, with the exception of 
infants under six months of age and pregnant women. Infants and pregnant women 
were not included in the studies reasons related to their biological state that makes 
them vulnerable to malarial infection that requires prompt and highest level possible 
care.  
 
The Ethiopian Science and Technology Commission (2005:7) guideline for health 
research ethics enforces compliance to the WHO and International Conference on 
Harmonization guidelines for good clinical practice. Accordingly, the antimalarial drug 
efficacy study protocol developed by the WHO was selected in line with the Ethiopian 
guidelines for health research ethics. 
 
3.3.1.2 Sampling 
 
This study aimed to achieve complete review of all available published and unpublished 
antimalarial drug efficacy studies conducted in Ethiopia. Accordingly, the approach was 
to achieve full coverage of review of all available documents and publication without a 
specific need for sampling. Although total coverage of all studies was considered in this 
study, describing the sampling approach employed in the original studies is of relevance.  
 
The sample size determination approaches used in the original studies was not well 
explained in most of the studies while some studies had a clear sampling approach and 
sample size determination. The major nationwide studies conducted in Ethiopia in the 
late 1990s involved the Double Lot Quality Assurance sampling that allows minimum 
sample size without compromising statistical precision (WHO 1996:16).  
 
In most of the recent studies conducted in the 2000s, sample size determination based 
relevant statistical assumptions and approaches were employed. For example, to detect 
treatment failure of 20% in the population with 10 percentage point precision at 95% 
confidence interval and study power of 80, a sample size of 73 subjects including a 
contingency of 20% for loss and withdrawal was considered. Irrespective of such 
statistical sampling approaches, the WHO (2003:46) study protocol for antimalarial drug 
efficacy tests recommends a minimum of sample size of 50 as adequate to generate 
evidence required to support antimalarial drug policy decisions. 
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3.3.1.3 Ethical issues related to sampling 
 
The sample selection in the original antimalarial drug efficacy studies was based on 
enrolment of patients who met the inclusion criteria. Once the inclusion criteria were met, 
patients were informed of the objectives of the study and requested to express their 
consent verbally or in writing on whether they wished to participate in the study.  
 
To ensure protection of safety of patients, investigators in the reviewed studies 
indicated that patients who had clinical conditions that require further medical attention 
and support were referred to the nearest health facility for further care. For patients 
whom, during the follow-up period, had confirmed treatment failure or resistance to the 
antimalarial drug being tested, rescue treatment with other effective antimalarial 
medicines was placed.  
 
The sampling considered in this study, aimed to ensure review of all available study 
publications and documents on antimalarial drug efficacy studies conducted in Ethiopia. 
Therefore, no study was excluded on any ground or no study was preferred than the 
other. Therefore, by ensuring review of all available antimalarial drug efficacy studies 
conducted in Ethiopia, the sampling followed ethically correct approach of all-
inclusiveness.  
 
3.3.2 Data collection 
 
3.3.2.1 Data collection approach and method 
 
The study didn’t involve the use of raw secondary data that could have required 
permission from the originators. Data from the published and unpublished studies was 
extracted and entered in to a Microsoft Excel (Microsoft Corporation 2009) based data 
collection form. As the studies involved different methods that included in vivo, in vitro 
and genetic analysis methods, the variables measured in each of the studies were not 
uniform. Although collection of the data from the studies related to the findings, 
conclusions and recommendations was relatively manageable, the relevance of findings 
and recommendation and the follow-up action that will be taken was mostly unavailable 
or loosely mentioned in the publications and reports.  
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The data collection was done through internet based search using Internet Explorer 
version 8 (Microsoft Corporation 2009). Library search for periodicals, mainly at the 
WHO library in Geneva was done to access early publications and reports for which 
electronic versions were not available. The internet based search mainly relied on 
search engines such as the Google Scholar (2011), NCBI (2009), the University of 
South Africa library online services (University of South Africa 2011). 
 
The main search words used included a combination of the following key words: 
Ethiopia, malaria, treatment policy, antimalarial drugs, treatment failure, resistance, 
efficacy, Plasmodium falciparum, and Plasmodium vivax. For specific search on articles 
whose authors were known, the name of the author together with the key search words 
was used. For country specific information on health service system in general and 
malaria prevention and control services in particular, drug regulatory issues and other 
relevant health and socio-economic information, specific web-sites of the organisation 
run by the government of Ethiopia and other non-governmental and United Nations 
organizations' web sites were consulted.  
 
To ensure review of the antimalarial drug efficacy and treatment policy in Ethiopia in 
light of the regional context, antimalarial drug policies and antimalarial drug efficacy 
monitoring system in the neighbouring Horn of African countries, namely: Eritrea, 
Djibouti, Kenya, Somalia and Sudan was conducted. The main data search approach 
used was websites based mainly the WHO and country specific scientific publications 
and reports. In addition to the internet based search on websites of institutions such as 
the WHO, publications and reports of regional antimalarial treatment monitoring 
networks of the East African Network for Monitoring Antimalarial Treatment (EANMAT) 
and the Horn of African Network for Monitoring Antimalarial Treatment (HANMAT) were 
consulted.  
 
The search for publications started in November 2010 and 420 articles and reports were 
obtained of which relevant data and information was cited from 231 published and 
unpublished reports and web based resources. In additions to the publication and 
reports, text books relevant to the study subject have been consulted and referenced as 
appropriate. 
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3.3.2.2 Development and testing of the data collection instrument 
 
The data collection tool used to capture data from the published and unpublished 
studies was developed using Microsoft Excel (Microsoft Corporation 2003). The tool 
was designed to suit collection of the variables measured in each of the studies. 
Although no special field testing was necessary to test the data collection format, its 
appropriateness has been assessed during the course of the data collection.  
 
Through this process, the data collection format was regularly revised to suit the 
purpose based on actual experience obtained during its use. Depending on the type of 
the antimalarial drug study method, separate data entry and analysis sheets were used 
for the in vitro, in vivo and genetic methods of study for each parasite species studied 
and the antimalarial drug tested.  
 
3.3.2.3 Characteristics of the data collection instrument 
 
The data collection instrument used in this study was specifically constructed for the 
purpose of the study based on the type of variables in the original studies that were 
targeted for collection and analysis. A total of 30 data variables were collected 
(Annexure B). 
 
Depending on the type of the study technique such as in vivo, in vitro and molecular 
methods and the type of parasite and antimalarial drugs assessed, all the 45 data 
variables were not uniformly applicable to all and varied accordingly. The characteristics 
of the data collection formats are, therefore, mainly distinguished by the type of 
variables each format captures. Based on this approach, a total of 10 different data 
collection sections were developed and used. The data collection tool included the 
following section:  
 
a) in vivo therapeutic efficacy assessment of chloroquine for the treatment of 
Plasmodium falciparum  malaria (for published studies) 
b) in vivo therapeutic efficacy assessment of chloroquine for the treatment of 
Plasmodium falciparum  malaria (for unpublished reports) 
c) in vitro Plasmodium falciparum  sensitivity test to chloroquine  
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d) molecular marker analysis on Plasmodium falciparum  and Plasmodium vivax to 
analyse genetic markers related to resistance to AL, Quinine and Atovaquone 
proguanil 
e) in vivo therapeutic efficacy assessment of amodiaquine for the treatment of 
Plasmodium falciparum  malaria 
f) in vivo therapeutic efficacy assessment of sulfadoxine-pyrimethamine for the 
treatment of Plasmodium falciparum  malaria 
g) in vivo therapeutic efficacy assessment of chloroquine for the treatment of 
Plasmodium vivax malaria 
h) in vivo therapeutic efficacy assessment of chloroquine plus primaquine for the 
treatment of Plasmodium vivax malaria 
i) in vivo therapeutic efficacy assessment of artemether-lumefantrine for the 
treatment of Plasmodium falciparum  malaria 
j) in vivo therapeutic efficacy assessment of artemether-lumefantrine for the 
treatment of Plasmodium vivax malaria 
 
3.3.2.4 Data collection process 
 
The data collection process first involved search for published and unpublished 
antimalarial efficacy studies from as early period available until 2011. Copies of the 
articles were saved electronically and in printed versions. Once the search was 
completed, the articles and reports were classified based on the method of the study 
employed, the malaria parasite studied and the antimalarial drug evaluated.  
 
Following grouping of the studies, data variables available in the reports were extracted 
and entered into the relevant data collection format developed on Microsoft Excel 
(2003).  
 
3.3.2.5 Ethical considerations related to data collection 
 
The data collection and analysis was based on data extracted from published and 
unpublished reports. In the data collection and analysis and interpretation, 
confidentiality was maintained by strictly ensuring the collection and analysis of data 
without making any reference to individuals or their identity. In the selection of the 
studies for analysis, fairness was ensured by including findings from all antimalarial 
  
70 
drug efficacy studies conducted in the country. There was no any study excluded from 
being considered in the analysis for any reason whatsoever and the findings of each of 
the studies were fairly and equally reflected in the study without any sentiment of 
judgment.  
 
The researcher has also verified from the reports if the investigators and subjects 
enrolled in the original studies had adhered to standard ethical practices. In all the 
studies reviewed, researchers confirmed that patient enrolment and participation in the 
studies was fully voluntary and based on informed consent and the required ethical 
clearance was obtained from relevant institutional and national authorities prior to the 
conducting the studies. With the exception of a three studies, most of studies ensured 
verbal consent and didn't use consent forms.  
 
The investigator asserts that the principal pillars of health research ethics (Pilot & Beck 
2008:167) that refer to non-maleficence, beneficence, respect for autonomy, and justice 
were adhered to by the researchers who conducted the original studies. This is 
confirmed from the reports which confirmed attainment of ethical clearance by 
responsible institutional or national authorities, informed consent of participants and the 
rescue interventions placed in order to provide the necessary medical support to ensure 
safety of patients. This study obtained ethical clearance by the University of South 
Africa Ethics Committee (Annexure A). 
 
3.3.3 Data analysis 
 
The statistical tests applied in the original studies included proportion of treatment 
failure and Kaplan Meier survival analysis with 95% confidence intervals and 
significance level of 0.05. In some studies that involved comparison of two different 
antimalarial drugs, a case-control approach of study design was applied and analysis 
outcomes presented in terms or proportion of treatment success or failure with the 
corresponding 95% confidence intervals at significance level of 0.05.  
 
In the analysis, comparison of the proportion of treatment failures reported by each 
study and the level of significance of the treatment failure detected was compared for 
each of the studies. Based on the comparison, the approaches used in the studies have 
been assessed. 
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A Microsoft Excel (Microsoft Office Excel 2003) based data entry and analysis was 
applied to calculate proportions, mean, median and range using the therapeutic efficacy 
data collected from the relevant studies. Statistical test such as comparison of 
proportions and determining the corresponding 95% CI (confidence interval) and P-
values was also calculated for study findings that required comparison. For the purpose 
of statistical analysis, Statistical Package for Social Sciences (SPSS) version 10 (SPSS 
Inc 2007) and MedCalc version 11.6 statistical software for biomedical research 
(MedCalc Software 1993-2011) were used as necessary.  
 
The main variables analysed include treatment failure rates through comparison of 
proportions of treatment failure. This comparison was used to test for significance of 
difference between study findings for which comparison was needed. Assessment 
related to the time duration between antimalarial drug efficacy studies was also one of 
the variables considered to determine the extent of timeliness and regularity of the 
studies. The time lapse between antimalarial drug treatment efficacy study reports that 
led to antimalarial drug policy and treatment guideline change and activities related to 
antimalarial drug efficacy monitoring in the interim period was also one of the most 
important features assessed.  
 
The main aim of this study was to assess the representativeness, timeliness and 
completeness of antimalarial drug efficacy studies to inform policy decision. Based on 
this a conventional numeric scoring was used to grade the representativeness, 
timeliness, completeness and adequacy of the studies to inform policy decision based 
on the scoring described below (table 3.1).  
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Table 3.1 Antimalarial drug efficacy study representativeness, timeliness and 
completeness scoring 
 
 
  
Measure  Score Attribute 
Representativeness 
 
0 
 
Sample size below 50 and number of study sites below four and study 
subjects pre-selected 
 
 
1 
 
 
Meets the minimum sample size of 50 or more and more than 4 study 
sites and study subjects selected on presentation  
 
 
2 
 
 
Meets both the minimum sample size and number study sites and 
subject selection approach 
 
Completeness 
 
0 
 
 
No blood film examination re-check, no drug quality analysis and no 
blood level of drug administered determined 
 
 
1 
 
Only one of the three tasks met  
 
 
2 
 
Only two of the three tasks met 
 
 
3 
 
All the three tasks completed 
 
Timeliness  
 
0 
 
Study conducted after two years from the date of publication of the 
preceding study 
 
1  
Study conducted within two years from the date of publication of the 
preceding study 
 
Study adequacy to 
inform policy  
Yes or 
No 
 
Yes = Study achieved a score of above 60%, 
No = Study achieved a total score of 60% of less 
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3.4 INTERNAL VALIDITY AND EXTERNAL VALIDITY OF THE STUDY 
 
Polit and Beck (2008:295) defines internal validity as the extents of certainty of the 
effect of interventions on the outcomes while external validity is the applicability of the 
research findings in the real world beyond the controlled research setting. 
 
The sampling approach used in this study aims to ensure review of all published and 
unpublished studies on antimalarial drug efficacy conducted in Ethiopia. The fact that all 
available sources are covered in the study ensures that the highest possible sample 
size was considered for the study. Therefore, the risk of having findings and conclusions 
that are based on unrepresentative sample is minimal.  
 
The conclusions derived from this study being exhaustive in covering all published and 
unpublished studies has enabled to avoid errors that might have arisen from low 
sampling. The data collection tool used to extract the data also picks all the relevant 
variable data points that are used to measure the level of antimalarial treatment failure. 
Therefore, appropriate approach and data collection and analysis has been used to 
measure the main outcome variables of this study that are related to representativeness, 
timelines and completeness of antimalarial drug efficacy studies in Ethiopia.  
 
Based on the findings on representativeness, timeliness and completeness of 
antimalarial drugs conducted in Ethiopia, it was also possible to assess if this was 
adequate to inform antimalarial treatment policy decisions and development of malaria 
treatment guidelines that appropriate to the Ethiopian setting. The specific issues 
related to sampling, study power and precision of the instruments used in the original 
studies was critically reviewed and presented in the chapter 5 that covers the study 
findings.  
 
3.5 CONCLUSION 
 
The research method and design presented in this chapter provided detailed description 
and justification on the type of design applied and components of the research method. 
In the research method section, specific description on the study population, sampling, 
data collection instrument and its characteristics and data analysis was covered.  
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In this chapter, ethical issues at the stage of sampling and data analysis have been 
described asserting that the standard followed was driven to meet high ethical 
standards. A detailed description on the internal and external validity of the research 
was also presented with a specific explanation on how this was achieved in the study.  
 
In the following chapter 4, analysis, description and presentation of the research 
findings is presented based on the data collection and analysis approaches explained in 
chapter 4. The relevance of the research findings in terms of representativeness, 
completeness and timeliness and completeness of antimalarial drug efficacy studies in 
Ethiopia and its relevance to informing antimalarial treatment policy and guideline 
development is also one of the main elements presented in chapter 4.  
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CHAPTER 4 
 
ANALYSIS, PRESENTATION AND DESCRIPTION OF THE RESEARCH 
FINDINGS 
 
 
4.1 INTRODUCTION 
 
The research design and method in chapter 3 presented the approaches applied in the 
data collection and analysis. In chapter 4, the research findings are presented with the 
relevant analysis and description of the findings in relation to antimalarial drug efficacy 
studies representativeness, completeness and timeliness and its implication and 
adequacy to inform antimalarial drug policy and malaria treatment guidelines in Ethiopia.  
 
The type of data collected from the antimalarial efficacy studies conducted in Ethiopia 
varied depending on the study method applied, the antimalarial drug tested and the 
parasite species subjected. In addition to these differences, the antimalarial drug 
efficacy assessment protocols and the specific study approaches employed by the 
researchers have not been uniform.  
 
As a result of such differences, which in most cases are quite unambiguous, the data 
collection and analysis approach has been tailored to suit the design of the studies and 
findings have been grouped accordingly to the category they fall into. Based on this 
approach the study findings from in vivo, in vitro and molecular studies by type of 
antimalarial drug evaluated and the malaria parasite species subjected and the duration 
of the study and findings reported have been complied and analysed.  
 
While the broader approach was to critically review finding from all studies, the main 
focus of the analysis was on in vivo antimalarial drug efficacy studies as this method is 
the recommended data collection approach to guide antimalarial treatment policy 
decisions (WHO 2009a:9). The modelling approach to antimalarial treatment policy 
change based on financial implication of antimalarial treatment policy change proposed 
by Yeung Pongtavornpinyo, Hasting, Mills and White (2004:179), seem to focus more 
  
76 
on the budgetary implication of treatment policy change than the public health problem 
that need to be addressed.  
 
The strengths and gaps in antimalarial drug efficacy monitoring and the use of evidence 
for policy and guideline development has been critically assessed in order to draw 
recommendations and best practice approaches for the Ethiopian setting. The data 
collection and analysis has also taken in to considerations antimalarial drug monitoring 
practices in the neighbouring countries where the malaria transmission epidemiology 
shows some similarity.  
 
The common pattern of seasonal malaria transmission in the Horn of African countries 
and the similar profile of parasite response to antimalarial drugs indicated in the WHO 
(2005a:103) envisages a harmonised approach to defining and applying the antimalarial 
treatment options. In this chapter, findings and analysis of the study is presented in 
relevant sections grouped according to their focus and outlines the strength and gaps of 
the studies conducted and their implications to influencing antimalarial treatment policy 
decision making and updating antimalarial treatment guidelines in Ethiopia.  
 
4.2 DATA MANAGMENT AND ANALYSIS 
 
4.2.1 Data collection and analysis approach 
 
The data extracted from published and unpublished studies was entered and analysed 
using a Microsoft Excel based data management tool that has ten different sections 
suitable for the different types of the study approaches used.   
 
The data collected included values for a total of 30 variables of which 15 variables that 
are of high relevance to the study objectives were selected for in-depth analysis. The 
variables collected included data related to study area and population, test drug type 
and batch, expiry date, study findings, duration to dissemination of the study findings 
and its implication to antimalarial drug policy and treatment guideline change.  
 
The number of variables collected and analysed do not apply for all types of studies. In 
vivo therapeutic efficacy studies, for example, have more data variables compared to 
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the in vitro parasite sensitivity assessment studies to antimalarial drugs and molecular 
methods of analysis.  
 
The overall data collection and analysis was designed to provide summary measure 
that can be used to assess the representativeness, timeliness and completeness of the 
studies conducted in Ethiopia. A detailed list of the variables and summary measures 
considered during the analysis is presented in Annexure B. The main measures used 
during the analysis include the following: 
 
a) Study design  
i Study protocol for the setting  
ii Samples size 
iii Parasite species studied  
iv Antimalarial drugs tested  
v Number of study sites 
vi Duration of patient follow-up 
 
b) Test drug 
i Quality analysis of the antimalarial drug tested for active ingredient 
ii Blood level of drug and its metabolite at the date of confirmed treatment 
failure 
 
c) Study quality control 
i Slide examination result cross-checking by a second  
 
d) Study outcomes / in vivo therapeutic efficacy studies  
i Total number of subjects who completed the study  
ii Per cent total treatment failure   
iii Per cent treatment failure (Plasmodium vivax) 
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e) Study findings and policy implication 
i Number of years lapsed since the immediate previous similar antimalarial 
drug efficacy study 
ii Implication of the findings on antimalarial drug policy and treatment 
guidelines 
iii Changes introduced as a result of the study findings 
 
4.2.2 Detailed review and data analysis to determine adequacy of the studies 
 
Study reports from published and unpublished sources have been individually reviewed 
to determine completeness, timeliness, representativeness and policy actions taken as 
a result of the study finding and recommendations.  Analysis of the studies to estimate 
the representativeness, timeliness and completeness was done based on a numeric 
score attained by each of the studies and a scoring approach presented in table 4.1. 
Based on this assessment and scoring, the adequacy of the studies to informing 
antimalarial drug policy decision in Ethiopia is presented in section 4.6.  
 
4.3 RESEARCH RESULTS 
 
4.3.1 Overview of antimalarial drug studies conducted in Ethiopia 
 
Published and unpublished reports reviewed through this research show that the first 
antimalarial drug testing in Ethiopia was conducted in 1974 by Dennis et al (1974:241). 
In the period from 1974 to 2011, a total of 28 published and unpublished documents on 
44 antimalarial efficacy studies involving 5,949 study subjects in 159 study sites across 
the country have been conducted. Of these, 26 of the reports on 39 studies (89%) were 
published in peer-reviewed journals while 2 reports on 5 (11%) studies conducted by 
the Federal Ministry of Health in 1997–1998, the findings of which led to the treatment 
policy in 1998 were not published in peer reviewed journals.  
 
  
  
79 
The studies were conducted to assess the efficacy of nine different antimalarial drugs 
which the majority of 24 (55%) were on chloroquine, 8 (18%) on sulfadoxine-
pyrimethamine and 6 (14%) on AL. Most of the studies (80%, n=35) were conducted to 
assess the efficacy of five different antimalarial drugs used as first second-line 
antimalarial drugs for Plasmodium falciparum malaria while the remaining 9 (20%) 
studies were conducted to assess four different antimalarial drugs for the treatment of 
Plasmodium vivax infections.  
 
The antimalarial drug assessment technique involved in vitro methods in 4 (9%) of the 
studies and in vivo and genetic analysis methods in 34 (77%) and 6 (14%) of the 
remaining studies, respectively. Most of the in vivo studies (69%, n=20) conducted 
involved a period of follow-up of seven or 14 days while the remaining (41%, n=14) in 
vivo studies involved a follow-up period of 28 days. A summary of the studies conducted 
in Ethiopia is presented in table 4.1.  
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Table 4.1 Summary of antimalarial drug studies conducted in Ethiopia, 1972–
2011 
 
Test Drug, 
Parasite Study protocol Studies Sites Sample Outcome Year 
Chloroquine, 
 
Plasmodium 
falciparum   
In vitro 4 7 130 0--70%a 1974–1985 
Genetic analysis 1 1 69 78.3--95.7b 2006 
In vivo 7 days  1 55 2015 0—100c 1980–1996 
In vivo 14 days 1 24 837 47.7--73.6c 1998 
In vivo 28 days 2 12 213 0--22.4c 1985 
Sulfadoxine-
pyrimethamine  
 
Plasmodium 
falciparum  
In vitro - - - -  - 
Genetic analysis 1 1 69 81.2-82.6 a 2006 
In vivo 7 days  2 2 12 0--1.3b 1993–1996 
In vivo 14 days 3 9 369 5.6--21.1c 1998–2002 
In vivo 28 days 1 11 523 33.5 c 2003 
Artemether-
lumefantrine  
 
Plasmodium 
falciparum  
In vitro - - - -  - 
Genetic analysis r 1 1 35 0 2010 
In vivo 7 days  - - - - - 
In vivo 14 days 1 2 105 0 2006 
In vivo 28 days 2 5 294 0.9--6.7c 2003–2010 
Quinine   
 
Plasmodium 
falciparum  
In vitro - - - - -  
Genetic analysis 1 1 30 0 2010 
In vivo 7 days  - - - - -  
In vivo 14 days - - - - -  
In vivo 28 days - - - - -  
Atovaquone-
proguanil 
 
Plasmodium 
falciparum  
In vitro - - - - -  
Genetic analysis 1 1 32 0 2010 
In vivo 7 days  - - - - -  
In vivo 14 days - - - - -  
In vivo 28 days - - - - -  
Chloroquine  
 
Plasmodium vivax 
In vitro - - - - -  
Genetic analysis - - - - -  
In vivo 7 days  1 1 255 2  1997 
In vivo 14 days 5 7 298 3.6--8.8c  2008–2011 
In vivo 28 days      
Sulfadoxine-
pyrimethamine  
 
Plasmodium vivax 
In vitro - - - -  - 
Genetic analysis 1 1 31 3.2-6.5 2010 
In vivo 7 days  - - - - - 
In vivo 14 days - - - - - 
In vivo 28 days - - - - - 
Key for outcome  
a= per cent parasite growth in culture medium with chloroquine of greater than 1.5 nmol 
b= per cent samples with one or more gene polymorphic regions that conform resistance  
a= per cent of treatment failure cases  
  
81 
4.4 CHARACTERISTICS OF THE STUDIES 
 
4.4.1 Sample characteristics 
 
The review included all published and unpublished studies available with no specific 
need for sampling. The review being all inclusive, the presentation and analysis of the 
findings and the conclusion that can be drawn based on the analysis is expected to 
representative. The characteristics of the studies reviewed can be best described based 
on the objective of the assessment, method of study applied, sample size considered 
and implication of the study finding.  
 
In general, the studies reviewed involved sample size ranging from 1 to 1,706. The 
study referred to as having a sample size of 1 was a case report by Assefa (1987:209). 
Most studies did not present a detailed sampling approach and statistical assumption 
the sampling was based on. Although this can be a reasonable generalisation of the 
sampling characteristics of the antimalarial efficacy studies conducted in Ethiopia, the 
specific details of the sampling approach is presented under the specific study in the 
following sections.  
 
4.4.2 Study subjects 
 
Detailed methodological description of the antimalarial drug studies conducted in 
Ethiopia presented that, the studies were conducted on patients who met the inclusion 
criteria for the study and who consented voluntarily to take part in the study. In all 
studies, infants below six months of age and pregnant women were not included 
because of their biological vulnerability to malarial infection.  
 
Of the total 49 studies reviewed, 4 (8%) studies conducted in 36 (22%) of the study 
sites involved participation of 1,039 (15%) children from the age of 6 to 59 months. The 
remaining 44 (92%) studies in 129 study sites involving 5,830 (85%) study subjects 
were conducted in subjects in the five years of age and above category. In any of the 
studies, there was no specific mention of the highest age limit for study eligibility. The 
main groups that were strictly excluded were infants and pregnant women while 
inclusion of all other subjects was mainly based on meeting the specific inclusion criteria 
for the study. 
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4.4.3 Study site distribution 
 
The antimalarial efficacy studies conducted in Ethiopia were predominantly in malaria 
endemic localities. The only two studies exception to this are those conducted by 
Dennis et al (1974:241) and Teklehaimanot (1986:127) that were conducted in the 
capital Addis Ababa where malaria transmission does not normally occur.  
 
A total of 41 subjects aged between 5–44 years and 98 subjects aged between 14 to 58 
years were enrolled in the studies conducted by Dennis et al (1974:241) and 
Teklehaimanot (1986:127) respectively. Based on the travel history recorded at the time 
of enrolment in the study, none declared permanent residence in malarious localities but 
temporary visits and stays in malarious localities bordering the Sudan and Kenya.  
 
A total of 10 studies (54%) were conducted involving only one study site while 15 (35%) 
studies involved 2 to 7 study sites with the remaining 4 studies involving 11 to 36 sites. 
The WHO recommends the use of 4–8 study sites depending on the size of the country 
and the malaria transmission epidemiology for a study to be representative.  
 
4.4.3 Study protocols 
 
The antimalarial drug efficacy study protocols used in Ethiopia are the protocols 
developed by the WHO updated in 1967 and 1972 which was further revised in 1996, 
2001 and 2009, in a bid to address the appropriateness of the study protocols with the 
evolving pattern of efficacy of antimalarial drugs and drug resistance malaria endemic 
countries (WHO 2010a:15).  
 
As a reflection of the evolution of the antimalarial drug efficacy monitoring protocol, 
antimalarial drug efficacy study protocols used in Ethiopia employed follow-up period of 
7-days, 14-days and 28 days (Table 4.1). The appropriateness and adequacy of the 
follow-up duration and the advantages and disadvantages are presented in section 4.5 
of this chapter.  
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4.5 DETAILED REVIEW OF THE ANTIMALARIAL DRUG STUDIES 
 
4.5.1 Early studies on sensitivity of Plasmodium falciparum to chloroquine 
 
Early studies conducted in Ethiopia provided information on the sensitivity of 
Plasmodium falciparum  to single dose of chloroquine administered at 10 mg/kg, Since 
then a number of studies have been conducted.  
 
The objective and set-up of the studies, however, has never been fully described in the 
context of its implication to antimalarial treatment policy in Ethiopia. In this section, 
therefore, the studies conducted beginning from the early 1970s, which marks the 
starting of studies on the sensitivity of Ethiopian Plasmodium falciparum strains to 
antimalarial drugs is described and assessed.  
 
4.5.1.1 In vitro studies 
 
The first published study on the sensitivity of Plasmodium falciparum to chloroquine was 
conducted in vitro by Palmer, Townley, Yigzaw and Armstrong (1976:10) in the period 
from 1971–1972. The study involved 82 patients diagnosed for Plasmodium falciparum 
in three field stations of the United States Naval Medical Research Unit 5 (NAMRU 5) 
located in central and western parts of Ethiopia.  
 
The testing involved exposure and evaluation of parasite development in vitro in test 
vials containing 0.5, 0.75 and 1 nmol (nano mole) of chloroquine. Of the 82 parasite 
samples, 21 (25.6%) parasite samples showed continued growth and development in 
test vials containing 0.5 nmol of chloroquine while no growth was observed in the 0.75 
and 1.0 nmol drug containing test vials. In this study no simultaneous in vivo evaluation 
of the therapeutic efficacy of chloroquine was conducted. 
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4.5.1.2 In vivo and in vitro simultaneous Plasmodium falciparum sensitivity 
studies to chloroquine 
 
Dennis et al (1974:241) conducted a study involving simultaneous in vivo and in vitro 
evaluation of Plasmodium falciparum sensitivity to chloroquine at the NAMRU-3 hospital 
in Addis Ababa, Ethiopia. The individuals involved in the study were presumed to have 
encountered the infection in other malarious parts of the country as the study site, Addis 
Ababa, is a predominantly malaria free highland area. The primary aim of the study was 
to describe and define the clinical significance of in vitro sensitivity study findings.  
 
The in vivo follow up was done over a period of 28 days following treatment of subjects 
with confirmed Plasmodium falciparum mono-infection with 10 mg/kg single dose of 
chloroquine. The in vitro test involved exposure of the test parasite, Plasmodium 
falciparum, to drug concentrations of 0.5, 0.75 and 1.0 nmol of chloroquine. The findings 
of the study presented in table 4.2 showed 11 recrudescent cases over the 28-day 
follow-up and in vitro tolerance in 9 (37.5%) cases in test medium with 0.5 nmol and 5 
(20.8%) in the 1.0 nmol test vials.  
 
This finding clearly showed an increase in the number of chloroquine tolerant strains as 
parasite growth in the 1.0 nmol chloroquine concentration was not detected in the 
previous study by Palmer et al (1976:10). The conclusion drawn from the study was that, 
sensitivity of Ethiopian Plasmodium falciparum strain was between the sensitive 
Ugandan strain and the resistant Malayan strain indicating a relatively higher tolerance 
of the Ethiopian strain to chloroquine in the African region.  
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Table 4.2 In vivo and in vitro Plasmodium falciparum sensitivity study to 
chloroquine in Ethiopia, 1972 
 
Details Drug Evaluation Method In vivo In vitro 
No. of study sites 1 1 
 
No. of patients 
enrolled 
 
41 
 
24 
 
Study protocol 
 
In vivo 28-days test 
 
Rickemann in vitro test 
 
Test dosage 
 
10 mg/kg single dose 
 
0.5; 0.75 & 1 nmol 
 
Outcome 
 
11 recrudescent cases  
 
9 (37.5%) cases at 0.5 nmol, & 5 (20.8%) 
cases at 1 nmol 
 
(Dennis et al 1974:241) 
 
4.5.1.3 Second in vivo Plasmodium falciparum sensitivity test to single dose 
chloroquine 
 
A second in vivo test on the sensitivity of Plasmodium falciparum to 10 mg/kg single 
dose chloroquine was conducted by Armstrong, Asfaha and Palmer (1976:10) in a field 
setting. A total of 150 patients were recruited for the study in three endemic sites 
located in Arbaminch, Abela and Gambella in the Southern and Western parts of 
Ethiopia. After a follow-up period of 6 to 11 days, the team reported no recrudescent 
cases but sited the limitations of the study related to the logistic difficulty that hindered 
from completing a 28 days follow and assessment of treatment outcome.  
 
Compared to the previous studies, this study adopted a limited period of follow-up that 
does not allow complete evaluation of the efficacy of the antimalarial drug tested and 
the results from the finding were not supportive to take any action.  
 
4.5.1.4 Studies conducted in the early 1980s 
 
For nearly eight years from the study by Armstrong et al (1976:5), no chloroquine 
sensitivity studies were conducted. Following this long period, Gebremariam, Abdullahi 
and Mebrate (1982:1) conducted in vivo chloroquine efficacy study in Nazareth town, 
Central Ethiopia. In this study, a total of 21 subjects were enrolled for in vivo evaluation 
of Plasmodium falciparum response to 25 mg/kg of chloroquine administered over three 
  
86 
days and 14 isolates were subjected in vitro to chloroquine concentration levels ranging 
from 0.25 to 3 nmol.  
 
The findings at the end of the study summarised in table 4.3 showed no early treatment 
failure cases of the RI and RII type while parasite growth was recorded in 7 (50%) 
cases in test vials containing 0.5 nmol chloroquine; 2 (14.3%) cases in 0.75 nmol and 1 
(7%) case in 1.0 nmol. These finding led the investigators to conclude that the study 
findings were similar with the results of earlier studies reported by Dennis et al 
(1974:241) and Armstrong et al (1975:5) but called for more extensive and detailed 
study to be conducted.  
 
Comparing the results from this study and the results reported by Dennis et al 
(1974:241), there was no significant difference in the proportion of growth inhibition both 
at 0.5 nmol (z score 0.75; P=0.4515) and 1.0 nmol concentrations (z score 1.1; 
p=0.2642).  
 
Table 4.3 Plasmodium falciparum in vitro sensitivity test to chloroquine in 
Ethiopia in 1980 
 
Details Drug evaluation method In vivo In vitro 
No of study sites 1 1 
 
No of patients 
enrolled 
 
21 
 
14 
 
Study protocol 
 
In vivo 7-days test 
 
Rickemann in vitro test 
 
Test dosage 
 
25 mg/kg over 3 days 
 
0.25 to 3.0 nmol 
 
Outcome 
 
No recrudescent cases  
 
7 (50%) cases at 0.5 nmol,  
2 (14.3%) case 0.75 nmol 
1 case (7%) at 1.0 nmol   
 
(Gebremariam et al 1982:1) 
 
In a subsequent study, Gebremariam and Teklehaimanot (1986:1) evaluate 
Plasmodium falciparum sensitivity to full course of 25 mg/kg of chloroquine in 11 study 
sites from 1983 to 1984. The study involved in vivo therapeutic efficacy evaluation of 
chloroquine in 139 patients for seven days and 115 patients for 28 days and no 
recrudescent or treatment failure cases were detected in both groups.  
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This led the researchers to conclude that the sample size and sampling area covered 
was sufficiently representative and Plasmodium falciparum is still sensitive to 
chloroquine despite the continued use of the drug in the country for the past 25 years 
preceding the study.  
 
However, in view of the reported chloroquine resistant malaria cases in the 
neighbouring country Kenya and of the extensive population movements across the 
common borders and non-inclusiveness of these sites in the current study, 
Gebremariam and Teklehaimanot (1986:1) recommend conducting chloroquine 
sensitivity study in these locations as necessary.  
 
4.5.1.5 First report of Plasmodium falciparum resistance to chloroquine 
 
The first chloroquine resistant Plasmodium falciparum cases were reported by 
Teklehaimanot (1986:127) in a study conducted on 98 subjects with confirmed 
Plasmodium falciparum malaria. The subjects declared travel to malarious areas while 
the study was conducted at the National Malaria Control Laboratory located in the 
capital Addis Ababa which is a predominantly malaria free area.  
 
In the 28-days follow-up period after treatment with standard dose of chloroquine at 25 
mg/kg administered over three days, parasitaemia persisted in 22 (22.4%) of the cases. 
In vitro testing of blood samples from 10 of the patients with chloroquine resistant 
parasites detected during the study also showed parasite growth in test vials containing 
more than 1.5 nmol of chloroquine which is believed to be the maximum growth 
inhibitory concentration for sensitive strains.  
 
There were no other major studies covering wider sample size, area or follow-up 
duration of up to 28 days for nearly seven years since the first confirmed report of 
chloroquine resistance by Teklehaimanot (1986:127). In 1993, Wezam (1993:271) 
reports no recrudescent or treatment failure Plasmodium falciparum cases in a 7-day in 
vivo assessment of 23 patients treated with standard course of chloroquine and 24 
patients treated with sulfadoxine-pyrimethamine. 
 
After three years from the study conducted by Wezam (1993:271) and Tulu et al 
(1996:556) report 86% (n=29) recrudescent Plasmodium falciparum  and 2% (n=255) 
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Plasmodium vivax cases following completion of a 7-day in vivo follow-up after 
treatment with standard course of chloroquine in the study site of Debrezeit 40 km east 
of the capital, Addis Ababa. In this same study, Tulu et al (1996:556), Plasmodium 
falciparum sensitivity to single dose standard dose of sulfadoxine-pyrimethamine was 
also assessed in 80 subjects and 1 (1.3%) recrudescent case was reported. In 
concluding, Tulu et al (1996:556) highlight the need further studies in other Geographic 
regions of the country to evaluate the sensitivity of Plasmodium falciparum to 
chloroquine while the response of Plasmodium vivax to chloroquine and Plasmodium 
falciparum to sulfadoxine-pyrimethamine was considered as effective.  
 
4.5.1.6 Malaria case detection and treatment posts report 
 
The increasing reports of chloroquine resistant Plasmodium falciparum cases led the 
National Malaria and Other Vector-Borne Diseases Control Program to introduce a 
follow-up procedure to confirm treatment outcomes in malaria patients treated in the 
laboratories managed by the programme.  
 
The procedure introduced in August 1989 and implemented by 36 malaria case 
detection and treatment posts across the country involved daily supervised 
administration of chloroquine to Plasmodium falciparum infected patients and blood 
examination for three consecutive days to monitor parasite clearance. Further follow-up 
was done in all Plasmodium falciparum cases who return to the laboratory with clinical 
symptoms within two weeks from the preceding visit and treatment.  
 
Through this procedure, cases that didn't show parasite density reduction on day-3 of 
the follow-up to less than 25% compared to the parasite density on day-zero on which 
treatment was started and those with parasites on day-7 were considered as treatment 
failure cases and treated with sulfadoxine-pyrimethamine. Alene and Bennett (1996:810) 
analyse data collected through the new follow-up procedure from August 1989 to July 
1991 and confirm that of the 39, 824 Plasmodium falciparum patients detected, 1,706 
(4.3%) patients returned to the treatment posts with malaria clinical symptoms within 15 
days from the preceding treatment.  
 
The 1,706 returning patients were again treated with chloroquine under direct 
observation and their blood examined for four consecutive days. On the fourth follow-up 
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day, 1,488 (87.2) cases had parasite densities of more than 25% compared to the 
parasite density on day-zero and were parasitemic on day-7 as well. All these cases 
were considered as treatment failure cases and subsequently treated with sulfadoxine-
pyrimethamine.  
 
4.5.1.7 Multi-site supervised 28-days in vivo chloroquine efficacy assessment 
studies 
 
Although a number of studies reported confirmed indicative trends in the declining 
sensitivity of Plasmodium falciparum to chloroquine, the findings were not widely 
representative enough to inform decision making on the continued use or need to 
replace the drug.  
 
According to unpublished reports of the Ministry of Health (1998a:3) most of the 
antimalarial drug efficacy studies conducted in Ethiopia didn't have sample size that can 
allow statistically acceptable conclusions. Moreover, the proportion of drop-outs from 
the studies was unacceptably high and the studies were not representative of the 
diverse eco-epidemiological setting in Ethiopia that influences malaria transmission in 
the country.  
 
The lack of use of uniform study protocols being one of the major problems in the 
previous studies, the Ministry of Health conducted chloroquine efficacy studies for the 
treatment of uncomplicated Plasmodium falciparum malaria in 15 representative sites 
shown in figure 4.1 following the study protocol developed by the WHO (1996:3).  
 
The WHO (1996:3) describes that the study protocol was primarily developed for 
antimalarial drug efficacy assessment in areas with intense malaria transmission 
involving children less than five years of age. However, due to the seasonal and 
unstable nature of malaria transmission in Ethiopia, the Ministry of Health (1998a:4) 
decides to conduct a study both in children under five years and in older children and 
adults. Accordingly, a study involving 527 children aged 5 to 59 months in 14 study sites 
and 298 patients aged five years and above were conducted in the period from October 
1996 to April 1998.  
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Figure 4.1 Distribution of anti-malarial drug efficacy study sites, 1996–1998 
(Federal Ministry of Health 2002) 
 
At the end of the study, the overall chloroquine treatment failure in children under five 
years of age detected in 14 study sites was 68.7% (95 CI, 64.5 to 72.8) (table 4.4). The 
levels of treatment failure varied by site from 0% in Bambasi, North-Western Ethiopia, to 
100% in Harbu, Northern Ethiopia. Although there was no specific explanation for the 
low treatment failure in the study site of Bambasi, the sample size of 16 patients was 
small compared to the other sites ranging from 2 to 65 patients.  
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Table 4.4 Therapeutic efficacy of chloroquine on uncomplicated Plasmodium 
falciparum in children under five years of age, Ethiopia, 1996–1998 
 
No Study site 
Subjects Treatment outcome Treatment failure 
Enrolled 
Follow-up 
completed 
(%) 
Adequate 
clinical 
response  
Treatment 
failure  Per cent 95% CI 
1 Harbu 45 42 (93.3) 0 42 100.0 - 
2 Chuko 26 17 (65.4) 1 16 94.1 82.9–105.3 
3 Serbo 36 27 (75.0) 3 24 88.9 77.0–100.7 
4 Bahirdar 50 44 (88.0) 5 39 88.6 79.2–97.9 
5 Alaba 23 18 (78.3) 3 15 83.3 66.0–00.5 
6 Tepi 24 21 (87.5) 4 17 81.0 64.2–97.7 
7 Zeway 50 48 (96.0) 11 37 77.1 65.2–88.9 
8 Metehara 38 36 (94.7) 11 25 69.4 54.3–84.4 
9 Pawi 36 35 (97.2) 11 24 68.6 53.2–83.9 
10 Dire Dawa 48 47 (97.9) 15 32 68.1 54.7–81.4 
11 Selekleka 65 57 (87.7) 20 37 64.9 52.5–77.2 
12 Angerguten 44 40 (90.9) 15 25 62.5 47.5–77.5 
13 Kella 26 26 (100) 11 15 57.7 38.7–76.6 
14 Bambasi 16 15 (93.8) 15 0 0 - 
Total 527 473 (89.8) 124 325 68.7 64.5–72.8 
 
(Ministry of Health 1998b:4) 
 
The follow-up and data analysis on therapeutic efficacy assessment in patients aged 
five years and above was done separately. Accordingly, a total of 107 subjects of above 
five years of age were enrolled in four study sites (table 4.5). At the end of the follow-up 
period of 28 days, an overall treatment failure of 47.7% (95% Confidence Interval (CI), 
23.8 to 41.5%) was detected. The level of treatment failure reported varied by site 
ranging from 32.7% in the study site of Kontir to 75% in the study site of Asendabo. 
 
Table 4.5 Therapeutic efficacy of chloroquine for uncomplicated Plasmodium 
falciparum malaria in children above five years and adults, 1997–
1998, Ethiopia 
 
No  
Subjects  Treatment outcome Treatment failure 
Enrolled 
Follow-up 
completed 
(%)  
Adequate 
clinical 
response  
Treatment 
failure  Per cent 95% CI 
1 Asendabo 25 24 (96.0) 6 18 75.0 57.6–92.3 
2 Gulti 20 18 (90.0) 8 10 55.6 32.6–78.5 
3 Adi Asmien 17 16 (94.1) 9 7 43.8 19.4–68.1 
4 Kontir 51 49 (96.1) 33 16 32.7 19.5–45.8 
Total 113 107 (94.7) 56 33 47.7 23.8–41.5 
 
(Ministry of Health 1998b:4) 
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According to the Ministry of Health (1998a:22) unpublished report the chloroquine 
efficacy study assessment findings were disseminated in a national workshop convened 
by the Ministry of Health in Nazareth, Ethiopia, 21–25 July 1998 (Ministry of Health 
1998b:5). The workshop participants questioned the representativeness of the study as 
most of the sites were in urban areas and recruiting study subjects attending health 
facilities could increase the risk of bias of selecting cases that might have been infected 
with drug resistant parasite strains.  
 
This led to the recommendation of conducting additional studies in other sites. 
Accordingly, the Ministry of Health (1998a:10) reports that in six rural study sites, a total 
of 257 children under five years diagnosed with Plasmodium falciparum  were followed 
for 28 days after treatment with chloroquine. At the end of the study, an overall 
treatment failure of 63.4% (95% CI, 57.5 to 69.3%) was reported. The level of treatment 
failure varied from 12.5% in Bambasi to 88.2% in Alaba (table 4.6). The sample size 
included in the Bambasi site was more than double compared to the previous study 
sample size of 16 patients and treatment failure of 12.5% which was significantly 
different that the 0% level reported in the previous study.  
 
Table 4.6 Therapeutic efficacy of chloroquine for uncomplicated Plasmodium 
falciparum malaria in children under five years of age in remote 
villages, 1998, Ethiopia 
 
No Study site 
Subjects Treatment outcome Treatment failure 
Enrolled 
Follow-up 
completed 
(%) 
Adequate 
clinical 
response 
Treatment 
failure Per cent 95% CI 
1 Alaba 60 51 (85.0) 5 45 88.2 79.4–97.1 
2 Harbu 41 35 (85.4) 8 27 77.1 63.2–91.0 
3 Bahirdar 55 48 (87.3) 12 36 75.0 62.8–87.3 
4 Zeway 59 56 (94.9) 16 40 71.4 59.6–83.2 
5 Gambella 50 35 (70.0) 24 11 31.4 16.0–46.8 
6 Bambasi 33 32 (97.0) 28 4 12.5 1.0–24.0 
 
Total 298 257 (86.2) 93 163 63.4 57.5–69.3 
 
(Ministry of Health 1998a:13) 
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4.5.1.8 Therapeutic efficacy of alternative antimalarial drugs 
 
Based on the recommendation of the national workshop, the Ministry of Health (1998b:2) 
also conducts baseline efficacy studies on sulfadoxine-pyrimethamine and amodiaquine 
as the potential candidate to replace the failing chloroquine, studies were conducted in 
seven sites for each drug in 1998.  
 
Five of the seven study sites where assessment of the efficacy of sulfadoxine-
pyrimethamine was conducted were the same sites used for the study on chloroquine 
efficacy. Of the 224 subjects recruited for the study in the seven sites, 206 (92.0%) 
completed the follow-up and an overall treatment failure rate of 5.3% (95% CI 2.2 to 8.4) 
was detected (table 4.7).  
 
The Ministry of Health (1998b:6) reports that despite the wide use of sulfadoxine-
pyrimethamine as a second-line treatment for malaria in Ethiopia since the late 1980s, 
the level of treatment failure detected in the study conducted in 1998 was acceptably 
low at 5.3% (95% CI 2.2 to 8.4). This finding was supportive of the possible decision of 
introducing the drug as the first-line treatment.  
 
Table 4.7 Therapeutic efficacy of sulfadoxine-pyrimethamine on uncomplicated 
Plasmodium falciparum malaria in children under 5 years of age, 
Ethiopia, 1998 
 
No Study 
site 
Subjects Treatment outcome Treatment failure 
Enrolled Follow-up 
completed (%) 
Adequate 
clinical 
response 
Treatment 
failure Per cent 95% CI 
1 Chuko 30 23 (76.7) 14 9 39.1 19.2–59.0 
2 Metehara 60 60 (100) 60 0 0.0 0 
3 Kella 23 21 (91.3) 20 1 4.8 -4.3–13.9 
4 Merti Jeju 29 25 (86.2) 24 1 4.0 -3.7–11.7 
5 Harbu 27 23 (85.2) 23 0 0 0 
6 Sille 12 12 (100) 12 0 0 0 
7 Zeway 43 42 (97.7) 42 0 0 0 
Total 224 206 (92.0) 195 11 5.3 2.2–8.4 
 
(Ministry of Health 1998b:6) 
 
On the other hand the therapeutic efficacy of amodiaquine for the treatment of 
uncomplicated Plasmodium falciparum malaria in seven sites was unacceptably high. 
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Of the 227 subjects who completed the 28-day follow-up, a mean treatment failure of 
21.1% (95% CI, 15.8 to 26.4) was detected (table 4.8). The treatment failure levels 
varied by site with the lowest of 6.3% (95% CI, -5.6 to 18.2) in the study site of Harbu 
and 66.7% (95% CI, 42.9 to 90.6) in the study site of Asendabo. The treatment failure of 
chloroquine in the study site of Bambasi was 22.9% (95% CI, 11.0 to 34.8%) which was 
higher than the chloroquine treatment failure of 12.5% reported in the same study site in 
1997.  
 
Table 4.8 Therapeutic efficacy of amodiaquine on uncomplicated Plasmodium 
falciparum cases in children under five years of age, Ethiopia, 1998  
 
N
o 
Study 
site 
Subjects Treatment outcome Treatment failure 
Enrolled Follow-up 
completed (%) 
Adequate 
clinical 
response 
Treatment 
failure Per cent 95% CI 
1 Asendabo 16 15 (93.8) 5 10 66.7 42.9–90.6 
2 Zeway 28 24 (85.7) 13 11 45.8 25.9–65.7 
3 Bambasi 50 48 (96.0) 37 11 22.9 11.0–34.8 
4 Gultie 42 37 (88.1) 30 7 18.9 6.3–31.5 
5 Kontir 48 41 (85.4) 36 5 12.2 2.2–22.2 
6 Bahirdar 49 46 (93.9) 43 3 6.5 -0.6–13.6 
7 Harbu 18 16 (88.9) 15 1 6.3 -5.6–18.2 
 
Total 251 227 (90.4) 179 48 21.1 15.8–26.4 
 
(Ministry of Health 1998b:5) 
 
4.5.1.9 Monitoring efficacy of sulfadoxine-pyrimethamine after its introduction 
as a first line antimalarial drug 
 
Although there is no documented evidence on the first date of entry and use of 
sulfadoxine-pyrimethamine for the treatment of malaria in Ethiopia, from personal 
experience while working in the program, large-scale use of the drug for malaria 
treatment was practiced since 1986 mainly for mass treatment of tens of thousands of 
highlanders from the northern part of the country who were re-settled then in to malaria 
endemic regions in the Western and North-Western parts of Ethiopia.   
 
Olliaro (2001:207) explains the mechanism of resistance to sulfadoxine-pyrimethamine 
being due to mutation in the dihydrofolate reductase and dihydropteroate synthetase 
coding genes of Plasmodium falciparum which are the target enzymes of the drug. 
Gatton, Martin and Cheng (2004:2116) illustrate that mass use of the drug has been 
  
95 
shown to increase drug pressure that enhances selection of resistant strains. Although 
there are no studies on the effect of mass use of the sulfadoxine-pyrimethamine in the 
Ethiopian setting, the uncontrolled use of the drug in settlement villages was likely to 
have contributed to increasing drug pressure and selection of sulfadoxine-
pyrimethamine resistant Plasmodium falciparum strains. 
 
Most of the studies conducted on the efficacy of sulfadoxine-pyrimethamine after its 
introduction as the first-line drug in 1998 were isolated studies conducted by individual 
researchers and research institutions. As presented in table 4.9, from 2004 to 2005, a 
total of four studies were known to have been conducted but published in 2005 after the 
nationwide treatment guideline change was introduced. In these studies, Degefa 
(2004:35) reports sulfadoxine-pyrimethamine treatment failure of 2.6% in the study site 
of Alamata, northern Ethiopia, Kassa et al (2005:167) report 12.3% treatment failure in 
Metehara, Central Ethiopia and Worku et al (2005:1) 45.3% in Jima, western Ethiopia.  
 
Table 4.9 Therapeutic efficacy of sulfadoxine-pyrimethamine (SP) for the 
treatment of Plasmodium falciparum malaria, Ethiopia 
 
Details 
Studies reviewed 
Degefa et al 
(2004:35) Kassa et al (2005:167) Worku et al (2005:11) 
Study site location (#) Alamata, Northern Ethiopia (1) 
Metehara, Central 
Ethiopia (1) Jimma, Western Ethiopia (1) 
Study dates Sep. to Nov. 2001 Oct.  to Nov. 2002 Oct. 2003 
Year of publication 2004 2005 2005 
No. of patients 
enrolled 41 57 86 
Study protocol 14-day follow-up WHO 1996 protocol 
14-day follow-up WHO 
1996 protocol 
14-day follow-up WHO 1996 
protocol 
Test drug dosage As per national guideline 
As per national 
guideline As per national guideline 
% Treatment Failure 2.6 12.3 45.3 
Recommendation 
Findings suggest that 
sulfadoxine-
pyrimethamine is 
effective and its use 
can continue 
The Ministry of Health 
should search for 
economically feasible 
replacement to SP. 
SP may no longer be 
considered adequate for 
treating Plasmodium 
falciparum  in the study area 
 
(Degefa 2004:35; Kassa et al 2005:167; Worku, Girma & Shiferaw 2005:11) 
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With the exception of the studies conducted in these isolated sites (table 4.9), there was 
no regular monitoring of the efficacy of sulfadoxine-pyrimethamine until 2003 and since 
the last multi-site study in 1998. Following the heavy rains after a prolonged period of 
drought in Negash et al (2005:186) report a major malaria epidemic in 2003 that 
affected more than 2000 villages causing over 3 million malaria cases and 3,663 
malaria death.  
 
Cognisant of the possible effect of the reduced efficacy of sulfadoxine-pyrimethamine 
and the disruption of malaria vector control activities as some of the major contributors 
to the major epidemics, the Ministry of Health decided to conduct nationwide efficacy 
study on sulfadoxine-pyrimethamine in the same sentinel sites where previous major 
antimalarial efficacy studies were conducted. At the end of the study conducted 
between September-December 2003 in 11 study sites, Jima et al (2005:391) report 
treatment failure of 35.9% (95% CI 31.8 to 40.3) in a 14-days follow-up completed on 
474 patients (table 4.10). 
 
Table 4.10 Therapeutic efficacy of sulfadoxine-pyrimethamine for uncom-
plicated Plasmodium falciparum malaria, in vivo 28-day test results, 
Ethiopia October–December 2003 
 
No Study site 
Subjects Treatment outcome Treatment failure 
Enrolled 
Follow-up 
completed 
(%) 
Adequate 
clinical 
response 
Treatment 
failure Per cent 95% CI 
1 Zuway 66 56 (84.8) 8 48 85.7 76.5–94.9 
2 Metehara 61 44 (72.1) 8 36 81.8 70.4–93.2 
3 Awassa 57 49 (86.0) 9 39 79.6 68.2–90.9 
4 Angergutin 72 42 (58.3) 10 32 76.2 63.3–89.1 
5 Pawe 43 35 (81.4) 9 26 74.3 59.8–88.8 
6 Serbo 65 45 (69.2) 13 32 71.1 57.9–84.3 
7 Selekleka 55 45 (81.8) 14 31 68.9 55.4–82.4 
8 Alaba 53 47 (88.7) 15 32 68.1 54.8–81.4 
9 Bambasi 59 10 (16.9) 4 6 60.0 29.6–90.4 
10 Harbu 59 49 (3.1) 20 29 59.2 45.4–73.0 
11 Bahirdar 67 53 (79.1) 25 28 52.8 39.4–66.2 
 Total 657 474 (72.1) 135 339 71.5 67.4–75.6 
 
(Jima et al 2005a:391) 
 
Due to the growing concern and a number of reports of high level of Plasmodium 
falciparum resistance to the most commonly and widely used antimalarial drugs such as 
chloroquine and sulfadoxine-pyrimethamine, the WHO (2001:18) recommends the use 
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of ACTs. In addition to the high cure rate of cases treated with ACTs, the drugs were 
also effective for the treatment of multi-drug resistant malaria parasites and effect on 
gametocytes which contribute to reducing malaria transmission (Tangpukdee, Krudsood, 
Srivilairit, Phophak, Chonsawat, Yanpanich, Kano & Wilairatana 2008:65). 
 
Expecting a high treatment failure rate of sulfadoxine-pyrimethamine and recalling the 
earlier evidence of high treatment failure of amodiaquine, artemether-lumefantrine was 
considered the best option that can be introduced as the first-line antimalarial drug for 
the treatment of Plasmodium falciparum replacing sulfadoxine-pyrimethamine.  
 
Accordingly, along the evaluation of efficacy of sulfadoxine-pyrimethamine, base-line 
efficacy study on artemether-lumefantrine for the treatment of uncomplicated falciparum 
malaria was conducted in four study sites in advance. Jima et al (2005b:387) reports 
treatment success of 99.1% in a follow-up period of 28-days on 213 Plasmodium 
falciparum  patients treated with the ACT drug artemether-lumefantrine in four study 
sites (table 4.11).  
 
Table 4.11 Baseline study on the efficacy of Artemether-Lumefantrine on 
uncomplicated Plasmodium falciparum malaria in Ethiopia 
 
No Study site 
Subjects Treatment outcome Treatment failure 
Enrolled Follow-up 
completed (%) 
Adequate 
clinical 
response 
Treatment 
failure Per cent 95% CI 
1 Assendabo 60 59 (98.3) 57 2 3.4 -1.2–8.0 
2 Alamata 39 36 (92.3) 36 0 0 0 
3 Humera 64 62 (96.9) 62 0 0 0 
4 Nazareth 56 56 (100) 56 0 0 0 
Total 219 213 (97.3) 211 2 0.94 -0.4–2.2 
 
(Jima et al 2005b:387) 
 
4.5.2 Recent antimalarial drug efficacy study findings 
 
The new malaria diagnosis and treatment guideline with artemether-lumefantrine for 
uncomplicated Plasmodium falciparum malaria was introduced nationwide in July 2004. 
At the start of implementation of the new guideline, the emphasis was on ensuring 
adequate supply of artemether-lumefantrine to replace the stock of the obsolete 
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antimalarial drug sulfadoxine-pyrimethamine. This was not achieved until the end of 
2005 by which time a huge supply of artemether-lumefantrine procured through the 
support of the Global Fund, the WHO and UNICEF started to enter the country. In the 
following sections, studies conducted after the newly introduced antimalarial treatment 
guideline was introduced are presented. 
 
4.5.2.1 In vivo therapeutic efficacy studies on Plasmodium falciparum 2006–2010 
 
Since the introduction of the new malaria treatment guideline in Ethiopia in 2004, four 
studies were conducted in the period from 2006 to 2010. Despite the World Health 
Organisation recommendation of a follow-up period for clinical and parasitological 
assessment of 28 days, the study by Seboxa, Mao, Pinchouk, Anbessie, Alemu and 
Diro (2010:285) assessing the efficacy of artemether-lumefantrine in one arm and 
artesunate plus sulfadoxine-pyrimethamine on the other was done only for 14-days. 
Through the 14-day follow-up, no treatment failure cases were detected. Although 
conducting a 14-day test can provide useful information (WHO 2003:16), continuing the 
follow-up until day-28 is critical to check for late treatment failures especially when no 
early treatment failure have been detected. Data from such short duration follow-ups, 
therefore, may not generate the required type and amount of information.  
 
Kefyalew, Animut, Tamene, Jima, Hailemariam and Legesse (2009:129) report no 
treatment failure with artemether-lumefantrine in 102 Plasmodium falciparum patients 
followed for 28 days in the study site of Alaba, Southern Ethiopia. However, Assefa, 
Kassa, Tadese, Mohamed, Animut, Mengesha (2010:1) report artemether-lumefantrine 
treatment failure of 6.7% in a study conducted from November 2007 to January 2008 
involving 90 Plasmodium falciparum  diagnosed patients in Kersa, western Ethiopia.  
 
Compared to the baseline efficacy study conducted in 2004 that reported a 0.9% 
treatment failure in a 28-day follow-up by Jima et al (2005b:387), the treatment failure 
reported by Assefa et al (2010:1) has shown a significant increase (P=0.0004) that 
warrant for a more representative study and follow-up through a multi-site monitoring.  
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Table 4.12 In vivo therapeutic efficacy study of artemether-lumefantrine on 
Plasmodium falciparum  
 
Details  
Studies reviewed 
Seboxa et al 
(2010:285) 
Seboxa et al 
(2010:285) 
Kefyalew et al 
(2009:129) 
Assefa et al  
(2010:1) 
Study site 
location (#) 
Assendabo and 
Dimtu, Western 
Ethiopia (1) 
Deneba, Western 
Ethiopia (1) 
Alaba, Souther 
Ethiopia (1) 
Kersa, Western Ethiopia 
(1) 
Study dates 
28 November to 
26 December 
2006 
28 November to 
26 December 
2006 
October December 
2007 
November 2007 to 
January 2008 
No. of 
patients 
enrolled 
99 35 102 90 
Study 
protocol 
WHO 2001 (14-
day follow-up) 
WHO 2001 (14-
day follow-up) 
WHO 2003 (28-day 
follow-up) 
WHO 2003 (28-day 
follow-up) 
Test drug 
dosage 
Artemether-
Lumefantrine 
Artesunate plus 
sulfadoxine-
pyrimethamine 
Artemether-
Lumefantrine Artemether-Lumefantrine 
% Treatment 
Failure 0 0 0 6.7% 
Conclusion 
Both artemether-
lumefantrine and 
Artesunate plus 
Sulfadoxine-
pyrimethamine 
are effective 
Both artemether-
lumefantrine & 
Artesunate plus 
Sulfadoxine-
pyrimethamine 
are effective 
AL has excellent 
level of efficacy 
AL is still effective but 
more follow-up is needed 
 
(Seboxa et al 2010:285; Kefyalew et al 2009:129; Assefa et al 2010:1) 
 
4.5.2.2 In vivo therapeutic efficacy studies on Plasmodium vivax 2009 – 2010 
 
The first report of chloroquine treatment failure on Plasmodium vivax malaria of 2% was 
reported by Tulu et al (1996:556) in a 7-day follow-up study conducted in Debrezeit, 
Central Ethiopia. The reported treatment failure cases were not confirmed with PCR 
based detection of parasite DNA, considered diagnosis which is believed to be the gold 
standard. Moreover, the blood level of the drug administered and its metabolite, 
desethychloroquine, was not measured to confirm if parasite persistence in the 
treatment failure cases was happening despite the presence of the minimum inhibitory 
concentration of the drugs in blood which is >100 ng/mL of whole blood (Baird, Leksana, 
Masbar, Fryauff, Sutanihardja, Suradi, Wignall & Hoffman 1997:621). 
 
  
100 
Following the first report of treatment failure of chloroquine for the treatment of 
Plasmodium vivax reported by Tulu et al (1996:556) and Yeshiwondim et al (2010:105) 
reported PCR corrected Plasmodium vivax treatment failure of 2.9% after treatment with 
chloroquine and 0.74% after treatment with chloroquine plus primaquine in the same 
and areas adjacent area to the town of Debrezeit in a study completed in 2003. 
 
In later similar studies conducted in Debrezeit and Nazareth in 2005 by Yohannes et al 
(2011:137) and in Debrezeit alone in 2006 by Teka et al (2008:1) PCR corrected and 
chloroquine blood level verified resistance to chloroquine of 4.8% and 3.5%, 
respectively was reported. In other locations, chloroquine treatment failure on 
Plasmodium vivax of 3.8% in Serbo, Western Ethiopia (Ketema et al 2009:1) and 13.8% 
in Halaba, Southern Ethiopia (Ketema, Getahun & Bacha 2011:1) were reported. In both 
reports, PCR confirmation of the treatment failure cases and determination of 
chloroquine and desethylchloroquine blood level concentration was not reported 
indicating that there was no confirmation if the treatment failure cases were due to 
Plasmodium vivax resistance to chloroquine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 4.13 In vivo therapeutic efficacy study of chloroquine, chloroquine plus primaquine and artemether-lumefantrine on 
Plasmodium vivax 
 
Details 
Studies reviewed 
Yeshiwondim et al 
2010 
Yeshiwondim et al 
2010 
Yohannes et al 
2011 
Yohannes et al 
2011 
Teka  et al  
2008 
Ketema et al 
2009 
Ketema et al 
2011 
Study site location 
(#) 
Debrezeit and 
Nazareth, Central 
Ethiopia 
Debrezeit and Nazareth, 
Central Ethiopia 
Debrezeit and 
Nazareth, Central 
Ethiopia 
Debrezeit and 
Nazareth, Central 
Ethiopia 
Debrezeit, 
Central Ethiopia 
(1) 
Serbo, South 
Western 
Ethiopia (1) 
Alaba, 
Southern 
Ethiopia (1) 
Study dates Jan to Aug 2003 Jan to Aug 2003 Oct 2004 to May 2005 
Oct 2004 to May 
2005 Jun to Aug 2006 
Oct 2007 to 
Jan 2008 
Jan to Feb 
2009 
Test drug Chloroquine plus primaquine Chloroquine Chloroquine 
Artemether-
lumefantrine Chloroquine Chloroquine Chloroquine 
Study protocol WHO 28-day test WHO 28-day test WHO 28-day test WHO 28-day test WHO 28-day test 
WHO 28-day 
test 
WHO 28-day 
test 
No. of patients 
enrolled 136 141 57 75 83 78 80 
% Treatment 
Failure 0.75 5.8 8.8 25.3 4.8 3.8 13.8 
Conclusion 
emergence of 
resistance/treatment 
failure to 
chloroquine plus 
primaquine in 
Plasmodium vivax 
confirmed 
emergence of 
resistance/treatment 
failure to chloroquine 
Plasmodium vivax 
confirmed 
Chloroquine 
resistant 
Plasmodium 
vivax confirmed 
Artemether-
lumefantrine may 
not be effective for 
the treatment of 
Plasmodium vivax 
Chloroquine-
resistant 
Plasmodium 
vivax parasites 
are emerging in 
Debrezeit, 
Ethiopia 
Chloroquine 
resistant 
Plasmodium 
vivax strains in 
Serbo town 
confirmed 
Chloroquine 
treatment 
failure 
increasing from 
earlier levels 
 
(Yeshiwondim et al 2010:105; Yohannes et al 2011:137; Teka et al 2008:1; Ketema, Bacha, Birhanu & Petros 2009:1; Ketema et al 
2011:1) 
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4.5.2.3 Genetic analysis based antimalarial drug efficacy studies 
 
Genetic analysis based determination of polymorphic genes associated with antimalarial 
drug resistance was one of the study methods implemented in one site in Southern 
Ethiopia. In this study, the prevalence of polymorphic genes of Plasmodium falciparum  
and Plasmodium vivax associated with resistance to chloroquine and sulfadoxine-
pyrimethamine showed high prevalence of polymorphic genes associated with 
resistance to the drugs (Schunk, Kumma, Miranda, Osman, Roewer, Alano, Löscher, 
Bienzle & Mockenhaupt 2006:1). 
 
Although it is of interest from scientific information point of view, the study did not 
elucidate the potential benefit of the findings from such study in a situation where both 
drugs are not recommended anymore for the treatment of Plasmodium falciparum 
malaria in Ethiopia. Moreover, the investigators didn't provide justification on the desire 
and objective of conducting genetic analysis on Plasmodium vivax dihydrofolate 
reductase (dhfr) and dihydropteroate genes conforming to polymorphic genes that 
predict resistance to sulfadoxine-pyrimethamine when the drug is actually not 
recommended for the treatment of Plasmodium vivax malaria in the national guideline.  
 
Table 4.14 Parasite genetic analysis and prevalence of genes associated with 
resistance to chloroquine and sulfadoxine-pyrimethamine, Dilla, 
Southern Ethiopia, 2006 
 
Details  
Test drug and parasites 
Plasmodium falciparum  Plasmodium vivax 
Chloroquine Sulfadoxine-pyrimethamine 
Sulfadoxine-
pyrimethamine 
Study site (#) Dilla, Southern Ethiopia (1) 
Dilla, Southern 
Ethiopia (1) 
Dilla, Southern 
Ethiopia (1) 
Subjects enrolled 66 66 31 
Recrudescent cases (28-day follow-up) No information No information No information 
Polymorphic Genes analysed    
Pfmdr1 56 -  
Pfcrt762 69 -  
dhfr3 - 60 29 
dhps4 - 59 23 
(Schunk et al 2006:1) 
 
Key:  1=multi-drug resistant; 2=Plasmodium falciparum cytochrome76; 3=Plasmodium falciparum 
dyhydrofolate reductase; 4=Plasmodium falciparum dihydropteroate synthetase 
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Another genetic analysis based study conducted on Plasmodium falciparum  and 
polymorphic genes associated with resistance to quinine, artemether-lumefantrine and 
atovaquone-proguanil was conducted by Eshetu, Berens-Riha, Fekadu, Tadesse, 
Gürkov, Hölscher, Löscher and Miranda (2010:1) in Jimma, Western Ethiopia. In this 
study, in vivo treatment failure rates with quinine, artemether-lumefantrine and 
atovaquone-proguanil of 8.6%, 0% and 6.3%, respectively was detected. Following 
confirmation of in vivo treatment failure, genetic analysis of polymorphic genes that are 
associated with resistance to the drugs tested was conducted and showed high number 
of the cases being due to parasites with mutations that confer resistance (table 4.14).  
 
Table 4.15 Plasmodium falciparum genetic analysis and prevalence of genes 
associated with resistance to Quinine, Artemether-lumefantrine and 
Atovaquone-proguanil, Jimma, Western Ethiopia, 2010 
 
Details 
Test drugs 
Quinine Artemether-Lumefantrine 
Atovaquone- 
proguanil 
Source  
   
Study site (#) Jima, Western Ethiopia (1) 
Jima, Western 
Ethiopia (1) 
Jima, Western 
Ethiopia (1) 
Subjects enrolled 35 30 32 
Recrudescent cases 
(28-day follow-up) 4 0 2 
Polymorphic Genes 
analysed    
Pfdhfr1 - - 1 
Pfdhps2 - 
 
2 
Pfmdr186Y3 3 0 - 
Pfserca4 - 0 - 
Pfcytb5 - - 0 
 
(Eshetu et al 2010:1) 
 
Key:  1=Plasmodium falciparum dyhydrofolate reductase; 2=Plasmodium falciparum dihydropteroate 
synthetase; 3=Plasmodium falciparum multi-drug resistant 186Y; 4=Plasmodium falciparum 
sarco/endoplasmic reticulum calcium-ATPase; 5=Plasmodium falciparum cytochrome b 
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4.6 REPRESENTATIVENESS, TIMELINESS AND COMPLETENESS OF THE 
STUDIES AND THEIR ADEQUECY TO INFORM ANTIMALARIAL POLICY IN 
ETHIOPIA 
 
The adequacy of antimalarial drug studies conducted in Ethiopia in terms of their 
representativeness, timeliness and completeness to inform antimalarial drug policy and 
development of treatment guidelines in Ethiopia are the main parameters assessed. 
The data collected and analysed provided important findings that can inform the 
representativeness, timeline and completeness of the studies.  
 
In order to ensure simplistic and systematic approach to assess the representativeness, 
timeliness and completeness of the studies, a numeric scoring based assessment was 
used.  All measures being of equal importance, equal weight was considered for study 
representativeness, completeness and timeliness. Based on this, the following scoring 
approach was applied.  
4.6.1 Study representativeness 
 
 
Representativeness, is defined as serving as a typical or characteristic example, 
(Merriam-Webster Incorporated Online Dictionary 2011). Due to the logistic and 
resource requirements and the need to collect representative data in a short period of 
time, studies on antimalarial drug efficacy may not be conducted in all parts of a country, 
region or district. To avoid the unnecessary challenge of trying to reach everywhere, 
statistical methods such as sampling are used to conduct the study only on a 
manageable but representative sample.  
 
The findings from such sample on the level of antimalarial drug efficacy can then be 
used to make inference about the rest of the Geographic area, which the sample 
represents. In the absence of representative sampling, the study findings and 
conclusion that may be derived therefore would not be representative and may be 
misleading. Operationally, representativeness is determined based on the statistical 
approaches that can ensure appropriate sampling and random selection of samples and 
allocation of samples to study sites. The decision criteria used to ensure 
representativeness is based on statistical tests on sample size determination and 
randomisation.  
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Study representativeness has been estimated based on the statistical adequacy of the 
sample size considered in the study and the number of study sites involved. For a study 
to be representative, the WHO recommends a sampling approach based on an 
assumption of 50% treatment failure if the rate of treatment failure in the study area is 
not known. Regardless of the rate of treatment failure, the WHO (2009a:5) recommends 
that follow-up on a minimum of 50 subjects each be completed in at least 4–8 selected 
representative sites. Based on this, studies have been scored based on a scale of 0 to 2 
presented in table 4.1 in the research design and method section.  
 
4.6.2 Study completeness 
 
Completeness is defined as having all the necessary parts, elements and steps 
(Merriam-Webster Incorporated Online Dictionary 2011) has been of high relevance to 
antimalarial efficacy studies. The antimalarial drug studies conducted in Ethiopia, 
although were following a specific study protocol, most of the studies failed to report on 
the quality of the antimalarial drug tested and the pharmacokinetic information of the 
drugs tested at the time of the confirmed treatment failure.  
 
Pre-testing the quality of the antimalarial drug used in antimalarial efficacy studies for 
product quality is critical. This is particularly of high importance in light of the high 
prevalence of counterfeit and poor quality drugs in the markets of malaria endemic 
countries. Bate, Coticelli, Tren and Attaran (2008:1) confirm that an estimated 35% of 
antimalarial drugs sampled from six African countries to have failed quality standards. In 
the absence of proof of quality of the antimalarial drug tested, asserting that the 
observed treatment failure was due parasite resistance would not be possible.  
 
Determining the amount of the antimalarial drug and its metabolite in the blood of 
patients with presumed treatment failure is also critical information. Study completeness 
was scored based the availability of confirmed results that are critical is resolving doubts 
about the conclusion derived from the findings. For a certain level of treatment failure or 
treatment success to be declared beyond doubt, the following three criteria are 
proposed as mandatory a) examination of blood films by two different readers and 
analysis that excludes discordant results b) the antimalarial drug was tested for quality 
and content of its active ingredient and c) the blood level of the drug tested and its 
metabolite was above the minimum effective concentration at the time of the confirmed 
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treatment failure. Based on this, study completeness was scored on a scale of 0 to 3 as 
presented in table 4.16 and table 4.17.  
 
4.6.3 Study timeliness 
 
Timeliness is defined as appropriate or adapted to the times or the occasion (Merriam-
Webster Incorporated Online Dictionary 2011). Monitoring the efficacy of antimalarial 
drugs at regular and appropriate time interval and use of the evidence to guide policy is 
an important aspect of studies. Studies of irregular interval fail to detect trends of an 
imminent or potential threat to the efficacy of antimalarial drugs. Delays in making use 
of evidence from such studies to update or change antimalarial drug policy or guideline 
also contributes to further deterioration of the health service resulting in more health 
problems. Operationally, timelines is measure by calculating the time laps between two 
similar studies as compared to the recommended time laps. The decision criteria are 
based on the calculated time laps and durations that are equal to the recommended 
duration are said to have the desired timeliness while durations less or over the 
recommended duration are not. 
 
The WHO (2009a:3) recommends regular assessment of the efficacy of antimalarial 
drugs of every two years. Studies conducted within two years from the preceding study 
would be considered timely compared to studies conducted after more than two years 
from the previous study. The scoring developed to rate the representativeness, 
completeness and timeliness of antimalarial efficacy studies is summarised in table 4.16. 
Based on this scoring method, a study that fulfils all the scores without missing any of 
the elements is considered as adequate to inform antimalarial policy decision. Based on 
approach, the score for each of the antimalarial drug studies conducted in Ethiopia is 
presented in tables table 4.16 and table 4.17.    
 
Based on the scoring proposed for each of the main parameters assessed, a study that 
fulfils all the scores (100%) without missing any element is considered as adequate to 
inform antimalarial policy decision and treatment guideline updating. However, 
considering the lack of local capability in the Ethiopian setting to conduct PCR based 
confirmation of malarial infection and drug quality and blood level concentration 
determination in the early days, a score of 60% of above was arbitrarily set as a cut-off 
for adequacy. 
  
Table 4.16 In vivo therapeutic efficacy study on Plasmodium falciparum  and adequacy score of studies 
No Author 
No of 
study 
sites 
Sample 
size 
Method and 
follow-up 
duration 
Test 
drug Outcome 
Score of adequacy Adequacy 
to inform 
policy 
Recommended action 
Rep Com Tim % Total Score 
1 Dennis et al 1974 1 41 In vivo, 28 days  CQ* 26.8 0 0 1 16.7 No Further study 
2 Dennis et al 1974 1 24 In vivo, in vitro CQ 0a 0 0 1 16.7 No Further study 
3 Armstrong et al 1976 4 99 In vivo, 6-11 days  CQ 0 1 0 1 16.7 No Further study 
4 Gebremariam et al 1982 1 21 In vivo, 7 days  CQ 0 0 0 0 0.0 No Further study 
5 Gebremariam et al 1986 11 136 In vivo, 7 days  CQ 0 2 0 0 33.3 No Further study 
6 Gebremariam et al 1986 11 115 In vivo, 28 days  CQ 0 2 0 0 33.3 No Further study 
7 Teklehaimanot et al 1985 1 98 In vivo, 28 days  CQ 22.4 1 0 1 33.3 No Further study 
8 Wezam 1993 1 23 In vivo, 7 days  CQ 0 0 0 0 0.0 No Further study 
 
9 Alene and Bennett 1996 36 1706 In vivo, 7 days  CQ 87.2 1 0 0 16.7 No 
Further study and need to consider 
alternatives antimalarial drug 
10 Tulu et al 1996 1 29 In vivo, 7 days  CQ 86.2 0 1 0 16.7 No  Further study 
11 Assefa  19897 1 1 In vivo, 7 day CQ 100 0 0 1 16.7 No  Further study 
12 Ministry of Health 1998a 14 473 In vivo, 14 days  CQ 73.6 2 1 0 50.0 Yes Treatment policy change 
13 Ministry of Health 1998a 6 257 In vivo,14 days  CQ 63.4 2 1 0 50.0 Yes Treatment policy change 
14 Ministry of Health 1998b 4 107 In vivo,14 days  CQ 47.7 2 1 0 50.0 Yes Treatment policy change 
15 Wezam 1993 1 24 In vivo, 7 days  SP 0 0 1 0 16.7 No  Further study 
16 Tulu et al 1996 1 80 In vivo, 7 days  SP 1.3 1 1 0 33.3 No  Further study 
17 Ministry of Health 1998b 7 232 In vivo,14 days  SP 5.6 2 1 0 50.0 Yes Treatment policy change  
18 Degefa 2004 1 77 In vivo,14 days  SP 2.6 1 1 0 33.3 No  Further study 
19 Kassa et al 2005 1 60 In vivo,14 days  SP 21.1 1 0 1 33.3 No  Further study 
20 Jima et al 2005ª 11 523 In vivo,28 days  SP 33.5 2 1 1 66.7 Yes Treatment policy change 
21 Jima et al 2005b 4 213 In vivo,28 days  AL 0.9 2 1 1 66.7 Yes Treatment policy change 
22 Seboxa et al 2010 2 105 In vivo,14 days  AL 0 1 1 0 33.3 No  Further study 
23 Assefa et al 2010 1 81 In vivo,28 days  AL 6.7 1 0 0 16.7 No  Further study 
Key for outcome: a=per cent parasite growth in culture medium with chloroquine of greater than 1.5 nmol 
  b=per cent samples with one or more gene polymorphic regions that conform resistance  
  a=per cent of treatment failure cases Rep.=representativeness  
  Com.= completeness; Tim.= timeliness 
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Table 4.17 In vivo therapeutic efficacy study on Plasmodium vivax and adequacy score of studies 
 
No Author, Year 
No. of 
study 
sites 
Sample size Protocol Test drug Outcome Score  
Adequacy 
to inform 
policy 
Recommended 
actual 
Rep Comp Time Total 
1 Tulu et al 1996 1 255 In vivo, 7 days  CQ  2 1 1 1 50.0 No  Further study 
2 Yeshiwondim et al 2010 2 145 In vivo, 28 days  CQ 5.76 1 1 0 33.3 No Further study 
3 Yeshiwondim et al 2010 2 136 In vivo, 28 days  CQ + PQ 0.75 1 1 0 33.3 
No 
Further study and co-
administration of 
Primaquine 
4 Teka et al 2008 1 83 In vivo, 28 days  CQ 4.8 1 3 0 66.7 
Yes 
 Further study and co-
administration of 
Primaquine 
5 Ketema et al 2009 1 78 In vivo, 28 days  CQ 3.6 1 1 1 50.0 No   
6 
Yohannes et al 2011 2 75 In vivo, 28 days  AL 25.3 1 2 1 66.7 Yes 
Strengthen diagnosis 
to minimize the 
chance of clinical 
malarial cases due to 
Plasmodium vivax with 
AL 
7 Yohannes et al 2011 2 57 In vivo, 28 days CQ 8.8 1 2 1 66.7 Yes 
  Further study and co-
administration of 
Primaquine 
8 Ketema et al 2011 1 80 In vivo, 28 day CQ 6.7 1 0 1 33.3 No 
 Further study 
 
Key for outcome  
a=per cent parasite growth in culture medium with chloroquine concentration of greater than 1.5 nmol 
b=per cent samples with one or more gene polymorphic regions that conform resistance  
a=per cent of treatment failure cases  
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4.7 ANTIMALARIAL DRUG POLICY AND TREATMENT GUIDELINES CHANGE 
PROCESS 
 
4.7.1 Use of antimalarial drug efficacy data for policy 
 
Following the recommendation by Bloland, Kazembe, Oloo, Himonga, Baratand 
Ruebush (1998:543), clinical failure of 25% after treatment with chloroquine within a 
follow-up period of 14 days was considered a high level of failure that should warrant 
change in the treatment policy. Based on this cut-off point and specific methodological 
approach the 1996 WHO (1996:17) study protocol for the in vivo assessment of 
antimalarial drugs was developed. However, the protocol was mainly intended for areas 
with intense malaria transmission and study subjects of under five years of age and no 
methodological approaches for the assessment of antimalarial drug efficacy in low to 
moderate malaria transmission settings where all ages are equally affected by malaria 
was included.  
 
The therapeutic efficacy data used to change from chloroquine to sulfadoxine-
pyrimethamine in Ethiopia in 1998, for example was collected using the protocol 
developed based on the WHO (1996:3). However, the Ministry of Health decided to also 
collect chloroquine efficacy data from the age group of five and above, who are the 
most affected in the Ethiopian setting. Irrespective of the recommendation of the WHO 
(1996:3), the decision to broaden the scope of the protocol to include all age groups 
was a locally sound decision based on the malaria transmission pattern that affects all 
age groups.  
 
Following a practical field experience in using the WHO 1996 protocol the WHO has 
been revising the protocol for the assessment of antimalarial drug efficacy to fit all 
malaria endemicity settings, types of antimalarial drugs tested, age group of study 
subjects involved, duration of follow-up and classification of treatment outcomes (WHO 
2010:15). 
 
The overall treatment failure cut-off level to decide whether to change a failing first-line 
antimalarial drug of 25% was lowered to 10% over a follow-up period of 28 to 42 days 
depending on the type of antimalarial drug tested and the malaria parasite subjected 
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(WHO 2009:5). The antimalarial treatment policy change effected in Ethiopia 2004 was 
based on the 25% treatment failure cut off (Jima et al 2005a:391).  
 
4.7.2 Studies’ results dissemination and policy change process 
 
In the Ethiopian context dissemination of therapeutic efficacy studies conducted at 
national level under the leadership of the Ministry of health was done through a national 
workshop (WHO 2001:34). Participants of the national workshop include Regional 
Health Bureaus, academic and research institutions, referral hospitals, UN agencies, 
civil societies and non-governmental organizations.  
 
The dissemination process and implementation of the new antimalarial drug treatment 
guidelines introduced both in 1998 and 2004 were never assessed and the lessons 
learned have not been documented.  
 
The major preparatory issues that determine success of a new malaria treatment 
guideline described by the WHO (2001:38) include:   
 
a) resources required by the health sector and the community seeking treatment 
b) human and technical resources and health care infrastructure capacity to 
implement the policy 
c) awareness-raising, health promotion and information dissemination to ensure 
smooth implementation 
d) education and training of health workers in public, private and community sectors 
e) drug supply, distribution, price regulation and quality assurance 
f) monitoring and evaluation of the policy and its impact 
 
In an effort to assess the pace of introduction of the new malaria treatment guideline 
developed in 2004 and to identify implementation challenges such as those described 
by Bosman and Mendis (2007:193), a full assessment at national, regional, district and 
health facility level is essential. The most challenging issues in the implementation of 
new antimalarial treatment guidelines is also related to the quantification and 
procurement of the amount of antimalarial drug needed. Therefore, although the 
eventual aims is to ensure availability of good quality drugs to all who need them (Coll-
Seck, Van Erps & Halil 2008), the exercise of need estimation must to be well 
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developed (Kindermans, Vandenbergh, Vreeke, Olliaro & D'Altilia 2007:91) in order to 
secure appropriate quantities of antimalarial drugs.   
 
4.7.3 Antimalarial drug efficacy monitoring and the use of evidence for policy in 
Horn of Africa Region 
 
The EANMAT comprising national programs and research institution in Kenya, 
Tanzania, Uganda, Tanzania, Burundi and Rwanda was established to bring 
complementary skills of malaria researchers and to provide technical support in malaria 
treatment issues in the region (East African Network for Monitoring Antimalarial 
Treatment [EANMAT] 2001:891). 
 
East African Network for Monitoring Antimalarial Treatment [EANMAT] (2003:860) 
reported that due to increasing levels of chloroquine resistance, Kenya, Uganda, 
Tanzania, Zanzibar, Rwanda and Burundi changed their first-line antimalarial drug in a 
window period of three years from 1998 to 2001. Most countries changed their first-line 
antimalarial drug to sulfadoxine-pyrimethamine or chloroquine plus sulfadoxine-
pyrimethamine while Burundi and Zanzibar introduced amodiaquine plus artesunate. 
 
EANMAT's eventual aims being to gear approaches towards a single antimalarial 
treatment policy in light of the uniform nature of malaria epidemiology in the region, the 
network focused on assessing the efficacy of Sulfadoxine-pyrimethamine and 
amodiaquine which are the major components of the new combination therapy 
approach. Accordingly, to the data collected from the countries, clinical response with 
sulfadoxine-pyrimethamine showed a slight decline from 88.8% (range: 86.9 to 90.3) in 
three study sites conducted before the year 2000 to 83.8 (range; 71.8 to 93.8) in six 
studies conducted after the year 2000. The efficacy of amodiaquine on the other hand 
was 93.5% in two study sites conducted before 2000 and 95.2% after 2000. The 
relatively comparable level of efficacy of the antimalarial drugs has been indicative of a 
possibility of adopting similar treatment policy in the region.  
 
A similar antimalarial drug resistance monitoring sub-regional network was also 
established by the horn of African countries that comprises, Djibouti, Eritrea, Ethiopia, 
Somalia, Sudan and Yemen. The HANMAT was formally established in 2004 (WHO, 
East Mediterranean Regional Office 2004). The network aims to share antimalarial drug 
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efficacy data information in the countries that can influence policy decision. Although 
there are no publications released, this network has been convening annual meeting to 
share country level report on antimalarial drug efficacy monitoring activities.  
 
In general, although regional antimalarial treatment monitoring networks have been 
instrumental in collecting and disseminating country specific data and information on 
antimalarial treatment, the main policy decision and process seems to be governed by 
more of an internal process than a regional effort. The activities of some of the regional 
networks have been declining. However, continued effort to coordinate information 
sharing harmonisation of antimalarial drug resistance and monitoring approaches is still 
supported by some of the member countries (Ministry of Health of Rwanda 2011).   
 
4.8 CONCLUSIONS 
 
Plasmodium falciparum resistance to chloroquine was first reported in the Thailand-
Cambodian Border by Harinasuta et al (1965:657) in 1965 while Plasmodium vivax 
resistance to chloroquine was reported by Schuurkamp, Spicer, Kereu, Bulungol and 
Rieckmann (1992:192) in Papua New Guinea nearly 27 years later. The first 
chloroquine resistant Plasmodium falciparum in Ethiopia was reported in 1986 
(Teklehaimanot 1986:127). Although such reports were communicated, the technical 
approach on how to conduct systematic representative assessment of resistance to 
antimalarial drugs and the decision making process whether to replace an existing 
antimalarial drug has not been clearly defined until the late 1990s.  
 
The first country to replace chloroquine was Thailand in 1973 while its use in Africa 
continued until the early 1990s. Although chloroquine resistant Plasmodium falciparum  
was first reported in cases encountered in Kenya (Fogh, Jepsen & Effersoe 1979:228) 
the first country in Africa that replaced chloroquine with a combination of chloroquine 
plus sulfadoxine-pyrimethamine at national level was Malawi in 1993 (Talisuna et al 
2004:253). 
 
After the start of implantations of the new malaria treatment guideline, antimalarial drug 
efficacy studies in Ethiopia have been conducted on a range of antimalarial drugs used 
for the treatment of Plasmodium falciparum and Plasmodium vivax. The antimalarial 
drug efficacy test protocols used in the earlier studies were not uniform and this was 
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creating problems in aggregating data collected from different studies. With a more 
complete protocol for the therapeutic efficacy assessment of antimalarial drugs 
developed by the WHO (2003:5), hopes were high that all such studies will follow the 
same protocol and that findings from such studies can be used for meta-analysis. 
However, what was observed in practice was not as expected. 
 
In Ethiopia and Kenya for example, despite the first reports of chloroquine resistant 
malaria cases in the mid-1980s and 1970, respectively and the significant amount of 
data collected afterwards, the decision to replace the filing drug chloroquine with 
sulfadoxine-pyrimethamine was reached in the late 1990s in Kenya and Ethiopia (WHO 
2000:13).  
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CHAPTER 5 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
 
5.1 INTRODUCTION 
 
The development of antimalarial drug policy should be based on evidence on 
antimalarial drug efficacy data and evidence collected in the local setting, 
recommendations by national health authorities and the WHO as the lead normative 
agency on health matters. Ogbonna and Uneke (2008:621) explain that the lack of 
effective national anti-malarial policies in many African countries and the high cost of 
ACTs, low drug quality and under-resourced health care delivery systems among others 
as the major obstacles to the implementation of effective malaria treatment approaches. 
 
Kramer, Dickinson, Anderson, Fowler, Miranda, Mutero, Saterson and Wiener 
(2009:133) report that the development of an appropriate policy based on evidence has 
been shown to have significant effect in improving malaria program management. 
Hasting, Korenromp, Bloland (2007:739) recommend that regularly updating malaria 
treatment policy based on combined evidence from in vitro parasite sensitivity studies 
and parasitological and clinical antimalarial efficacy studies as a scientifically sound 
approach that should be implemented in malaria endemic countries in order to ensure 
implementation of effective malaria treatment services.  
 
Based on the strengths and weaknesses in antimalarial drug efficacy monitoring and the 
use of evidence to inform antimalarial drug policy in Ethiopia, therefore, the following 
recommendations relevant to the antimalarial efficacy study protocols in general and the 
Ethiopian need in particular is presented. 
 
5.2 CONCLUSIONS ON THE RESEARCH FINDINGS AND RECOMMENDATIONS 
 
The antimalarial drug efficacy studies conducted in Ethiopia over the last 37 years 
(1974–2011) have had significant contribution to the scientific knowledge on the efficacy 
of antimalarial drugs in the country. However, most of the studies recommended the 
need for additional studies to be conducted further as the findings were not conclusive 
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and generalisable and substantive enough to initiate or indicate an antimalarial policy or 
change in treatment guidelines.  
 
Of the 44 studies conducted in the period from 1972 to 2011, only findings from four 
studies had direct impact on the antimalarial drug policy and malaria diagnosis and 
treatment guidelines in the country. Therefore, for antimalarial drug efficacy studies to 
have relevance in influencing antimalarial drug policy and treatment guideline 
development, adequate representativeness, timeliness and completeness and closer 
collaboration with the institutions that have institutional mandate in leading antimalarial 
treatment policy and treatment guideline changes is critical. 
 
For an effective collaboration and coordination to happen, identifying the specific 
components of the antimalarial drug efficacy monitoring and use of evidence for policy 
is essential. The following section, therefore, clarifies the areas that require specific 
attention and the actions that need to be in place.  
 
5.2.1 Antimalarial drug efficacy studies’ protocols 
 
As indicated in section 4.4.3, the development and dissemination of antimalarial drug 
efficacy study protocols by the WHO appears to have been time taking. A study protocol 
that can be used in both in high transmission areas and areas with low to moderate 
transmission was made available only in 2003 (WHO 2003:16). For countries like 
Ethiopia where malaria transmission is seasonal and unstable, applying the correct 
study protocol is of critical importance. The lack of such protocols might have been 
delaying timely action and application of locally appropriate antimalarial drug policy and 
treatment guidelines.  
 
Beyond assessing the efficacy of antimalarial drugs, the availability of quality 
replacement drugs in adequate quantities and affordable prices is also another critical 
issue that can influence the pace at which treatment policies are introduced. Therefore, 
beyond the task of timely developing tools to determine the level of efficacy of 
antimalarial drugs, countries that need to change their antimalarial treatment guideline 
should be provided a hands-on technical support by relevant international institutions 
such as WHO and other local partners.  
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Through this process, data collection and use of data for decision making and rapid 
introduction of the newly recommended antimalarial drugs can be properly managed 
through the support of international and local partners.  
 
5.2.2 Appraisal of antimalarial drug efficacy proposals 
 
The use of an appraisal process for antimalarial drug efficacy studies in Ethiopia can be 
a good mechanism to check and confirm the appropriateness of the study, its aims and 
the scientific and operational data and information it can generate. Therefore, appraisal 
of study proposals along the ethical review process would advantageous.  
 
The ethical clearance for antimalarial drug efficacy studies in Ethiopia passes through 
institutional or national review process conducted by the Ethiopian Science and 
Technology Commission (2005:10). Although the process involves assessment of the 
ethical aspects of the study, the process usually doesn't focus on the merits of the study 
and on the opinions of the relevant responsible institution on the potential advantages of 
the study for the health services improvement in the country. 
 
Therefore, a letter of recommendation from the Ministry of Health on the significance of 
the study and a possible future use of the study findings can pave the way for the 
Ministry of Health to engage in seeking important data and information from such 
studies for timely use.  
 
Therefore, the ethical clearance issuing authority should assume the responsibility of 
confirming that the studies planned have public health importance by addressing 
potential or actual knowledge and information gap in the efficacy of antimalarial drugs 
used in the country. 
 
5.2.3 The use of antimalarial efficacy studies’ findings and treatment guidelines 
changes 
 
Studies on antimalarial drug efficacy should ideally contribute to the existing scientific 
knowledge and also be of use to inform local policy issues and guide to determine 
appropriate treatment guidelines and policy decisions. Malaria treatment policy changes 
in Ethiopia have been preceded by reports of antimalarial efficacy studies. However, the 
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timing of the studies was usually late and the results happen to emerge after a 
significant problem of widespread antimalarial drug resistance has occurred. According 
to the WHO (2010a:5), malaria treatment policy change initiation should be considered 
when the treatment failure rate with a given antimalarial drug exceeds beyond 10%.  
 
As presented in section 4.3 of the results section, the use of antimalarial drug efficacy 
study findings are usually delayed due to lack of appropriate consultation mechanisms 
that can lead a process of consensus building on how best to use the findings. Williams 
et al (2004:356) assert that even after determining the level of treatment failures in a 
given country or area, convening the right forum to review the results and agree on the 
change process has been challenging.  
 
According to Williams et al (2004:356), the factors that influence antimalarial treatment 
policy change include political climate cost, treatment seeking behaviour of the 
population, replacement drug selection related to safety efficacy cost availability, 
procurement and distribution system and lead-time to policy change among others.  
 
Therefore, the value and use of antimalarial drug efficacy study findings can be very 
much influenced by the other preconditions stated above and meeting these 
preconditions is equally important to having the antimalarial drug efficacy data.  
 
5.2.4 Sentinel antimalarial efficacy studies 
 
The selection of sentinel antimalarial drug efficacy monitoring approach in Ethiopia has 
been used in two of the nation-wide studies conducted in 1997–98 by the Federal 
Ministry of Health and Jima et al in 2003. All the other isolated studies were conducted 
mostly in other locations. The use of such sentinel monitoring sites can enable compare 
findings over-time in the same location and avoids the risk of other confounding effect 
that may arise from the site changes and the local malarial epidemiology in the new 
study sites.  
 
The in vitro test kits developed by the WHO (2001:6) for different antimalarial drugs are 
also useful tools to provide baseline information on parasite sensitivity to antimalarial 
drugs. Therefore, when conditions permit, use of such test kits to determine baseline 
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parasite sensitivity data to antimalarial drugs and monitoring over time should be used 
every year in order to advice decision on whether to conduct in vivo therapeutic efficacy 
studies. 
 
In addition to the in vitro malaria parasite sensitivity studies to selected antimalarial 
drugs of interest for the country, routine in vivo therapeutic efficacy study on the first line 
antimalarial drug currently in use in the country should be conducted based on the 
WHO study protocol every two years (WHO 2009a:3).  
 
5.2.5 Selection and effective use of antimalarial drugs 
 
According to WHO (2010b:15), the recommended ACTs for the treatment of malaria 
include artemether-lumefantrine, artesunate plus amodiaquine, artesunate plus 
mefloquine and artesunate plus sulfadoxine-pyrimethamine. The efficacy of the 
combination of these drugs is dependent on the efficacy of each of the partner drugs 
(Guerin et al 2009). 
 
Reports on the declining efficacy of sulfadoxine-pyrimethamine (SP) for the treatment of 
Plasmodium falciparum  has been documented from studies conducted in Djibouti and 
Somalia (Abdel-Hameed 2003) and Sudan (A-Elbasit, Elbashir, Khalil, Alifrangis & Giha 
2006:604). Therefore, the use artesunate plus amodiaquine combination in these 
countries is basically conflicting with the WHO recommendations. The use of such 
ineffective combinations is likely to expose the Artemisinin component of the 
antimalarial drug to risk of development of resistance by the malaria parasites, 
especially Plasmodium falciparum parasites.  
 
Malaria in younger people and in patients with high initial temperature and high 
parasitaemia has been shown to have strong association with treatment failure and 
higher probability of worsening anaemia in cases treated with chloroquine (Hamer, 
MacLeod, Addo-Yobo, Duggan, Estrella, Fawzi, Konde-Lule, Mwanakasale, Premji, 
Sempertegui, Ssengooba, Yeboah-Antwi & Simon 2003:422). The use of such 
indicators, however, cannot replace the need to conduct regular antimalarial efficacy 
studies. 
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The treatment of malaria based on confirmed diagnosis is a very important tool to 
prevent irrational use of antimalarial drugs that may contribute to building drug pressure 
that may lead to the selection and spread of antimalarial drug resistant parasites. The 
WHO (2012b:6) recommends treatment of malaria based on confirmed parasitological 
diagnosis. As can be seen from table 2.4, the coverage of malaria diagnosis services in 
Ethiopia and most of the neighbouring countries has been increasing over the last few 
years with the exception of Kenya and South Sudan where there is no data to show the 
trends of increased used of malaria diagnostic services.  
 
Although the coverage of confirmed diagnosis for malaria using microscopy or 
RDTs)has been increasing over the years, treatment of most of the malaria cases in 
Ethiopia and the neighbouring countries is still largely based diagnosis using clinical 
sign and symptoms. Eritrea is an exception in this case. While the coverage of 
diagnostic services in most of the other countries is increasing, malaria diagnostic 
services in Eritrea seems to show some level of decline.  
 
Fever or history of fever in the last 48 hours which is the main clinical sign used to 
diagnose malaria can occur due to many other infectious diseases. Moreover, clinically 
distinguishing the cause of fever is always challenging (Cunha & Cunha 2008:194-199). 
Treatment of malaria based on clinical signs and symptoms therefore can result in 
misdiagnosis and over/under-treatment and irrational use of antimalarial drugs (Amexo, 
Tolhurst, Barnish & Bates 2004:1896). Misdiagnosis has been shown to slow down 
learning and use of new health technologies for diagnosis (Adhvaryu 2011:1). 
 
5.3 RECOMMENDATONS FOR ANTIMALARIAL DRUG EFICACY MONITORING 
AND USE OF EVIDENCE FOR POLICY IN ETHIOPIA 
 
5.3.1 A model for an antimalarial drug efficacy monitoring system 
 
The study protocol recommended by WHO should be used as the main standard 
guideline for the assessment of efficacy of antimalarial drugs that aim to inform 
antimalarial drug policy and treatment guideline development and updating. The current 
WHO (2009a:1) antimalarial drug efficacy study protocol clearly states the need to 
ensure quality of test drugs and patient follow-up schedule. With regard to the quality of 
test drugs and patient follow-up, the following should be critically adhered: 
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a) The quality of the test drug should be confirmed not only based on the quality 
analysis report provided by the manufacturer but also by an independent 
laboratory. This will also detect any quality deterioration that might have occurred 
during manufacturing, transportation and storage of the drug. 
b) Whenever possible, patients involved in antimalarial drug efficacy studies should 
be followed in an in-patient setting and all treatment doses should be supervised. 
In situations where this is not feasible, study subjects should be provided with 
and strongly advised to use insecticide treated bed nets at home to prevent 
possible re-infection. 
c) Study participants should also be asked to confirm that they have taken the 
prescribed amount of drug at the right time and that they also confirm if there was 
vomiting or diarrhoea during the course of the treatment. Depending on the 
frequency and pattern of the vomiting or diarrhoea episodes, the clinician should 
determine if the subject should continue in the study.  
d) In the absence of adequate sample size of study subjects, a statistically sound 
approach should be used to determine if data from different sites could be 
aggregated or the study could be continued over an extended period. In either 
case, the approach should be cleared from being a potential or actual source of 
bias.  
e) For all cases enrolled, blood samples should be taken for microscopy and PCR 
based detection of parasites. In the absence of PCR based confirmation, blood 
slides from study subjects should be prepared in duplicates for simultaneous 
reading by two microscopists. In case of a discordant result, the examiners 
should demonstrate presence or absence of parasitaemia to the second 
examiner. The jointly agreed result should be binding. 
 
5.3.1.1 Organisation and management of antimalarial efficacy studies 
 
The study team should be supplied with all the necessary laboratory material, stationary, 
sanitary supplies, waste disposal containers and the agreed payment right at the start of 
the study. Transport should be arranged for the trained study team and their study 
material to ensure safe arrival of all the necessary items to the point of the study site. A 
list of the materials required for antimalarial drug efficacy studies in presented in 
Annexure F. 
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5.3.1.2 Coordination with development partners and timeframe of activities 
 
The study should be organised and planned as a joint venture of the Ministry of Health 
and the Regional Health Offices together with the National Pharmaceutical Regulatory 
Authority, relevant Research and Academic Institutions, International organisation such 
as WHO and UNICEF, funding agencies and health care workers in the study health 
facilities.  
 
Through a joint consultation with these institutions, a small technical group composed of 
democratically selected experts should be formed to carry management responsibility of 
the study. The technical group should prepare a study proposal, implementation plan, 
mobilise fund and selection and training of study teams from each of the study sites.  
 
To prevent discontinuation of study due to problems faced by study team members, the 
study team that should be trained for each site should be double of the minimum 
number required. Training of the study teams should be conducted in an actual health 
facility setting and all procedures of the study protocol should be covered through both 
theoretical and practical training. Once preparation for the study is completed, the team 
should organise start of the study, conduct follow-up supervision, data quality validation, 
data entry, analysis and report writing as per the time frame. An example of time frame 
that can guide local planning is presented in Annexure D.  
 
5.3.1.3 Supervision and reporting 
 
Members who participated in the training will perform the study. However, to ensure 
adherence to the study protocol and for the direct inspection of blood film preparation, 
slide reading and parasite density estimation, all study sites should be visited on weekly 
basis by supervisors trained for the task.  
 
The team will have to submit detailed written report, all record forms, and all study 
slides properly wrapped and labelled to the study coordinator(s). Data analysis and 
writing of the report should be completed by the technical working group. Once a final 
version of the report and recommendations are prepared, this should be submitted to an 
independent expert group for review and clearance. Following the clearance process, 
the following actions need to be coordinated by the Federal Ministry of Health:  
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a) The Ministry of Health and the participating partners to organise a national 
workshop to disseminate the findings and agree on a plan to implement the 
recommendations. 
b) The national workshop to nominate responsible institutions at national and 
regional level that will be guide the overall implementation of the new 
recommendation.  
c) The national team together with the regional teams should prepare an overall 
implementation plan of the recommendation together with a detailed plan needed 
for guideline revision, health workers training, procurement and supply chain 
management of the new product needed and preparation and mobilisation of the 
required budget. 
d) The national team should coordinate with the regional teams to regularly assess 
implementation status of the recommendation and progress towards the 
achievements by the due dates. Any challenge and obstacles in implementing 
the plan should be immediately notified to the Ministry of Health for action.  
 
The overall implementation plan of any new recommendation for malaria treatment 
should be planned for completion within 12 to 18 months in order to prevent 
unnecessary delay in ensuring rapid access to effective antimalarial drugs. In the event 
of lack of funding to fully implement the new recommendation, the national and regional 
teams should have a fully endorsed alternative exit plan to address immediate malaria 
treatment issues.  
 
5.4 BEST PRACTICE APPROACHES FOR ANTIMALARIAL DRUG EFFICACY 
MONITORING FOR ETHIOPIA 
 
5.4.1 Establishment of antimalarial drug efficacy early warning system 
 
The emergence of resistance to antimalarial drugs is a gradual process and starts with 
signs related to delayed parasite clearance.  Sowunmi, Adewoye, Gbotsho, Happi, 
Sijuade, Folarin, Okuboyejo and Michael (2010:1) report that the causes for delayed 
resistance are multifaceted and are not attributed to a single cause. Early indications of 
delayed parasite clearance is a reliable early indicators that can be used to initiate 
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closer follow-up of patients treated with such antimalarial drugs to ensure that the 
required efficacy pattern of the antimalarial drug in use is continuing as expected.  
 
According to White (1999:739), delayed parasite clearance is defined as occurrence of 
parasite in blood sample two days after the start of treatment. However, as parasite 
clearance time may vary according to the blood level and concentration of the 
antimalarial drug as well, Flegg, Guerin, White Stepniewska (2011:1) recommends that 
setting cut-off points to determine delay need to be based on local studies. In addition to 
the overall delay in parasite clearance time, Barnes, Little, Mabuza, Mngomezulu, 
Govere, Durrheim, Roper, Watkins and White (2008:1605) and Dondorp, Nosten, Yi, 
Das, Phae, Tarning, Lwin, Ariey, Hanpithakpong, Lee, Ringwald, Silamut, Imwong, 
Chotivanich, Lim, Herdman, Yeung, Singhasivanon, Day, Lindegardh, Socheat and 
White (2009:455) also report that parasite gametocytemia increases with increasing 
level of delayed clearance or parasite resistance.  
 
The practice of early detection of delayed treatment response, reporting of such cases 
and further follow-up in the Ethiopian setting is not part of the antimalarial efficacy 
monitoring approach in Ethiopia. Therefore, given the advantage of such early detection 
of delayed response as a precursor for further closer follow-up, the following early 
monitoring approaches for early warning and reporting of delayed treatment response 
are proposed. 
 
5.4.1.1 Health facility based early warning system 
 
Health facilities providing malaria diagnosis and treatment services to patients on 
routine basis should keep detailed patient records to allow compilation of the required 
information. One of the main patient records worth including in medical records is travel 
history and overnighting in to another area over the last two weeks. The two weeks cut-
off is based on the incubation period of malaria parasites which differs by the type of 
malaria parasite species which generally from 7 to 30 days (Centres for Disease 
Prevention and Control 2010). 
 
The main activities that need to be implemented by the health facilities in order to 
ensure the early warning system include the following: 
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a) Record details of patients returning to the health facility with malaria clinical sign 
and symptoms within 15 days of the initial treatment for malaria administered 
based on microscopic examination of RDT, The patient specific record should 
include: 
• Name, sex and age and measured body weight 
• Residential address 
• Patient confirmation that all the antimalarial drug doses prescribed for a 
recent malarial illness were taken as instructed and there was no vomiting 
or diarrhoea 
• Travel during the last two weeks 
b) Conduct parasitological examination to determine malarial infection and retain 
blood films with positive findings.  
c) The use of RDTs to determine malarial infection for the purpose of the early 
warning system may not be reliable as parasite antigens that can be detected by 
the RDTs are known to persist up to two weeks after the parasite was eliminated 
following treatment (Kyabayinze, Tibenderana, Odong, Rwakimari & Counihan 
2008:221). Therefore, although the use of RDTs is recommended to track 
resistant malaria parasites (Houzé, Boly, Le Bras, Deloron & Faucher 2009:211) 
its use should be cautious.   
d) The health facility should also monitor clustering by village of such patients 
returning to health facilities within two weeks after treatment to identify localities 
where most of the cases are coming. 
e) Compile and submit quarterly report on returning patients to the district health 
office. 
 
5.4.1.2 District health offices-based early warning system 
 
a) Identify pattern of patients returning with clinical sign and symptoms of malaria 
within two weeks after the initial treatment by time and location. 
b) Ensure regular supply of second-line antimalarial drugs to health facilities in 
areas where the frequency of returning patients is higher. 
c) Identify areas and request the Regional Health Bureau to assign experts to 
determine the need to investigate the pattern of response of the parasites to 
standard regimen on antimalarial drugs and determine if there is unexpected 
delayed response. Delayed response to antimalarial treatment is defined as 
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persistence of parasitaemia and clinical symptoms two days after treatment with 
an antimalarial drug (Sowunmi et al 2010:1). 
d) Record parasite species and laboratory examination parasitological diagnosis 
malaria cases treated with the recommended antimalarial drug and who return to 
the facility with clinical sign and symptoms of malaria within two-weeks of the 
initial treatment. 
 
5.4.1.3 Regional and national level early warning system 
 
The Regional Health Bureau and Federal Ministry of Health at national level are 
responsible for the identification of areas where increasing frequency of returning 
patients are reported from. In this regard the health authorities at these levels should 
put in place measures for the following actions: 
 
a) Identify and select area with high frequency of returning patients for further 
follow-up study. 
b) Conduct parasite clearance rate assessment studies following full course of 
treatment and identify area with high frequency of patients whose parasite 
clearance took three or more days. 
c) Investigate other possible reasons that contribute to delayed response to 
treatment such as quality the antimalarial drug administered and compliance of 
patients to prescribed treatment regimens. 
d) Review pattern and concentration of returning patients and determine the need 
for a full antimalarial drug efficacy study. 
e) Consider drug resistance containment actions in areas where delayed response 
to Artemisinin or resistance have been confirmed. 
f) Ensure availability of second-line antimalarial drugs that can be used to treat 
patients and to contain spread of resistance. 
g) Conduct full-scale representative and complete antimalarial efficacy study every 
two years in selected sites by ensuring timeliness, completeness and 
representativeness of the studies as per the most up-to-date study protocol 
recommended by the WHO.  
h) For some isolated case studies to determine the susceptibility of the Plasmodium 
falciparum  parasites to artemisinin, considering applying the methods used by 
Stepniewska, Ashley, Lee, Anstey, Barnes, Binh, D’Alessandro, Day, De Vries, 
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Dorsey, Guthmann, Mayxay, Newton, Olliaro, Osorio, Price, Rowland, Smithuis, 
Taylor, Nosten and White (2010:570) could be advantageous. 
 
5.5 POLICY AND REGULATORY ISSUES 
 
5.5.1 Antimalarial drug policy issues 
 
The use of oral Artemisinin mono-therapies is likely to contribute to increasing 
prevalence of resistant strains to Artemisinin. The use of Artemisinin oral mono-therapy 
therefore may put at risk other ACT drugs containing artemisinin and its derivatives to 
be exposed to development of resistance by malaria parasites, especially Plasmodium 
falciparum. In this regard, therefore, at national level the following policy and regulatory 
measures should be in place.  
 
a) The Ministry of Health and Drug regulatory authorities at national level should 
enforce ban of local manufacturing, importation or marketing of oral Artemisinin 
mono-therapies. 
b) The national essential drug list should not include antimalarial drugs that are not 
recommended by WHO.  
c) For additional products that need to be included in to the national drug list, 
inclusion should be ensured with supporting recommendation from normative 
agencies such as WHO. 
 
To ensure importation of antimalarial medicines of proven quality and to prevent 
circulation of substandard, counterfeit or fake formulations, drug quality inspection at 
point of entry should be enforced.  
 
5.5.2 Appropriate policy and guidelines implementation 
 
Access to prompt and effective treatment for malaria will remain one of the main 
interventions for malaria prevention and control in Ethiopia. The success of this 
intervention will depend not only on the availability a malaria diagnosis and treatment 
guideline but also on ensuring the efficacy and safety of the medicines recommended 
for use in the country.  
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Ensuring efficacy of antimalarial drugs in use in the country involves regular monitoring. 
The regular monitoring of efficacy of antimalarial drugs and the use of the study findings 
to inform policy should be based on internationally recommended approaches endorsed 
by internationally mandated organisations such as the WHO and other in-country 
regulatory and normative guidelines. 
 
In all cases, the antimalarial drug efficacy monitoring should be tailored to fit the local 
needs. To ensure this, the following best-practice approach is recommended based on 
the existing WHO’s guideline and the findings from this study.  
 
Antimalarial drug efficacy monitoring studies is Ethiopia have contributed significant 
amount of information on the pattern of sensitivity of the parasites and efficacy of the 
antimalarial drugs used in the country. However, the research question of some of the 
studies, justification for the method used, implementation of the studies and strength of 
the findings has not mostly been adequate requiring for more extensive and 
representative study. 
 
From the Ethiopian context, the findings from isolated antimalarial efficacy studies have 
not been adequately used to inform policy due to the methodological disparities, lack of 
timeliness, representativeness and completeness of the data and information collected 
through the studies. Williams et al (2004:356) described a number of actions that need 
to be taken in order for evidence on antimalarial drug efficacy to be effectively used for 
antimalarial drug policy development and its implementations. Based on the actions 
proposed by Williams et al (2004:356), the antimalarial drug efficacy monitoring and use 
of evidence for policy change in Ethiopia can be said to have attempted to ensure all the 
necessary actions.  
 
However, most of the actions taken in Ethiopia seem to have been driven by disease 
epidemic imposed need to change the first-line antimalarial drug. As a result, 
implementation of the new antimalarial drug policy and treatment guideline change has 
not been well coordinated and implemented in a reasonably short period of time.  
 
Therefore, to ensure timely and smooth introduction of antimalarial drug policy and 
treatment guideline change, the following actions are proposed:  
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a) Raise the issues and inform stakeholders that treatment policy change might be 
needed based on the evidence collected. 
b) Confirm the data that raise concern and present data to appropriate audience in 
a clear manner. 
c) Strengthen consensus building among stakeholders emphasising that a change 
may be required by clearly presenting the evidence. 
d) Promote for the necessary change to take place and be implemented at the 
same time. 
e) Identify replacement antimalarial drugs, options of introducing the change and 
possible alternatives. 
f) Develop policy document and specific directions on the change process and time 
line for implementation. 
g) Ensure completion of timely preparatory activities. These include: 
- revise and print the new guideline including in local languages for all levels 
of health workers 
- prepare training plan and conduct the training  
- advice local manufacturers and importers to manage stocks of the old 
antimalarial drugs that may not be needed any more 
 
5.6 CONTRIBUTIONS OF THE STUDY 
 
The study has attempted to map the pattern of antimalarial drug efficacy monitoring 
studies and their contribution to the wealth of scientific information and use of the 
evidence for policy in the Ethiopian context. This has enabled identify the strengths and 
weakness of the previous antimalarial drug efficacy studies so that such future studies 
will have better design, conduct and dissemination of results and assessing the 
potential policy implication of the findings and alerting authorities of the possible actions 
required.  
 
Through this study effort has also been made to obtain the overall and specific picture 
of the antimalarial drug efficacy studies conducted in Ethiopia over a period of 39 years. 
Although the contribution of the studies to the overall scientific knowledge is remarkable, 
the use of the findings has been seriously hampered by methodological disparities and 
lack of timeliness, completeness and representativeness and coordination with the 
decision making bodies such as the Ministry of Health.  
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Therefore, apart from conducting and publishing antimalarial drug efficacy studies, 
creating a mechanism to ensure use of the data to inform decision or identify next steps 
needs to be strengthened. To assist the overall management of antimalarial drug 
efficacy monitoring system and use of evidence for policy in Ethiopia, the best practice 
approaches and recommendations proposed are believed to be of significant 
importance to malaria treatment and monitoring of antimalarial drug efficacy in Ethiopia.  
 
5.7 LIMITATIONS OF THE STUDY 
 
The study employed an approach that allows reviewing and document findings of 
antimalarial efficacy studies conducted in Ethiopia and to assess their contribution to 
inform policy. The methodological approach and the data collection method used were 
appropriate for the study. However, ensuring a complete review of all available 
publications requires exhaustive search including work of individual researchers whose 
report was not published or shared in any form. Attaining this would have required 
identifying and interview with lead in-country experts. Although this can be seen as a 
potential methodological limitation, the researcher believes that, important study reports 
have been available. 
 
The status of implementation of a new antimalarial drug policy and treatment guidelines 
depends on its appropriate implementation. This also contributes to ensuring an 
appropriate system to continue further monitoring of efficacy of antimalarial drugs. In 
this case, the lack of on ground assessment and reports on the assessment of 
implementation of the new antimalarial treatment policy is also a major limitation of the 
study.  
 
The limitations identified in this study have no significant implication on the way forward. 
Therefore, implementing the recommendations and best practice approaches proposed 
in this report to strengthen antimalarial drug resistance early warning and monitoring 
system can significantly contribute to the improvement of malaria treatment in Ethiopia 
which contributes towards reducing malaria related illness and death and this 
contributes to improved public health and socio-economic development in the country.  
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5.8 CONCLUDING REMARKS 
 
An estimated 54 million people in Ethiopia live in areas at risk of malaria and the 
disease poses significant public health and socio economic problems. Plasmodium 
falciparum malaria which causes nearly all the malaria related deaths is also the 
parasite species that developed resistance to different antimalarial drugs.   
 
The success in malaria prevention and control in Ethiopia will continue to depend on the 
availability of safe, effective, affordable and accessible antimalarial drugs. Although 
public health service to prevent lack and delay in accessing prompt diagnosis and 
effective treatment services is improving through international support and national 
efforts, the issue of retaining the useful life of existing antimalarial drugs will depend on 
their rational use and advances to develop new effective antimalarial drugs. 
 
To date the development of resistance to antimalarial drugs is more rapid than the 
scientific and industrial advance to develop new effective antimalarial drugs. Currently 
there are ten antimalarial molecules globally that are completing phase IIb/III clinical trial 
(Medicines for Malaria Venture [MMV] 2012). These molecules are expected to enter 
the market in few years provided that the clinical trial findings are supportive and 
acceptable. On the other hand, the efficacy of the currently available and widely used 
ACT drugs is at risk of losing its useful life due to the development of resistance to the 
artemisinin component of the combination drug.  
 
Artemisinin resistance first started in localised foci in the Thai-Cambodia border and is 
now expanding to wider geographic areas (WHO 2010d). Although resistance to 
artemisinin has not yet been reported in Africa, the early symptoms of declining 
responsiveness have been confirmed in Kenya by Borrmann, Sasi, Mwai, Bashraheil, 
Abdallah, Muriithi, Frühauf, Schaub, Pfeil, Peshu Hanpithakpong, Rippert, Juma, Tsofa, 
Mosobo, Lowe, Osier, Fegan, Lindegårdh, Nzila, Peshu, Mackinnon and Marsh (2011:1). 
To strengthen antimalarial drug efficacy monitoring system and use of evidence for 
policy and planning will remain as the most important tool. The WHO (2010d) advises 
malaria endemic countries to establish a strong system for antimalarial drug efficacy 
monitoring system in order to timely detect problems and ensure placement of 
corrective actions.  
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For antimalarial drug efficacy monitoring study to be of use to develop relevant policies 
and treatment guidelines, data collected through these studies should be representative, 
timely and complete beyond any doubt. Failure to obtain high level of quality of the 
evidence on antimalarial drugs and the decision that may need to be taken may not 
attract full support from all stakeholders and this can cause delay in taking actions of 
public health relevance. 
 
Beyond the regular monitoring of the efficacy of antimalarial drugs, policy and regulatory 
environment that support the judicious use of existing antimalarial drugs should be 
enforced. These includes a) inclusion in the National essential drug list of antimalarial 
drug formulations that are recommended by the WHO and local evidence supported by 
the national health and regulatory authorities b) monitoring of quality and ascertaining 
prequalification status of antimalarial drugs authorised for marketing and c) ensure 
appropriate use of antimalarial drugs based on confirmed diagnosis and limit use of 
antimalarial drugs based on sign and symptoms.  
 
Antimalarial drug efficacy monitoring should be conducted on regular basis of every two 
years as recommended by the WHO. However, a routine system to monitor early 
indications of delayed response to antimalarial treatment and resistance should be 
gathered from selected early warning spots. The evidence gathered from these early 
warning spots should be used to guide selection of regular spots for a full antimalarial 
drug efficacy study. 
 
In conclusion, the recommendations and best practice approaches proposed in this 
report are sound both from scientific and international recommendation point of view 
and the local setting. Therefore, as a way forward, the researcher will work to present 
findings and recommendations of this study to relevant audience in Ethiopia.  
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Annexure C – Data variables and analysis 
 
 
Data category 
 
Variable 
 
 
Data collected 
 
Analysis 
 
 
Study Ares and 
population 
Locality, region 
 
Number of sites  
- Total number of 
study sites  
- Existence of the 
risk of malaria 
infection in the 
study site 
 
Per cent population at risk 
of malaria  
Total and population at 
risk of malaria  
Test drug  
Generic  name 
 
Name - Confirmation of 
expiry date of the 
test drug at the 
time of the time of 
use, 
- Quality analysis of 
the drug for active 
ingredient 
 
Batch 
 
Number 
Manufacturer, supplier 
 
Name 
Expiry date 
 
Date 
Quality analysis for active 
ingredient 
 
Pass, fail  
Study design  
Study population age 
group 
 
Under five years or five 
years and above 
- Appropriateness 
of the study 
protocol for the 
setting  
- Adequacy of the 
samples size 
- Random or 
purposive 
- In-patient or 
outpatient 
- Parasite species 
studied  
- Types of 
antimalarial drugs 
tested  
- Appropriateness 
of drug dosage in 
milligram per 
kilogram body 
weight 
Study protocol 
 Name  
Sampling assumptions 
 Description 
Calculated sample size 
 Number 
Patient allocation 
approach 
 Name 
Patient follow-up 
arrangement 
 Name 
Test parasites 
 Name 
Test drug 
 Name 
Drug dosage 
 dosage  
 
  
  
 
Annexure B – Data variables and analysis (continued) 
 
 
Data category 
 
Variable Data collected 
 
Analysis 
 
Study quality 
control 
Urine test for drug prior to 
treatment  
 
Number  
- Per cent with 
positive urine test 
- Per cent with drug 
concentration 
above the 
minimum effective 
concentration 
- Per cent slide 
examination result 
concurrence 
between two 
readers 
- Per cent 
microscopy 
examination 
results confirmed 
by PRC   
- Per cent treatment 
failure cases with 
drug or metabolite 
concentration 
above the 
minimum effective 
concentration 
Drug concentration in 
blood samples at the time 
of treatment failure  
 
Number  
Blood film result quality 
control  
 
Total or random  
PCR confirmation of 
microscopy based 
examination results  
 
Number 
Drug concentration in 
blood samples at the time 
of treatment failure  
Number 
Study outcome 
– in vivo studies  Follow-up outcome  
Number 
 
- Total enrolled  
- Per cent who 
completed follow-
up 
- Per cent loss and 
withdrawals 
- Per cent adequate 
clinical response  
- Per cent adequate 
clinical and 
parasitological 
response  
- Per cent early 
treatment failure  
- Per cent late 
treatment failure  
- Per cent total 
treatment failure   
- Per cent treatment 
failure  
- Per cent treatment 
success 
(Plasmodium 
vivax)   
- Per cent treatment 
failure 
(Plasmodium 
vivax)   
 
  
  
 
Annexure B – Data variables and analysis (continued) 
 
 
Data Category 
 
Variable  Data collected   
 
Analysis  
 
Study outcome 
in vitro studies  
Schizont maturation at 
0.025 nmol Number 
 
- Per cent schizont 
maturation at 
various drug 
concentrations 
(0.25, 0.5, 0.75 
and 1.0 nmol) in 
vitro studies 
 
Study outcomes 
- Molecular 
studies  
Genetic analysis for 
polymorphic genes 
conforming with resistance 
Number 
 
- Per cent parasite 
samples with 
polymorphic 
genes conforming 
resistance  
 
Publication 
 
Study period 
 
Year 
 
- Number of years 
that lapsed from 
completion of the 
study to 
communication of 
the findings 
- Number of years 
lapsed from 
completion of 
study to 
dissemination of 
results 
 
 
Year of publication 
 
Year 
Duration to publication Year 
Policy 
implication  
 
Study timelines 
 
Year 
- Number of years 
from the first 
report  
- Extent of missing 
information  
- Number of years 
needed to 
introduce revised 
malaria treatment 
guideline 
 
 
Study completeness 
 
Name 
Treatment policy change 
and updating treatment 
guidelines  
Year 
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Annexure C – Chronological list of antimalarial drug sensitivity and efficacy studies in Ethiopia 
 
 
No Year Author No. of 
study sites 
Sample 
size 
Subjects age 
group (years) 
Method and 
follow-up 
duration 
Test drug Test parasite 
% 
Treatment 
failure  
1 1974 Dennis et al 1 41 5 & above In vivo, 28 days  Chloroquine 
Plasmodium 
falciparum  26.8 
2 1974 Dennis et al 1 24 5 & above In vivo, in vitro Chloroquine 
Plasmodium 
falciparum  0a 
3 1976 Palmer et al 3 82 5 & above in vitro Chloroquine 
Plasmodium 
falciparum  0a 
4 1976 Armstrong et al 4 99 2—55  In vivo, 6-11 days  Chloroquine 
Plasmodium 
falciparum  0 
5 1980 Gebremariam et al 1 21 above 5  In vivo, 7 days  Chloroquine 
Plasmodium 
falciparum  0 
6 1980 Gebremariam et al 1 14 above 5  in vitro Chloroquine 
Plasmodium 
falciparum  0a 
7 1984 Gebremariam et al 11 136 1 to70  In vivo, 7 days  Chloroquine 
Plasmodium 
falciparum  0 
8 1984 Gebremariam et al 11 115 1 to 60 In vivo, 28 days  Chloroquine 
Plasmodium 
falciparum  0 
9 1985 Teklehaimanot et al 1 98 above 14 In vivo, 28 days  Chloroquine 
Plasmodium 
falciparum  22.4 
10 1985 Teklehaimanot et al 2 10 above 14 in vitro Chloroquine 
Plasmodium 
falciparum  70a 
11 1993 Wezam 1 23 All ages In vivo, 7 days  Chloroquine 
Plasmodium 
falciparum  0 
12 1993 Wezam 1 24 All ages In vivo, 7 days  SP 
Plasmodium 
falciparum  0 
13 1996 Alene 36 1706 1 to 80 In vivo, 7 days  Chloroquine 
Plasmodium 
falciparum  87.2 
14 1996 Tulu et al 1 29 1 to 76 In vivo, 7 days  Chloroquine 
Plasmodium 
falciparum  86.2 
15 1996 Tulu et al 1 80 1 to 76 In vivo, 7 days  SP 
Plasmodium 
falciparum  1.3 
16 1997 Tulu  et a. 1 255 1 to 76 In vivo, 7 days  Chloroquine 
Plasmodium 
vivax 2 
17 1997 Assefa 1 1 25 In vivo, 7 day Chloroquine 
Plasmodium 
falciparum  100 
  
 
No Year Author No. of 
study sites 
Sample 
size 
Subjects age 
group (years) 
Method and 
follow-up 
duration 
Test drug Test parasite 
% 
Treatment 
failure  
18 1998a MOH 14 473 Under five In vivo, 14 days  Chloroquine 
Plasmodium 
falciparum  73.6 
19 1998a MOH 6 257 Five and above  In vivo, 14 days  Chloroquine 
Plasmodium 
falciparum  63.4 
20 1998b MOH 4 107 Under five In vivo, 14 days  Chloroquine 
Plasmodium 
falciparum  47.7 
21 1998b MOH 7 227 Under five In vivo, 14 days  Amodiaquine 
Plasmodium 
falciparum  21.1 
22 1998b MOH 7 232 Under five In vivo, 14 days  SP 
Plasmodium 
falciparum  5.6 
23 2001 Degefa  1 77 Above 6 months In vivo, 14 days  SP 
Plasmodium 
falciparum  2.6 
24 2002 Kassa et al 1 59 1 to 7 In vivo, 14 days  Mefloquine 
Plasmodium 
falciparum  0 
25 2002 Kassa et al 1 60 1 to 8 In vivo, 14 days  SP 
Plasmodium 
falciparum  21.1 
26 2003 Yeshiwondim et al 2 145 4 to 65  In vivo,28 days  Chloroquine (CQ) 
Plasmodium 
vivax 5.76 
27 2003 Yeshiwondim et al 2 136 4 to 60 In vivo, 28 days  CQ + primaquine 
Plasmodium 
vivax 0.75 
28 2003 Jima et al 11 523 > 6 months In vivo, 28 days  SP 
Plasmodium 
falciparum  33.5 
29 2003 Jima et al 4 213 > 6 months In vivo, 28 days  AL 
Plasmodium 
falciparum  0.9 
30 2006 Teka et al 1 83 8 mo. to 52 yrs. In vivo, 28 days  chloroquine 
Plasmodium 
vivax 4.8 
31 2006 Seboxa et al 2 105 2 to 35 In vivo, 14 days  AL 
Plasmodium 
falciparum  0 
32 2006 Seboxa et al 1 36 2 to 35 In vivo, 14 days  Artesunate + SP 
Plasmodium 
falciparum  0 
33 2006 Schunk et al 1 69 All ages molecular Chloroquine 
Plasmodium 
falciparum  78.3--95.7b 
34 2006 Schunk et al 1 69 All ages molecular SP 
Plasmodium 
falciparum  81.2--82.6b 
35 2006 Schunk et al 1 31 All ages molecular SP 
Plasmodium 
vivax 
3.2--6.5b 
 
 
  
 
No Year Author No. of 
study sites 
Sample 
size 
Subjects age 
group (years) 
Method and 
follow-up 
duration 
Test drug Test parasite 
% 
Treatment 
failure  
36 2007 Kefyalew 1 102 1 to 50 28 days  AL 
Plasmodium 
falciparum  0 
37 2008 Ketema et al 1 78 9 mo. to 42 yrs. In vivo, 28 days  chloroquine 
Plasmodium 
vivax 82.6 
38 2010 Eshetu et al 1 35 All ages molecular AL 
Plasmodium 
falciparum  0b 
39 2010 Eshetu et al 1 30 All ages molecular Quinine 
Plasmodium 
falciparum  0b 
40 2010 Eshetu et al 1 32 All ages molecular AP 
Plasmodium 
falciparum  3.1--6.3b 
41 2010 Assefa et al 1 81 1 to 30yrs  In vivo, 28 days  AL 
Plasmodium 
falciparum  6.7 
42 2011 Yohannes et al 2 75 Above 1 year In vivo, 28 days  AL 
Plasmodium 
vivax 25.3 
43 2011 Yohannes et al 2 57 Above 1 year In vivo, 28 days Chloroquine 
Plasmodium 
vivax 8.8 
44 2011 Ketema et al 1 80 9 mo. to 52 yrs. In vivo, 28 day Chloroquine 
Plasmodium 
vivax 6.7 
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Annexure D – Antimalarial efficacy study implementation time frame 
 
No Activity July August September October November December January February March April 
 
1 
 
 
 
Preparation and 
endorsement of  
study proposal 
 
          
 
2 
 
Test drug 
analysis and 
mobilizing test 
materials and 
fund  
 
          
 
3 
 
Training of study 
team  
 
          
 
4 
 
Actual study 
period  
 
          
 
5 
 
Data entry and 
cleaning 
 
          
 
6 
 
Data analysis 
and report writing 
 
          
 
7 
 
Dissemination of 
result (workshop) 
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Annexure E – Proposed study team training 
 
 
Day  
 
 
Duration 
 
Topic 
1 
 
1 hour 
 
 
Back ground and objectives of the Therapeutic efficacy study 
and site & time selection 
 
2 hour 
 
Fundamental components of the WHO antimalarial efficacy 
study protocol 
 
 
2 hour 
 
Patient examination, inclusion & exclusion criteria,  Enrolment  & 
follow-up procedures 
 
 
3 hour 
 
Blood film preparation, staining, examination and recording 
results and materials required for the test  
 
2 
 
 
4 hours 
 
Practical session for laboratory technicians  
 
• blood slide preparation, staining, examination, 
• Parasite count and density estimation  
• Recording keeping  
 
 
4 hours  
 
Practical session for medical doctors  
 
• Patient screening, 
• Blood film result and parasite count, Inclusion and 
exclusion criteria,  
• Adherence to study protocol inclusion and exclusion 
criteria of patients,  
 
 
Day 3  
 
6 hours  
 
Actual practical in health facility  
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Annexure F – Study materials required 
 
Laboratory ware and Cleaning materials 
NO. ITEM UNIT Quantity Per Study 
Site 
1 Graduated cylinder 500 ml 2 
2 Graduated cylinder 100 ml 2 
3 Graduated cylinder  10 ml 2 
4 Staining rack and dish Large set 2 
5 Rinsing trough Each 2 
6 Timer Each 2 
7 Drying rack Each 4 
8 Slide tray Each 4 
9 Slide box 100 slides 2 
10 Compound microscope Each 2 
11 Weighing scale Each 2 
12 Digital Thermometer Each 4 
13 Plastic dropper for immersion oil Each 4 
14 Towel Each 2 
15 Detergent  Pack 2 
16 Hand Soap Each 2 
17 Soft Paper Roll 2 
18  Distilled Water Container of 5L   5 
19 Blue ink pen Each 4 
20 Red ink pen Each 4 
21 Pencil Each 4 
22 Carbon paper Box of 100 1 
23 Folders Each 4 
24 Rubber Band Box 2 
 
 
  
 
Laboratory Materials 
NO. ITEM UNIT Quantity Per Study Site 
1 Latex gloves Box of 50 pair 4 
2 Frosted slides Box of 50 40 
3 Lancets Box of 500 4 
4 Cotton 25 gm roll 4 
5 Alcohol 1 litre bottle 2 
6 Methanol 1 litre 1 
7 Giemsa stock solution  Litre 1 
8 Buffer tablets Bottle of 100 4 
9 pH indicator Roll 1 
10 Xylene Litre 0.5 
11 Microscope lens cleaning  tissue Pad 2 
12 Immersion oil 250 ml bottle 1 
13 Test drug  Treatment 
courses 
150 
14 Rescue treatment  Treatment 
courses 
150  
16 Other supportive treatment (e.g. 
antipain)  
Treatment course  150 
 
Stationary 
NO. ITEM UNIT Quantity Per Study 
Site 
1 Blood film slip Sheet 100 
2 Registration forms Pad 2 
3 Case record forms Each 300 
4 Enrolled form Each 50 
5 Follow-up forms Each 400 
6 Referral forms Each 100 
7 Study manual Each 1 
8 Location form Each 400 
9 Malaria diagnosis bench aids Each 1 
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Annexure G – WHO recommended methods for surveillance of antimalarial drug 
efficacy 
 
Available from http://whqlibdoc.who.int/publications/2009/9789241597531_eng.pdf 
 
 
